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Abstract
Malaria is a major public health concern for the one-third of the human population esti­
mated to be exposed to the threat of the most virulent species, Plasmodium falciparum. 
Modern molecular and computational tools from population genetics may help to better 
understand and fight the burden of drug resistant malaria.
Malaria biology is substantially different from the underlying paradigm of standard 
population genetics models, most notably because malaria has both a asexual haploid 
phase and a sexual diploid phase where selfing (i.e. mating between genetically identical 
parasites) is possible. It is therefore fundamental to understand if commonly used 
population genetics methods are robust to the deviations from standard expectations 
imposed by the malaria life-cycle.
We build novel models of malaria population genetics and provide guidelines to 
interpret empirical studies of the spread of drug resistance. Using realistic models of 
epistasis between genes involved in drug resistance we suggest that all signals of linkage 
disequilibrium (LD) are possible and that researchers should be confident in reporting a 
lack of statistical association between genes involved in resistance to antimalarials. We 
also suggest that researchers should be cautious in interpreting changes in the prevalence 
of drug resistance after control interventions as reductions in transmission can cause a 
change in prevalence without concomitant change in frequency of resistance.
We provide guidelines to better design and interpret studies related to estimating 
effective population size (Ne). We use computational simulations to study scenarios 
that can approximate control and elimination interventions (i.e. where a significant 
part of the population is killed). For Ne estimation our results suggest that researchers 
must increase the number of individuals and loci genotyped in order to have sufficiently 
precise Ne estimates. LD-based Ne estimators are more appropriate for early detection 
of control and elimination interventions than temporal-based Ne estimators. Long­
term estimators based on heterozygosity should not be used to make inferences about 
contemporary demographic processes. We also applied our analysis to disease vectors 
and we concluded that LD-based estimation is able to detect demographic seasonality
v
VI
patterns (i.e. changes in population size due to variations imposed by wet and dry 
seasons) whereas temporal estimators will provide averages over longer periods of time. 
We also studied selection detection using FgT-outlier approaches. Our results suggest 
that temporal Fst might not be appropriate for early detection of genes involved in 
drug resistance (e.g. in the case of artesunate derivatives). We also provide software 
and guidelines to better design and interpret studies (also across other taxa) of selection 
based on FsT-outlier approaches. Most notably our results suggest that sampling only 
one or two SNPs per locus (as it is done in many empirical studies) might not be sufficient 
to detect areas of the genome under selection, and that at least 4 SNPs per loci should 
be genotyped.
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Introduction
Malaria is a major public health concern for the one-third of the human population esti­
mated to be exposed to the threat of the most virulent species, Plasmodium falciparum, 
with an estimated number of clinical episodes ranging from 300 to 660 million per an­
num (Snow et ah, 2005). There is no effective vaccine for this species, and infection is 
controlled by insecticides targeted at vector mosquito species, and treatment by anti- 
malarial drugs. As might be expected, insecticide and drug resistance rapidly evolved 
and spread (Olliaro, 2005). Modern molecular and computational tools from population 
genetics may help to better understand and fight the burden of drug resistant malaria. 
This promise has gradually been fulfilled and the benefits have already been substantial, 
for instance modern molecular methods showed that resistance to several anti malarial 
drugs had, contrary to expectation, a very small number of independent origins (Roper 
et ah, 2004; Wootton et ah, 2002).
While there is a urgent need to develop new methods to analyse the ever increasing 
amount of data, especially with the advent of next generation sequencing, there is also 
the need to understand how existing population genetics approaches are robust to re­
alistic biological assumptions of P. falciparum biology and epidemiology. P. falciparum 
genetics (Tuteja, 2007) differs significantly from standard population genetics models 
(e.g. standard population genetics models assume diploidy, whereas P. falciparum has 
both a asexual haploid and sexual diploid phase) and epidemiological considerations, 
for instance control interventions (like treatment with antimalarials or the use of bed 
nets) potentially impose changes on the size of the population, whereas most population 
genetics models assume either constant sized or infinite populations. Are existing widely 
used methods robust to malaria assumptions? How can we improve the reliability of 
results? Should we simply avoid some approaches? Here we will try to answer some 
of these questions for methods used for discovery of loci under selection (which can 
be used, e.g., to find genes important in drug resistance) and early detection of popu­
lation bottlenecks (important to assess the impact of malaria control and elimination 
measures).
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Here we also address the relationship between theoretical and empirical work. Most 
modern theoretical work has a focus on prediction, for instance the prediction of the 
impact of drug deployment policies (Maude et al., 2009; Boni et al., 2008) or vaccination 
strategies (Smith et al., 2006) which has minor applicability to the interpretation of 
existing (past-related) empirical data. On the other hand it is not uncommon to find 
empirical researchers who seem to put little emphasis on the importance of theoretical 
findings. The approach followed here tries to bridge theoretical and empirical work 
by assessing the impact of, sometimes unconscious, theoretical assumptions made in 
empirical research work. One example should clarify this: Existing empirical population 
genetics studies normally assume that association (measured by Linkage Disequilibrium 
- LD) between loci involved in drug resistance should be positive, therefore linkage 
equilibrium between those loci is seen as a “negative result”. Such assumption is based 
on previous sound theoretical work (Dye and Williams, 1997) but more recent findings 
about the mode of action between genes involved in drug resistance of Sulfadoxine- 
Pyrimethamine (SP), where 2 genes are involved in drug resistance but one, dhfr is 
more important than the second dhps (Olliaro, 2001) require a revision of the idea of 
equal importance of loci. This can have, and indeed we will show that it has, impact on 
the expectation of positive LD.
The questions addressed in this thesis fall in two broad categories:
1. How do realistic models of the spread of drug resistant P. falciparum influence 
widely used population genetics measures (e.g. linkage disequilibrium)? Can 
more realistic population genetics models of drug resistance provide useful insights 
to better design drug deployment policies, curbing the spread of drug resistant 
malaria?
2. Can existing methods to detect selection and change in population size be ap­
plicable to P. falciparum malaria and its vectors? Can we improve experimental 
design in order to better estimate the impact of control and elimination policies 
on parasite genetic variability?
The first set of questions will be addressed by developing novel population genetics 
models of P. falciparum drug resistance. These models improve the field of malaria drug 
resistance modeling by accounting for epistasis relationships between drug resistance 
genes, selection heterogeneity (e.g. immunity or treatment compliance) and multiple 
simultaneous drug deployments. The work done to address these questions is imminently 
theoretical though great care was put on assuring that these novel models are realistic 
(i.e. can qualitatively approximate known field/empirical results).
In order to answer the second set of questions we will leverage existing knowledge in 
the field of conservation genetics. As it will become clear some of the existing methods 
are developed in the context of conservation (i.e. small population sizes) and it is not
3guaranteed that the parasitology community has even absorbed some more basic results 
of population genetics associated with the use of some of these methods. Indeed, it is 
fundamental to disseminate some very robust results from population genetics, which, 
if not correctly applied (and we will demonstrate that incorrect applications do exist) 
will cause misleading interpretations of field data resulting from control interventions. 
We will also discuss the implications of using methods and approaches that were mostly 
developed in the context of management and protection of species (i.e. conservation) 
versus a context of control, elimination and ultimately, eradication (parasitology). The 
work done to address these questions has a clear empirical approach: it is geared towards 
empirical data (re) analysis and provides constructive criticism with regards to commonly 
use data analysis strategies.
This thesis is split into three parts, one solely dedicated to the first set of questions 
(i.e. modeling the spread of drug resistance to understand its impact on data analy­
sis and control interventions), and two dedicated to the second set of questions: one 
supporting and evaluating methods for selection detection (specifically FsT-outlier ap­
proaches) and one dedicated to evaluating effective population size (JVe) estimators. For 
the first two parts all the methods (software) used were published in scientific journals, 
therefore each software application will have a dedicated chapter. Parts two and three, 
though they are dedicated to evaluating methods to analyse empirical data suffer from 
the lack of real P. falciparum datasets to analyse, such unfortunate event has had a 
strong impact on the development of this thesis and will be further discussed in this 
introduction and in the conclusion. We now present each part of this thesis starting 
with a small overview on its structure.
This thesis is presented in paper format (i.e. as a series of related papers), the 
majority of them already published in scientific journals. This imposes some constraints 
on this thesis structure namely:
1. The size, organisation and content of each chapter/paper varies substantially, 
mostly because of requirements imposed by journals on size and structure and 
on content by editors and reviewers. The most extreme example is probably chap­
ter 2 describing ogaraK, the software application implementing our population 
genetics models of drug resistant malaria: Application notes are limited to two 
pages on the journal Bioinformatics and as such most of the content formally 
describing the model was made available in the supplement (appendix A in this 
thesis).
2. Some repetition between manuscripts is unavoidable as standalone papers have to 
have enough information, especially on methods. This is particularly clear when 
comparing the supplements of chapters 2 (ogaraK) and chapter 3 (Environmental, 
pharmacological and genetic influences on the spread of drug resistant malaria) 
whose supplements (appendixes) are, respectively, A and B.
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3. The logical order presented here (method/software chapters preceed analysis chap­
ters) does not correspond to publication order. For instance, chapter 2 (method) 
references Antao and Hastings (2011b) (research), but the research chapter (ac­
cepted paper on Proc Roy Soc B) only points to the software web page, not to 
Antao and Hastings (2011a) as the software manuscript was published later.
4. Some of the content was imposed by reviewers (including title changes). This issue 
is further discussed in the conclusion.
5. Minor changes were made to the papers published, most notably, typos where 
corrected and references to funding sources were removed.
Several chapters reflect software applications (all of them published in scientific jour­
nals). The reader is encouraged to use and test the applications, all of them freely 
available online. The source code for the applications is also freely available and can be 
inspected and copied by anyone subject to the GNU public license version 3.
We present now an overview of each part of this thesis.
1.1 Population genetics models of drug resistant P. 
falciparum
This part is sub-divided in two: one chapter describing the software used to make 
simulations and three chapters with analysis based or inspired on the simulator results.
Software
In order to simulate realistic population genetics models of P. falciparum accounting 
for drug resistance a new simulator will be developed. All known previous studies of 
P. falciparum population genetics never made the software (either full applications or 
mathematical models developed using computer algebra systems) available. As far as 
we know only one epidemiological simulator (non population genetics based) of malaria 
is made publicly available (Smith et al., 2008)1. One of the objectives of this work was 
to do the computational part as transparent and replicable as possible, making all used 
software artifacts available for public inspection and re-use. While the best solution 
would be to use already existing general-purpose individual forward-time population 
genetics simulators, these were not suitable to simulate malaria for two main reasons:
1. As individual simulation is impossible from a computational performance perspec­
tive (individual-based simulation becomes prohibitive considering the number of 
different parasites, which can rise to 1012 inside a human).
during the course of this thesis, the author participated in the development of this other simulator, 
though no content related to that effort is included here.
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2. No existing simulator is capable of simulating a genome that has both a haploid 
and diploid phase over its life-cycle. The above limitations apply even to the most 
flexible population genetics simulator, simuPOP (Peng and Kimmel, 2005).
Therefore we will design and implement ogaraK (Antao and Hastings, 2011a) (chap­
ter 2), a population genetics simulator designed for malaria. ogaraK is originally based 
on the model presented in (Hastings, 2006), extended to support (Antao and Hastings, 
2011b) and simulates the frequency of infection genotypes (not individual parasites): it 
is thus a model of infinite-sized populations (i.e., no drift). It will allow us to simulate, 
among other factors, the genetic interactions leading to resistance, different human en­
vironments (e.g. untreated humans, treated humans with no immunity, treated humans 
with semi-immunity) and the multiplicity of infection (influencing inbreeding) inside 
each human. OgaraK can simulate different drug deployment policies like rotation of 
drugs over time (imposing different selection pressure over time) or multiple-first line 
therapies (Boni et ah, 2008) (imposing different selection pressures to different infec­
tions). As a side effect, unrelated to P. falciparum biology, and as ogaraK will be able 
to model flexible epistasis (genetic interactions) and different patterns of selection pres­
sure, it can also be used to simulate the Red-Queen Hypothesis and spacial selection 
heterogeneity used in sex-theory (Otto, 2009).
Research
Using ogaraK we will investigate in (Antao and Hastings, 2011b) (chapter 3, appendix 
B) how epistasis, inbreeding, selection heterogeneity and multiple simultaneous drug 
deployments interact to influence the spread of drug resistant malaria. We will study how 
different human “environments” within which treatment may occur (such as semi- and 
non-immune humans taking full or partial drug courses) influence the genetic interactions 
between parasite loci involved in resistance. We will discuss how the rate of spread varies 
according to different malaria transmission intensities, why resistance might stabilise at 
intermediate frequencies and also identify several factors that influence the decline of 
resistance after a drug is removed. We will try to understand how different transmission 
intensities might bias the conclusions of studies based on clinical outcomes with regards 
to the spread of resistant parasites. We will also study the importance of epistasis and 
LD in understanding the impact of transmission reduction measures on the relationship 
between prevalence and frequency of resistance. Most unfortunately we suggest that the 
potentially positive impact of transmission control measures on the spread of resistance 
might be overestimated. This chapter and supplement will also offer a brief introduction 
to the topic of modeling the spread of drug resistance malaria along with references to 
pertinent literature.
Current malaria drug deployment policies recommend using a single first-line therapy 
for most clinical malaria cases but recent research has suggested that using multiple first-
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line therapies (MFT) might yield a better clinical outcome by delaying the emergence 
and spread of drug resistance. In chapter 4 we will compare different drug deployment 
policies using several realistic parasite population genetics models of the spread of drug 
resistant malaria. We will account for differences in modes of genetic interaction, pro­
portion of infected humans treated, immunity, treatment compliance and the impact of 
transmission intensity on inbreeding. We will try to understand if MFT policies can de­
lay the spread of drug resistance, including multiple resistant genotypes. Our work will 
stress the importance of compliance with treatment guidelines as incomplete treatment 
can potentially increase the spread of resistant infections. We will also study how asso­
ciation between loci, measured by linkage disequilibrium, is fundamental to understand 
the dynamics of spread of resistance and the interactions between genes.
Finally, using the acquired knowledge in the previous three chapters, we will briefly 
comment (Antao, 2011) (chapter 5) on the importance of evolutionary biology in the 
context of drug deployment policies. We will discuss existing proposals of using sub­
curative antimalarial drug treatment and also the possible negative impact of elimination 
policies on the spread of drug resistance.
1.2 Fsx-outlier selection detection and discovering genes 
involved in drug resistance
In order to help evaluate the performance of FsT-outlier approaches we will develop 
two applications to reliably apply the method of Beaumont and Nichols (1996) to both 
co-dominant and dominant markers. The initial objective was to use these applications 
with P. falciparum data. As such data was not available we then will produce an 
empirical study using human data and a theoretical study using simulated data created 
with ogaraK and simuPOP (Peng and Kimmel, 2005). In order to access human data 
we also developed an application to access human data on the public HapMap project 
(International HapMap Consortium, 2007).
Software
We will develop two applications implementing the FgT-outlier method in (Beaumont 
and Nichols, 1996) commonly used to detect loci selection. The applications are, LOSI- 
TAN (Antao et ah, 2008) (chapter 6) for co-dominant markers and Mcheza (Antao and 
Beaumont, 2011) (chapter 7) for AFLPs. Our implementations will extend the original 
ones (FDIST and DFDIST, Mark Beaumont, unpublished) by including an easy to use 
interface, multitest correction and a more reliable approximation of nuisance parameters.
We will also implement interPopula (Antao, 2010) (chapter 8) a library to access the 
HapMap dataset (International HapMap Consortium, 2007) which includes millions of 
SNP polymorphisms from 11 different human populations. The HapMap dataset, by its
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size (in terms of number of markers, populations and individuals) and the amount of 
existing knowledge about the human genome allows to test existing population methods 
like the Fst selection detection method against empirical data and not just synthetic 
datasets. As we know many loci in the human species that are under selection in certain 
populations (e.g. Lactase) it is possible to evaluate a selection method against a species 
and a genome with a (partially) known selection history.
Fst evaluation
As datasets for P. falciparum were not available we will study the behaviour of Fst 
with one empirical dataset (the public human database of HapMap) and one simulated 
dataset created with ogaraK and simuPOP.
We will study, in chapter 9 the performance of Fst with single nucleotide polymor­
phisms (SNPs) which are increasingly used to identify genes under selection. However, 
researchers often genotype only a few SNPs per gene, so we quantify the sensitivity of 
using only a few SNPs in a gene to identify high FsT-outlier genes using large empirical 
data sets from humans in the HapMap project. We will try to understand if Fst can 
detect genes under selection and how many SNPs are necessary to detect it. We will 
research the impact of genotyping more than one SNP per gene on the false positive 
rate. We will discuss the consequences of current genotyping policies (sampling a single 
SNP per gene is not uncommon for many species) and the potential benefits of using 
next generation sequencing (i.e. more markers across the genome and also per gene).
As Plasmodium falciparum malaria is subject to artificial selection from antimalarial 
drugs which select for drug resistant parasites, detecting which genes are under selection 
can provide fundamental insights to help containing the spread and the burden of drug 
resistant malaria. We will evaluate, using computational simulations, the performance 
of temporal Fst to reliably detect genes under selection. We will try to understand 
in what conditions temporal Fst is more powerful (e.g. transmission intensity or time 
between samples). We will try to understand the scope of applicability of temporal Fst 
in several relevant epidemiological scenarios ranging from the impact of transmission 
seasonality (i.e. wet and dry seasons) to scanning for the genes involved in Artemisinin 
resistance. We will also discuss the appropriate sampling strategies (i.e. the necessary 
number of individuals to be sampled) to have a reliable estimation of Fst-
1.3 Effective population size and assessing the success of 
control and elimination measures
In an era where malaria control and elimination measures are being scaled up, it is 
important to have measures of success in terms of parasite genetic diversity and effective 
population size. It is indeed fundamental to assess, as soon as possible, if such measures
8 CHAPTER 1. INTRODUCTION
are having a positive impact in reducing parasite population size and diversity. We will 
start by evaluating the ability to rapidly detect a population decline using two widely- 
used contemporary effective population size estimators. As such estimators are usually 
studied in conservation genetics settings (with low Ne) our first analysis was still done 
using low Ne (i.e. not applicable to P. falciparum) as a baseline for further studies. 
We will then study Ne estimators in the context of disease vectors: disease vectors 
may have high Ne and are normally subjected to seasonality patterns (usually high 
population numbers in wet seasons, low population numbers in dry seasons). Finally 
we will discuss the usage of Ne estimators in the broad context of parasitology (i.e. 
considering both parasites and vectors), our discussion, though not novel, will point out 
several misunderstandings in recent parasitology research regarding Ne. We will now 
present all researched issues in more detail.
To evaluate the ability to rapidly detect a population decline we will compare in 
Antao et al. (2011) (chapter 11 with supplemental data available on the CD) a two- 
sample temporal method (Krimbas and Tsakas, 1971) and a one-sample method based 
on LD (Hill, 1981; Waples, 2006; Waples and Do, 2008). We will use simulated data 
representing a wide range of population sizes, sample sizes, and number of loci. For this 
simulation exercise we will use an existing forward-time individual based population 
genetics application (Peng and Kimmel, 2005) and we will simulate a small number 
(below 500) of diploid individuals. We will study how many generations are required 
to detect a bottleneck after such an event happens. We try to understand how many 
markers (SNPs and microsatellites) and how many individuals need to be sampled in 
order to have a reliable estimation of Ne. We will also study the relative importance of 
sampling more individuals or more loci. We will provide some guidelines regarding the 
design of studies targeted at monitoring population declines.
We then discuss, in chapter 12, the application of contemporary effective population 
size estimators to insect disease vectors. Ne in disease vectors can have two distin­
guishing features from common scenarios considered in most Ne studies: high effective 
population size (above 500) and seasonal population fluctuations (wet- and dry-season). 
We will research the impact of high Ne on the precision of estimators and the need to 
increase sampling sizes to cope with loss of precision due to high Ne. We will also try 
to understand the impact of seasonality on estimator performance.
We then discuss, on chapter 13 and appendix C the interpretation of effective popu­
lation size estimators and measures of heterozygosity in the context of recent empirical 
studies done with P. falciparum (e.g Gatei et al., 2010; Anderson et al., 2000a; Iwagami 
et al., 2009; Susomboon et al., 2008) and disease vectors (e.g. Lehmann et al., 1998; 
Simard et al., 2000; Pinto et al., 2002), we will discuss the validity of some observations 
made in such research and try to understand if observations are consequence of control 
interventions or simply a methodological artifact. We will re-interpret recently published
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studies in the light of realistic assumptions about the behaviour of heterozygosity and 
Ne estimators.
While the software to do the simulations required for this part is not published, its 
most complex parts are publicly available inside the software package newAge (http: 
//popgen.eu/soft/newAge). For this part, we essentially use the standard approach 
for most research based on computational simulations: we simply describe our method­
ological approach on each chapter.
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ogaraK: A population genetics simulator
for malaria
Tiago Antao and Ian M. Hastings 
Abstract
Motivation: The evolution of resistance in Plasmodium falciparum malaria 
against most available treatments is a major global health threat. Population ge­
netics approaches are commonly used to model the spread of drug resistance. Due 
to uncommon features in malaria biology existing forward-time population genetics 
simulators cannot suitably model Plasmodium falciparum malaria.
Results: Here we present ogaraK, a population genetics simulator for mod­
elling the spread of drug resistant malaria. OgaraK is designed to make malaria 
simulation computationally tractable as it models infections, not individual para­
sites. OgaraK is also able to model the life cycle of the parasite which includes both 
haploid and diploid phases and sexual and asexual reproduction. We also allow for 
the simulation of different inbreeding levels, an important difference between high 
and low transmission areas and a fundamental factor influencing the outcome of 
strategies to control or eliminate malaria.
Availability: OgaraK is available as free software (GPL) from the address 
http://popgen.eu/soft/ogaraK.
2.1 Introduction
Malaria is a major public health concern, as one third of the human population is esti­
mated to be exposed to the threat of the most virulent species, Plasmodium, falciparum. 
Antimalarial drug resistance has emerged as one of the major challenges facing malaria 
control. Drug resistance became widespread to most first line therapies and treatment 
failures are now being observed for their replacements, Artemisinin Combination Ther­
apies (ACTs) (Dondorp et ah, 2009). Mathematical and computational models of the 
spread of drug resistance are an important tool to understand the emergence and spread 
of drug resistance.
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Most mathematical and computational modelling of malaria have been based on epi­
demiology (e.g. Koella and Antia (2003)) or population genetics (e.g Hastings (1997)), 
though complex simulation models have also been developed (Smith et ah, 2008). While 
many forward-time population genetics simulators do exist (e.g. Peng and Kimmel 
(2005)), they are not suitable to model malaria, therefore all existing computational 
studies using a population genetics approach are based on applications and scripts de­
veloped for each study and not directly subjected to peer review or publicly available.
Standard individual-based forward-time population genetics simulators are not suit­
able to model P. falciparum biology for two main reasons: (i) population size in malaria 
can rise up to 1012 parasites per human host, making it computationally infeasible to 
simulate all individuals and (ii) P. falciparum life cycle includes both haploid and diploid 
phases and most existing simulators do not allow for the modelling of different genotypic 
structures over time. In order to address these issues we developed ogaraK, a popula­
tion genetics simulator designed to study the spread of drug resistance in P. falciparum 
malaria.
2.2 Approach
OgaraK features and limitations are based in P. falciparum population biology in the 
presence of treatment pressure. OgaraK was designed to study the spread of existing 
drug resistance and it can be used to understand how recognised important factors in 
malaria epidemiology (e.g. different transmission intensities) influence the spread of 
resistance and also to compare different drug deployment policies.
Drug treatments can be modelled as a form of selection pressure over the parasite 
population. OgaraK is able to simulate a wide variety of selection pressures modelling 
both temporal and spacial selection heterogeneity. Temporal heterogeneity is a proxy 
for a policy of drug rotation while spacial heterogeneity approximates the use of multiple 
first line drugs.
A wide range of epistasis modes of loci involved in drug resistance are also supported. 
While most existing theoretical research assumes that parasites require all mutations 
(full epistasis) related to a drug in order to resist treatment, ogaraK is able to model 
other epistasis modes, like duplicate gene function or asymmetry. These modes reflect 
existing empirical evidence for some drugs (e.g. Chloroquine or SP) where genes vary 
in their importance to confer resistance (Olliaro, 2005). Multiple epistasis modes are 
also useful to model poor drug compliance or host immunity: A weaker epistasis mode 
among drug resistance loci is enough to confer resistance in humans with no acquired 
immunity or who take an incomplete treatment; in humans who take a full course or 
have acquired partial immunity against malaria, a stronger epistasis mode is required 
to resist treatment.
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Multiplicity of infection (MOI) has been recognised as one of the factors that dif­
ferentiate between high and low transmission areas of malaria. MOI affects the spread 
of resistance, recombination and population inbreeding levels as the mating alternatives 
on the obligatory sexual phase in the mosquito are limited by the number of genetically 
different parasites ingested in a blood meal. OgaraK allows the simulation of different 
inbreeding levels, allowing for a varying MOI across simulations and also, within each 
simulation, simulating individuals with different MOL
Individual based simulation is replaced by exhaustive enumeration of all possible 
combinations of infection types (each infection having a specific genotype). This method 
was first used in Hastings (2006) and comparative analysis between results derived from 
epidemiological simulations and this approach show consistent results (Boni et ah, 2008).
The main purpose of the simulator is to study the spread of resistance but we also 
support mutation therefore allowing the study of de novo emergence. In the case of 
most antimalarials (e.g. Chloroquine or SP (Wellems and Plowe, 2001)) mutation is a 
rare event. Furthermore resistance already exists to most drugs, even Artemisinin based 
therapies (Dondorp et al., 2009), hence our focus on spread of existing mutations.
In order to study simultaneous usage of multiple ACTs which might share one re­
sistance gene (as they all have an Arteminisin derivative as principal component) we 
also provide models of multi-drug resistance where part of the resistance mechanism is 
shared among all drugs, A “standard” model where all drugs involved have unrelated 
loci is also available.
OgaraK has an easy to use interface which can be run from the web as a Java 
Webstart application. The code is available and can be also linked as a library or used 
in batch mode.
Results are exported in a text format (reporting the frequency of all genotypes over 
time) and also made available in the widely used Genepop (Rousset, 2008) format. 
Simple scripts for data analysis are provided using Biopython (Cock et al., 2009), but 
these mainly serve as examples as it is expected that most analysis will be done using 
standard population genetics packages owing to the ability to export data in Genepop 
format.
A supplement (appendix A) is included where the model is detailed and where ex­
ample applications and a user manual are also supplied.
2.3 Discussion
OgaraK is able to easily simulate most existing population genetics models studying 
the spread of drug resistance in malaria. It is made available as a public framework 
which can be used to evaluate new models or re-use old ones for new analysis. For 
instance it was already used and tested to research the impact of epistasis on linkage 
disequilibrium between loci involved in drug resistance (Antao and Hastings, 2011b) and
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can also simulate, from a population genetics perspective, promising drug deployment 
strategies (Boni et al., 2008).
We focused on modelling how resistance spreads and not de novo emergence, given 
that emergence is a rare event and that it is already widespread to most drugs therefore 
making the management of existing resistance a major concern. Nonetheless the ogaraK 
supports mutation, therefore permitting the study of de novo emergence.
While ogaraK was developed with malaria modelling in mind, epistasis and spacial 
and temporal selection patterns have clear parallels with some known models in sex 
theory (Otto, 2009), as temporal selection heterogeneity is the fundamental concept 
behind the Red-Queen Hypothesis and spacial selection heterogeneity has also been 
proposed as one explanation for sex and recombination. OgaraK can therefore be used 
to easily simulate and test some models relevant to sex theory.
OgaraK can serve as a framework to more easily evaluate drug deployment policies 
and help enhance the understanding of fundamental variables underlying the spread of 
drug resistant malaria.
Three
Environmental, pharmacological and 
genetic influences on the spread of drug
resistant malaria
Tiago Antao and Ian M. Hastings 
Abstract
Plasmodium falciparum malaria is subject to artificial selection from antimalar- 
ial drugs which select for drug resistant parasites. We describe and apply a flexible 
new approach to investigate how epistasis, inbreeding, selection heterogeneity and 
multiple simultaneous drug deployments interact to influence the spread of drug 
resistant malaria. This framework recognises that different human “environments” 
within which treatment may occur (such as semi- and non-immune humans tak­
ing full or partial drug courses) influence the genetic interactions between parasite 
loci involved in resistance. Our model provides an explanation for how the rate 
of spread varies according to different malaria transmission intensities, why resis­
tance might stabilise at intermediate frequencies and also identifies several factors 
that influence the decline of resistance after a drug is removed. Results suggest 
that studies based on clinical outcomes might overestimate the spread of resistant 
parasites, especially in high transmission areas. We show that when transmission 
decreases, prevalence might decrease without a corresponding change in frequency 
of resistance and that this relationship is heavily influenced by the extent of linkage 
disequilibrium between loci. This has important consequences on the interpreta­
tion of data from areas where control is being successful and suggests that reducing 
transmission might have less impact on the spread of resistance than previously 
expected.
Malaria is a major public health concern for the one third of the human population 
estimated to be exposed to the threat of the most virulent species, Plasmodium falci­
parum, with an estimated number of clinical episodes ranging from 300 to 660 million per 
annum (Snow et al., 2005). There is no effective vaccine for this species, and infection
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is controlled by insecticides targeted at vector mosquito species, and treatment by anti- 
malarial drugs. As might be expected, insecticide- and drug-resistance rapidly evolved 
and spread (Olliaro, 2005; Rogers et al., 2009; Dondorp et al., 2009). This manuscript 
focuses on the dynamics of antimalarial drug resistance although the approach we de­
velop herein may be generalised to other control agents such as insecticides, herbicides 
and anthelmintics.
Plasmodium parasites are haploid and reproduce asexually in humans. Humans 
often contain several genetically distinct P. falciparum clones acquired from different 
mosquito bites; the number of clones in a human is called the multiplicity of infection 
(MOI). MOI is a proxy for transmission intensity as higher transmission intensity in­
creases MOI due to repeated sequential infection (Anderson et al, 2000a). P. falciparum 
parasites undergo an obligate sexual phase in the mosquito before being transmitted back 
into humans as haploids. Mating between gametes from the same clone (selfing) involves 
sexual recombination between identical haploid genotypes resulting in clonal reproduc­
tion. Mating between different clones (outcrossing) results in genetic re-assortment of 
P. falciparum genes. Mating can only occur between clones transmitted from the same 
human, hence the rate of outcrossing depends on the MOI. Field estimates reveal that 
outcrossing is relatively common and can occur in more than 50% of matings (Mzila- 
howa et al., 2007). It has been postulated that clones within a human compete for 
resources and transmission and that removal of drug-sensitive clones following treat­
ment allows the surviving resistant clones to garner additional resources and to increase 
their transmission (Hastings, 1997; Hastings and D’Alessandro, 2000), an effect recently 
termed “competitive release” (Wargo et al., 2007); the higher the MOI the larger the 
potential effect of competitive release. MOI is therefore fundamental in the dynamics 
of the spread of resistance as it increases the rate of sexual recombination (outcrossing) 
which allows parasites with different resistance profiles to mate and also breaks down 
the association between alleles encoding drug resistance.
Mathematical models play an important role in understanding the forces driving 
resistance and in designing policies to minimise the rates at which resistance arises and 
spreads (e.g. Boni et al. (2008); Yeung et al. (2004)). Their importance arises for three 
main reasons: Firstly, it is near-impossible to address this issue empirically as anti- 
malarial drug deployments occurs on country - and even continent-wide scales - so the 
effects of local differences in deployment strategies are likely to be swamped by immigra­
tion of resistance driven by national deployment policies (Anderson and Roper, 2005). 
Secondly, it is difficult to generalise the lessons learnt from individual drugs because 
their dynamics are likely to differ substantially depending on the genetic basis of resis­
tance and the degree of resistance they encode: for example resistance arises incredibly 
rarely to Chloroquine (CQ) and Sulfadoxine-Pyrimethamine (SP) (Anderson and Roper, 
2005), the two drugs so far deployed worldwide, but very easily to other drugs such as 
Atovaquone (Looareesuwan et al., 1996) and Pyrimethamine (Plowe et al., 1997), and
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at intermediate rates - apparently due to gene duplications rather than point mutations 
- to Mefloquine (Price et ah, 2004). In addition, high-level resistance to Atovaquone 
occurs in a single mutational step, while resistance to SP requires sequentially accumu­
lation of mutations at several codons in two genes (Sibley et ah, 2001). Thirdly, basic 
population genetics predicts that the alleles encoding resistance increase in frequency 
exponentially so the most important dynamics occur when resistance is at undetectably 
low frequencies meaning there are few empirical data on the process.
All models make simplifying assumptions but the primary one we relax and inves­
tigate here, is the assumption that infections bearing a “resistant” genotype always 
survive drug treatment. Empirical evidence shows that the fate of a “resistant” infec­
tion, survival or death, is much more probabilistic and depends critically on the human 
“environment” within which drug treatment and selection occurs. Human immunity 
plays a huge role and drugs may be highly effective in semi-immune adults but highly 
ineffective in non-immune infants (Langhorne et ah, 2008; Rogerson et ah, 2010). Sim­
ilarly, “sensitive” infections may survive treatment in humans where drug levels are 
sub-optimal either through poor compliance with the drug regimen or because their 
pharmacogenetics means that drugs are poorly absorbed or rapidly eliminated (Guerin 
et ah, 2002), while “resistant” infections may be eradicated in humans with high drug 
levels. It is trivial to incorporate these effects into a single locus model (we simply assign 
a probability of survival in a treated individual) but dynamics become more realistic 
and complex in situations where two (or more) loci are required to encode resistance.
When more than one locus is involved in drug resistance it is important to quan­
tify the association between resistance alleles at different loci. Linkage Disequilibrium 
(LD), the non-random association of resistance alleles at different loci, has been shown 
to be a critical factor influencing the rate of spread of resistance (Dye and Williams, 
1997). Many genetic models have ignored LD and those that have measured it assumed 
complete epistasis between the mutations (i.e. only infections with mutations at all 
resistance loci would survive treatment) with the result that LD was always positive be­
tween mutations. We allow three different models of parasite genetic interaction: “full 
epistasis” where, as before, resistant mutation at both loci are required for the infec­
tion to survive; “asymmetric epistasis” where one locus has more impact on survival so 
resistance is determined primarily by that locus irrespective of the allele at the second 
locus; “duplicate gene action” where a resistant mutation at either locus will allow sur­
vival. It is axiomatic among geneticists that the mode of gene action is not fixed but 
depends on the environment in which they are expressed and this is what we address 
here: infections encountering “strong” selection environments (humans with high levels 
of immunity and/or drug) may require full epistasis to survive, while as the environ­
ment becomes “weaker” (less immunity and/or drug) then asymmetric and eventually 
duplicate gene action will best describe the fate of “resistant” mutations. These modes 
of selection are summarised on Table 3.1.
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Resistance profile Epistasis mode
Locus 1 Locus 2 Full Asymmetric DGF
Sens Sens Cure Cure Cure
Sens Res Cure Cure Resistance
Res Sens Cure Resistance Resistance
Res Res Resistance Resistance Resistance
Table 3.1: The outcome of human drug treatment according to genetic modes of resis­
tance. Cure occurs if all loci are sensitive. A single mutation at either loci is enough 
to confer resistance with duplicate gene function (DGF). In asymmetric epistasis, the 
first locus is necessary and sufficient to confer resistance. Mutations at both loci are 
necessary with full epistasis. Different environments can be present simultaneously and 
determine the mode of action: weaker epistasis modes (DGF or asymmetry) might be 
applicable for individuals with poor drug compliance or who are non-immune, while 
immune individuals or high drug dosage might require full epistasis. Asymmetric epis- 
tatis is only relevant in multi-environment model, where another epistasis mode is also 
present.
Herein we present a deterministic population genetics model of the spread of drug 
resistant P. falciparum using computational simulations to investigate how these key 
factors affect the spread of drug resistance (i.e. selection heterogeneity, number of 
resistance loci) within the context of local malaria epidemiology and local drug policies 
(for example, whether different drugs are co-deployed to reduce selection for resistance 
or whether they are rotated such that one is used until it fails and then replaced). The 
model presented is sufficiently general to study many different parameters but we will 
present results for scenarios of most practical importance and realism for P. falciparum 
population biology and drug deployment strategies. Practical policy considerations are 
discussed as we try to understand the implications of control and elimination measures 
for the spread of resistance.
3.1 Model and methods
We make the following assumptions in line with most previous modelling efforts: that 
clones co-infecting the same human are genetically unrelated; that clones have equal 
infectivity and mate at random so that if there are n clones in a human then selfing 
rate is ^ and outcrossing rate 1 — and that competitive release occurs. The spread 
of drug resistance is tracked using a time-scale of parasite generations (a generation is 
a parasite reproduction cycle from host to host which is likely to be around 5 per year). 
Loci are assumed to be physically unlinked, as is the case for loci known to be involved 
in malaria drug resistance (Osman et al., 2007), and each locus can have two alleles: 
resistant and sensitive. A resistant allele will incur a fitness penalty in the absence of
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the drug and all mutations are assumed to have the same fitness penalty. Genotypes 
with multiple mutations suffer a multiplicative fitness penalty.
Development of drug resistance can be seen as a two-step process, the de novo emer­
gence of the resistant mutation and its subsequent spread. Existing research shows that, 
for most drugs, resistance emerged extremely infrequently (Wellems and Plowe, 2001), 
the notable exceptions being Atovaquone (Vaidya and Mather, 2000) and Pyremethamine 
(Price et al., 2004; Roper et al., 2004). Understanding the appearance of de novo mu­
tations is an important topic, discussed elsewhere (e.g. White and Pongtavornpinyo 
(2003); Pongtavornpinyo et al. (2009)), so we assume that resistance alleles already ex­
ist at very low frequencies at the onset of the simulation and focus on understanding 
their subsequent spread.
The model is designed to study the spread of drug resistant alleles subjected to 
different drug deployment policies and a mathematical formalisation of the model is 
provided in the supplement (appendix B). There are evidently a very large number of 
parameter combinations that can be explored. Here we concentrate on seven illustrative 
scenarios, named and described below.
Single locus A single drug is deployed with resistance encoded at a single locus. There 
are two human environments: treated and untreated individuals. Resistant par­
asites survive in both environments (but may pay a fitness penalty in untreated 
humans) while sensitive survive in untreated humans but are cleared in treated. 
This is obliviously the simplest case, explored elsewhere, but is included as a base­
line simulation.
Pull epistasis A single drug is deployed with resistance encoded by two loci. Two en­
vironments are present, untreated and treated, and survival in the treated humans 
requires resistance at both loci (i.e. full epistasis).
Duplicate gene function (DGF) A single drug is deployed with resistance encoded 
by two loci. Two environments are present, untreated and treated, with selection 
in the latter sufficiently weak that resistance alleles at either locus can encode 
survival.
Asymmetric epistasis A single drug is deployed where resistance is encoded by two 
loci. Two environments are present, untreated and treated. The first locus is 
necessary and sufficient to encode resistance in treated individuals and the second 
is irrelevant. This scenario is therefore functionally identical to the single locus 
scenario, but asymmetric epistasis serves as a useful model of resistance when 
used in more complex and realistic environments, in conjunction with full epista­
sis. Asymmetric epistasis mimics SP resistance where the dhps resistance allele 
involved in the de novo folate production pathway cannot fully replace the dhfr
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gene involved in exogenous folate usage. This model is also applicable for the 
asymmetric importance of supplementary mdr gene to art in Chloroquine based 
resistance (Olliaro, 2001).
Full epistasis + DGF A single drug is deployed with resistance encoded by two loci. 
There are three environments: untreated, well-treated (treatment is sufficiently 
effective that full epistasis is required for survival) and poorly-treated (treat­
ment is sub-optimal so that resistance alleles at either locus can encode survival). 
The DGF environment can model non-immune individuals, incomplete treatment 
courses or any other situations where the parasite does not need all mutations 
to survive. The full epistasis environment models semi-immune individuals, com­
plete treatment courses or other events which require the parasite to have both 
mutations in order to resist treatment.
SP-based (Full and asymmetric epistasis) A single drug is deployed with resis­
tance encoded by two loci. There are three environments: untreated, well-treated 
(treatment is sufficiently effective that full epistasis is required for survival) and 
poorly-treated (treatment is sub-optimal so that resistance alleles at the more im­
portant locus can encode survival). The name of this scenario comes from the drug 
SP where resistance may be encoded by alleles at dhfr alone or, in well-treated 
individuals, may require resistant alleles at both dhfr and dhps loci.
Two drugs Two drugs are deployed separately (i.e., the parasites never encounter both 
simultaneously in the same generation) with 2 loci for each drug. There are five en­
vironments: untreated, well-treated with drug 1, well-treated with drug 2, poorly- 
treated with drug 1, poorly-treated with drug 2. Full epistasis is required for 
survival in well-treated individuals while asymmetrical epistasis determines sur­
vival in poorly-treated ones.
In scenarios with more than one treatment environment (i.e. the last three scenarios) 
it is assumed that there are equal proportions of each environment among the treated 
infections.
3.2 Results
The following outcomes are possible for each locus in a simulation: (i) one allele (sensi­
tive or resistant) tends towards fixation, or (ii) allele frequencies stabilise at intermediate 
levels. We opt to describe the dynamics of the fully sensitive form (i.e. with no muta­
tions) in order to simplify the presentation of results.
Figure 3.1 plots the frequency of sensitive alleles together with their rate of change 
under the one-locus scenario. The rate of change is dependent on the MOI. During
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the initial phases of spread, higher MOI entails a faster spread of resistant profiles, but 
this process is reversed when resistant parasites approach fixation. This reveals that the 
speed of spread is frequency dependent and consequently, that the total time to resistant 
fixation is a bad proxy of the speed of spread at low frequencies. This occurs because 
the total time in most cases is more influenced by what happens at high resistance 
frequencies rather than the dynamics at lower frequencies; it is the latter part of the 
dynamics, when resistance is starting to spread and cause drug treatment failures, that 
have the most implications for drug policy choice. Understanding the spread of resistance 
at important frequencies therefore requires analysis of the whole behaviour of the model 
and not just the time until the final outcome.
Frequency and increase rate of sensitive parasites
Figure 3.1: The frequency of sensitive parasites and its rate of change computed as the 
proportionate change per generation. The frequency of sensitive genotypes is depicted 
in dashed lines and the rate of change in solid lines. The rate is below one as resistance 
is increasing. At low levels of frequency (which are important for policy decision) bigger 
MOIs entail a faster decline of sensitive forms. Single locus model shown.
Figure 3.2 shows linkage disequilibrium, r, for the four scenarios where a single drug 
is deployed and resistance is encoded by two loci. Where full epistasis is required, r 
is positive (in line with comparable results in Dye and Williams (1997) and Hastings 
(2006)). This arises because genotypes co,i and c^o (a description of the genotype
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notation is presented in the supplement) provide no advantage in any environments as 
they are not resistant to treatment and are less fit than the sensitive clones in untreated 
individuals. With duplicate gene function, one mutation is sufficient to confer resistance 
and furthermore two simultaneous mutations are never advantageous, and r becomes 
negative. When more than one treated environment is available, as the full-epistasis 
plus DGF scenario and in the SP-based scenario where asymmetrical epistasis plus 
DGF occvir, the opposing effects tend to cancel each other out and LD is low. From a 
qualitative point of view epistasis has a tremendous impact in both signal and amplitude 
of LD.
LD patterns for single drug models
fitness penalty=0.3 and drug treatment rate=0.4
SP-based
Full epistasis + DGF
Full epistasis 
Duplicate gene function
Generation
Figure 3.2: Linkage disequilibrium (r) patterns for single-drug models with MOI of 2, 
drug usage rate of 40% and a fitness penalty of 30%. Different epistasis models have 
quafitatively different disequilibrium patterns.
Figures 3.3 and 3.4 illustrate how MOI and LD affect the relationship between the 
prevalence of a resistant mutation and its underlying allele frequency. The prevalence 
at a single locus, P, is given by the binomial distribution: 1 - (1 — Fi)* and is plotted 
on Figure 3.3 for various MOL A bigger MOI implies a bigger prevalence for the same 
frequency. The difference between frequency and prevalence is not maximised at the 
extremes frequencies (i.e. near 0.0 or 1.0) but at intermediate frequencies. We note that 
prevalence is inevitably higher than frequency unless the MOI is 1. This has implications
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for the interpretation of field data and is discussed below. It is quite easy to compute 
the frequency of resistance for the single locus model given the prevalence and the MOI, 
for more realistic models with two or more loci, the frequency also depends on linkage 
disequilibrium which is itself dependent on assumptions about epistasis. We can repeat 
the analysis of the relationship between frequency and prevalence considering one drug 
with two resistant loci. The prevalence is given by 1 — (1 — for full epistasis (this
is because only citi clones are resistant) and 1 - (1 - (F^i + jF^q + Eo,i)T for DGF (co,i, 
01,0 and ciq are all resistant). Assuming equal frequencies for both resistant alleles (a 
realistic assumption for all epistasis models except asymmetry) the frequency of resistant 
infections can be easily calculated for both models as a function of frequency of mutation 
of one gene and the linkage disequilibrium measure r. The relation between frequency 
of a locus involved in resistance and prevalence as a function of MOI and r is shown on 
figure 3.4 for an r of 0.0 and 0.5 for full epistasis. As expected higher 7’ entails a bigger 
proportion of individuals harbouring a resistant infection in a full epistasis scenario (the 
converse is expected and observed for duplicate gene function). In all cases, higher MOI 
implies a larger proportion of individuals harbouring one resistant infection, but the 
behaviour of the function is difficult to quantify with precision.
MOI and epistasis influence whether stabilisation of resistance occurs at intermediate 
frequencies. Table 3.2 presents the proportion of scenarios which stabilise at intermediate 
frequencies for the scenarios considered (the supplementary material provides details on 
the parameter ranges investigated). Single locus and full epistasis models are included 
for comparison as they have been widely studied before (e.g., Dye and Williams (1997); 
Hastings (2006)). Our results are consistent with those studies as both scenarios tend 
to fixation in a very large part of the search space. Duplicate gene function, by making 
all parasites with two mutations less fit than parasites with just a single mutation even 
in treated individuals, has a much bigger portion of the search space where stability 
occurs at intermediate frequencies. This is analogous to the situation of over-dominance 
in diploids which is known to produce stable allele frequencies. In this model, two 
non-mutated loci are bad for the parasite (it is drug sensitive), one mutated locus is 
optimal (resistance) while two mutated loci pay a double fitness penalty: they are the 
least competitive genotype in untreated hosts and less fit than single-mutated parasites 
in treated hosts. In all models, increasing MOI increases the size of the parameter space 
where stable intermediate frequencies occurs.
We also investigated a single-locus scenario where the frequency of resistance was 
started at 99% and no drugs were used. This allows us to isolate and investigate the 
effect of untreated individuals on the spread of drug resistance and provides insight 
into the likely effect of removing a drug from circulation. In the simple situation of 
MOI=l then the frequency of resistant infections remains unchanged even if a drug is 
removed, because the fitness penalty was modelled as competition within the human 
host (Equation 1 of the Supplement) this assumption was made for convenience but an
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Relationship between prevalence and frequency of resistance
Frequency
Figure 3.3: Relationship between prevalence and frequency of resistance with multiplic­
ity of infection (MOI) in the single locus model. For the same frequency, higher MOI 
entails higher prevalence.
Model MOI 1 MOI 2 MOI 4
Single locus 0 8 24
Full epistasis 0 5 23
Duplicate gene function 0 53 70
Full epistasis + DGF 0 12 31
SP-based 0 10 24
Two drugs 2 13 27
Table 3.2: Percentage of scenarios which stabilise at intermediate frequencies of resis­
tance by MOI. MOI affects both effective fitness costs and the level of sexual recombi­
nation.
additional factor s(i) could be added to this equation to incorporate other factors such 
as increased parasite clearance or lower gametocyte densities that may occur and be 
independent of MOI. When MOI is bigger than 1, it becomes an important factor in 
the loss of resistance when a drug is removed. Higher MOI increases the rate of spread 
of sensitive parasites and this effect is stronger at higher frequencies of resistance (data
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The impact of frequency and LD on prevalence
MOI 4, r 0.0
Frequency of the resistant allele
Figure 3.4: Prevalence as a function of the frequency of the resistant allele with full 
epistasis for linkage disequilibrium (r) of 0.0 and 0.5 for the full epistasis model.
not shown). This arises because both factors increase the probability that a sensitive 
clone will compete with resistant clones within untreated humans; the formers’ supe­
rior competitive ability (they lack fitness penalties associated with resistant mutations) 
within humans helps drive their spread through the population.
3.3 Discussion
The methodology described above shows that it is conceptually straightforward to incor­
porate a flexible genetic basis of resistance into models of antimalarial drug resistance, 
and that this may have important qualitative implications for important factors such 
as the rate at which resistance evolves and whether it may stabilise at intermediate 
frequencies. This entails a slight redefinition of the concept of “resistance” away from 
hard-wired genetic determinism and towards a more subtle realisation that drug “resis­
tance” is determined by both the parasite genome, and the “environment” of the infected 
host: two hosts might carry infections with exactly the same genotype but have different 
treatment outcomes depending on their immune status, pharmacogenetics and/or com­
pliance to the recommended drug regimen. Chloroquine provides a useful illustration
28 CHAPTER 3. SPREAD OF DRUG RESISTANT MALARIA
of this. There was widespread “resistance” in Guinea Bissau, but when that country 
adopted a policy of doubling the CQ dosages, the problem of “resistance” largely dis­
appeared (Ursing et ah, 2007): the mutations, probably in crt, encoded resistance to 
normal levels of CQ but remained drug-sensitive when exposed to high levels. The pres­
ence of multiple epistasis environments in the host population (Table 3.1) reflects the 
importance of human immunity and pharmacological variables, such as drug quality and 
correct dosage. A key strength of this approach lies in its flexibility as it can also easily 
be used to incorporate other factors besides the main ones of immunity, pharmacoge­
netics and compliance explicitly discussed above. Other factors could be human genetic 
variation in malaria susceptibility and the role of residual drugs in driving resistance. 
Most antimalarial drugs have long half-lives and are frequently taken in many areas to 
presumptively treat any fever, with the consequence that a large proportion of people 
(up to 80%, e.g. Talisuna et ah (2002)) carry “residual” levels of drug from previous 
treatments. Most antimalarial drugs do not affect P. falciparum during its initial in­
cubation in the liver and parasites emerging from the liver may encounter drug and 
be subject to “accidental” drug action which may be an important driver of resistance 
(Hastings et al., 2002; Hastings and Watkins, 2006). It is easy to envisage a plausible 
situation where full epistasis may describe survival to direct therapeutic treatment while 
in the bloodstream, asymmetric epistasis may describe resistance to high residual drug 
levels encountered on emergence from the liver and DGF describe survival to low levels 
of drug encountered after liver emergence. It would be straightforward to extend our 
approach to this situation by constructing a new scenario similar to those described 
above.
Fixation of sensitive alleles is far more likely to occur in the “two drugs” scenario 
(data not shown). This occurs because mutations encoding resistance to one drug offer 
no protection against the second drug but are deleterious in untreated individuals. If 
we extrapolate this result and assume that the sensitive alleles are more likely to be 
fixed if more drugs are used, and that the resistant mechanisms to all drugs involved 
are independent, then it should be possible to treat higher number of individuals before 
resistance spreads. This is consistent with the results presented elsewhere (Koella and 
Antia, 2003; Boni et al., 2008).
Simulations of drug removal following fixation of resistance allele illustrates the im­
pact of untreated infections in the spread of drug resistance. Untreated infections delay 
the spread of drug resistance because sensitive infections are favoured in these hosts. 
This effect is more pronounced in higher transmission settings as MOI is high, increas­
ing competition between clones, and is especially significant with higher frequencies of 
resistance. This highlights, and quantifies, a fundamental conundrum in drug deploy­
ment: an individual-centred, medical approach dictates that symptomatic patients be 
identified and cured, while drug policies aim to reduce the overall amount of drug used 
to minimise selection for resistance. These are not entirely incompatible considerations,
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for example better diagnostics can reduce drug usage without reducing patient care, but 
it is an important component of models that they can quantify the impact of changes in 
drug deployment policies. Population genetics models also clearly highlight the tension 
between measures for control (defined as the reduction in incidence of the disease) and 
elimination (the reduction to zero of the incidence in a specific human population) of 
malaria. If control is the main objective, semi-immune, asymptomatic hosts provide a 
reservoir of sensitive parasites, where these are fitter than resistant parasites. Prom a 
control perspective having a reservoir of sensitive parasites is a positive development 
which slows the spread of resistance and increases the time a drug will remain effective. 
From an elimination perspective asymptomatic reservoirs have to be treated in order to 
completely remove the parasite from the host population and are a source of concern 
as they are difficult to detect in the human population. Any attempt at elimination, 
if unsuccessful, will probably have negative consequences for long-term control as selec­
tion against sensitive parasites in elimination policies will most probably increase the 
frequency of resistance against any drugs used in the elimination phase.
It is generally assumed that mutations encoding drug resistance pay a fitness penalty 
and are deleterious in the absence of the drug. Consequently, the frequency of resistant 
parasites should fall once that drug is removed from general use. This effect is impor­
tant as reintroduction of the drug might be considered if the frequency of resistance to 
a certain drug drops to very low levels. For example CQ reintroduction as a partner 
drug in combination therapy, probably with artesunate, has been considered in Malawi 
(Laufer et ah, 2006). Our results (data not shown) suggest the rate of fall will be faster in 
high transmission settings as a consequence of higher MOI and hence higher competition 
within hosts. This can be observed in the field where the return of Chloroquine sensitive 
parasites was observed after the introduction of the replacement drug SP, especially in 
high-transmission areas like Malawi (Kublin et ah, 2003) and to some degree in Gabon 
(Schwenke et ah, 2001) but less in low-transmission areas like Colombia and Venezuela 
(Cortese et ah, 2002) suggesting that intensity of transmission might be a factor in 
decreasing levels of drug resistance. However these areas differ in many other aspects 
besides MOI (for example, migration from border countries or provinces with different 
drug deployment policies) and the results need to be interpreted with caution; for ex­
ample, the fall in resistance was faster in areas of low MOI in Yunnan province, China 
(Yang et ah, 2008), but the area shows highly heterogeneous patterns of transmission 
so other factors might have a substantial impact.
A large body of existing research predicts that once drug resistance arises it will 
spread rapidly to fixation. Hastings (2006) postulated that forces driving resistance 
(genetic recombination, intrahost dynamics, natural selection) vary with frequency and 
could cancel out to allow stable intermediate frequencies; he used a model of full epistasis 
and showed that stable intermediate frequencies could occur, but was fairly uncommon, 
especially for lower MOI. In contrast, many field studies suggest stabilisation is relatively
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common; for example, for SP in Malawi (Plowe et al., 2004) and Tanzania (Pearce et al, 
2003) and for CQ in Eastern Sudan (Babiker et al., 2005) and Guinea-Bissau (Ursing 
et al., 2007). The more biologically realistic “Full Epistasis + DGF” and “SP-based” 
models of host heterogeneity described here exhibit an increase in intermediate stable 
frequencies especially with lower MOI (Table 3.2). In summary, realistic modes of gene 
interaction are more compatible with field observations, demonstrating the importance of 
accurately modelling gene interactions and also suggesting the need of further empirical 
research on the basis of drug resistance.
Previous models based on an assumption of full epistasis, always predict strong 
positive linkage disequilibrium (Dye and Williams, 1997) here we show that LD depends 
on the mode of gene action (Figure 3.2), which is not well understood for most drugs 
and which will, as stressed above, depend on the selection environment of the treated 
human. This has implications for interpretation of field data. Studies have investigated 
LD between loci in the belief that significant positive LD would be indicative that 
both loci are important for encoding resistance, the most obvious examples being mdr 
and cr£ loci in CQ resistance. This is true if full epistasis is required, but Figure 3.2 
shows that “negative” results (i.e. absence of LD or negative LD) cannot be taken 
as evidence that they do not have a joint role in determining resistance. LD also has 
a strong impact on genotype inference and on the ability to accurately calculate the 
frequency of resistance from prevalence (Figure 3.4). Many clinical studies present the 
prevalence or frequencies of each locus separately, and normally no attempt is made 
to report multilocus genotypes because it is often impossible to determine a multilocus 
genotype (i.e. linkage phase in the population genetic terminology) when MOI > 1. 
The frequency of multilocus resistance genotypes, and the direction and extent of LD 
between the loci, provides clues as to the underlying genetic mechanisms of resistance 
so a strong a case could be made for future studies to attempt genotype inference and 
LD estimation from multiple infections (Hastings and Smith, 2008).
Intensity of transmission determines MOI, which determines the proportion of in­
dividuals carrying resistant infections (i.e., the prevalence of resistance). This has two 
main implications for comparative analysis of clinical studies from areas with different 
transmission intensity, or for temporal studies from the same area if the transmission 
rate has changed:
1. The potential confusion between frequency and prevalence of resistance should be 
avoided. Different transmission settings change the relationship between frequency 
and prevalence and higher MOI clearly entails higher prevalence for the same 
frequency of resistance.
2. For longitudinal studies where transmission has decreased, an observed drop in 
prevalence of resistance does not always reflect decreased frequency of resistance. 
Any conclusion that cutting transmission decreases the frequency of resistance
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should be carefully evaluated as such observation could be explained, partially if 
not totally, by a lower MOI generating a smaller prevalence for the same frequency 
(Figure 3.3). The relationship becomes much more complex when more than one 
locus is involved as LD and epistasis also affect prevalence (Figure 3.4).
Our theoretical conclusions on the relationship between transmission, frequency and 
prevalence are consistent with a recent study (Hastings et ah, 2010) which analysed field 
data from Tanzania and Papua New Guinea.
P. falciparum biology has several features that preclude simple analysis using stan­
dard population genetics equations. Studying the implications of parasite inbreeding, 
epistasis between drug resistance loci, and heterogeneity in human host “environments” 
will allow a better understanding of the dynamics of resistance spread of P. falciparum 
malaria. This explicit and flexible framework of gene action can be used in the future to 
study deployment strategies for the new generation of antimalarial drugs, the artemisinin 
combination therapies (ACTs), such as simultaneous drug deployment policy proposed 
by Boni et al. (2008) and to understand the epidemiological consequences of different 
genetic mechanisms of resistance. A notable omission from previous analyses has been 
the recognition that resistance depends on both parasite genotype and the human “en­
vironment” in which treatment occurs. Incorporating this effect should allow enhanced 
understanding of parasite population genetics of drug-resistance genotypes allowing us 
to identify public health deployment practices that may minimise selection for resistance 
and ultimately to better mitigate the public health impact of malaria.
Four
The promise and dangers of recent 
antimalarial deployment policies
Tiago Antao 
Abstract
Malaria is one of deadliest infectious diseases, imposing a significant health, 
social and economical burden, particularly on poverty-stricken countries and popu­
lations. Antimalarial drug resistance is pervasive and several strategies have been 
proposed to reduce the spread of drug resistance and extend the useful therapeutic 
life of existing therapies. Recent research has suggested that using multiple first-line 
therapies (MFT), mstead of a single-drug policy, might delay the emergence and 
spread of drug resistance. Here we compare different drug deployment policies using 
several realistic population genetics models of the spread of drug resistant malaria 
focusing on the spread of multidrug resistance. We simulate realistic models of ge­
netic interaction, immunity, treatment compliance and the impact of transmission 
intensity on inbreeding. Our results suggest that MFT policies can delay the spread 
of drug resistance, including multiple resistant genotypes, if resistance levels are 
maintained inside World Health Organisation recommendations. This work stresses 
the importance of compliance with treatment guidelines as incomplete treatment can 
potentially increase the spread of resistant infections. We also show that association 
between loci, measured by linkage disequilibrium, is fundamental to understand the 
dynamics of spread of resistance as it is the main driver for the spread of multidrug 
resistance.
Malaria is a major public health concern, as one third of the human population 
is estimated to be exposed to the threat of the most virulent form, Plasmodium fal­
ciparum (Snow et ah, 2005), Antimalarial drug resistance has emerged as one of the 
major challenges facing malaria control as it became widespread to most first line ther­
apies based on monotherapies (Olliaro, 2005). Treatment failure is now being observed 
even for Artemisinin based combination therapies (ACTfe) (Rogers et al., 2009). It is 
now mandatory that antimalarial drugs be deployed as combinations because modeling
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suggested this was a much more sustainable policy than using monotherapies (World 
Health Organization, 2006). Historically, in the era of monotherapies there was little 
room for policy manoeuvre: one drug, Chloroquine (CQ), was used before it became 
ineffective when Sulphadoxine-Pyremethamine (SP) was deployed until it too because 
ineffective. We are presently in a slightly more advantageous (but still tenuous) posi­
tion compared to the monotherapy era because we have several effective combination 
therapies available based around Artemisinins using Amodiaquine, Lumefantrine, Meflo­
quine, Piperaquine and SP (where the latter is still effective) and even CQ as a possible 
partner-drug (Laufer et al., 2006). It therefore seems sensible to consider how best to 
deploy these ACTs for maximal therapeutic lifespan. Current drug deployment policies, 
hereafter termed “sequential”, make use of a single first line therapy which is used until 
the level of treatment failure rises above an acceptable level, at which time the drug 
is replaced with a new treatment. A different strategy would be to deploy multiple 
first line therapies (MFT) simultaneously, resulting in humans and thus infections being 
treated with different drugs.
The benefits of MFT are intuitively obvious. It is generally accepted that it is more 
difficult for organisms to evolve in a heterogeneous environment, in this case caused by 
different drug treatment, than in a homogeneous treatment environment associated with 
single drug use. The benefits become even more pronounced if fitness penalties are as­
sociated with mutations encoding drug resistance. Koella and Antia (2003) recognised a 
"tipping point” in this situation whereby the advantage of a mutation in encoding drug 
resistance in treated humans is balanced against its fitness cost in untreated individuals; 
resistance will only spread if its benefit outweighs its cost. MFT reduces the propor­
tion of infections treated by each drug, so, in principle, it could reduce a mutation’s 
advantage below this tipping point and the mutations would be selected out of the par­
asites population. Under a best-case scenario this could prevent resistance spreading to 
any of the drugs and could even reverse its spread once started (Hastings and Donnelly, 
2005). Even if the cost/benefit does not cross the tipping point, the use of MFT will still 
be advantageous because reducing drug use has a disproportionate impact on selection 
for resistance. For example halving drug use may reduce selective advantage 2.5 fold 
(Babiker et al., 2009).
However, there is also a potent intuitive threat posed by MFT: the parasite has an 
obligatory sexual phase inside the mosquito so infections that are, individually, resistant 
to a single drug can recombine to create multi-drug resistance. A worst-case scenario is 
that resistance mutations become genetically associated so that multi-drug resistant par­
asites rapidly spread that are resistant to all drugs in the MFT arsenal and completely 
undermine the benefits of MFT. If true this would suggest that sequential use of drugs 
might be a better policy. This effect, termed linkage disequilibrium (LD), is known to be 
an important dynamics in the evolution of drug resistance (Dye and Williams, 1997; An- 
tao, 2010). Note that LD does not require resistance to be physically linked on the same
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chromosome; it is a statistical association caused by resistance mutations “hitch-hiking” 
with each other because of their mutual benefit in withstanding all drug treatments. 
It would be impossible to recommend the use of MFT without explicitly considering 
the risk posed by multi-drug resistant infections (see current concerns about, for ex­
ample, multidrug resistant Tuberculosis (Zignol et al., 2006) and Methicillin-resistant 
Staphylococcus aureus (MRSA) (Enright et al., 2002)).
A second potential threat to MFT arises because most of the current batch of anti- 
malarial drugs (except the Artemisinins) have long half-lives and may persist at active 
concentrations in humans for weeks after treatment. This effect is known to drive re­
sistance (Hastings and Watkins, 2006) because parasites emerging from the liver may 
encounter, and have to survive, residual drug levels persisting from previous treatments. 
Many patients in areas of high drug use may have residual levels of drug so MFT will 
often morph into a type of de facto combination therapy whereby parasites must be 
simultaneously resistant to Drug A to survive residual drug levels and establish an 
infection, and also resistant to Drug B to survive later therapy by that drug. It is there­
fore important to understand the interactions of drug deployment policies and residual 
drug levels, especially on the spread of multi-drug resistance and, more optimistically, 
whether MFT may be an inexpensive method of harnessing the additional known ben­
efits of combination therapy.
A previous evolutionary-epidemiological study (Boni et al., 2008) suggests that MFT 
would result in longer overall periods of drug effectiveness, but only briefly considered 
the threat posed by the emergence of multi-resistant genotypes through the P. falci­
parum sexual reproduction phase; in particular they assumed random breeding among 
P. falciparum parasites within the whole parasite population whereas we explicitly allow 
recombination only between P. falciparum clones co-infecting the same human. This is 
important because, by definition, only resistant genotypes survive treatment so recom- 
binational loss of resistance will be reduced or eliminated in infections transmitted from 
treated humans; this will increase the genetic stability of multidrug resistance greatly 
enhancing its spread.
Any endorsement of the use of MFT should consider the risk posed by creating LD 
and multi-drug resistance. We also take the opportunity to include several other factors 
omitted from the previous MFT study in particular: the impact of different modes of 
genetic interactions (epistasis) between loci conferring resistance; the impact of intrahost 
dynamics and competitive release (Hastings, 2006; Wargo et al., 2007). In this study 
we construct explicit population-genetic models to investigate how parasite population 
structure and genetic mechanisms of resistance influence the outcome of different drug 
deployment policies. Key questions to be addressed are: How do different types of 
selection pressure influence the spread of resistant genotypes? What is the impact of 
control and elimination programmes which decrease transmission? If MFT is to be tried, 
should we start in high or low transmission areas? Is MFT always the best strategy in
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all epidemiological settings? Do any of these strategies increase the spread of multiple 
resistant clones? As MFT might already be a de facto policy due to the widespread 
availability of multiple drugs through informal sector (Bate et al., 2008), should this 
be encouraged or suppressed? The model presented is general enough to study many 
different parameters but we will concentrate on scenarios of most practical importance 
and realism as regarding P. falciparum population biology.
4.1 Modeling and theory
We used ogaraK (Antao and Hastings, 2011a), a population genetics simulator of the 
emergence and spread of drug resistant P. falciparum that incorporates multiple loci, 
sexual recombination, LD, differing levels of multiplicity of infection (MOI, see below) 
and different genetic modes of resistance. Here we present a summary of the relevant 
features of the application and the parameters used in this study.
Population genetic models for P. falciparum have to address several non-standard 
features of its biology. Plasmodium malaria parasites are haploid and reproduce asex- 
ually in humans and are briefly diploid in the mosquito vector, where they reproduce 
sexually. The number of simultaneous infections in a human is termed the Multiplicity 
of Infection (MOI) which typically ranges from 1 to 12. The number of mating options 
inside the mosquito are dependent on the MOI of the human providing the blood meal. 
Different infections might have different resistance profiles. Sexual reproduction in the 
mosquito entails recombination but self-fertilisation (i.e., selfing) occurs frequently as 
mosquitoes might ingest parasites having a single clone (Arnot, 1998) (mosquitoes feed 
approximately every three days so mating between parasites in blood meals obtained in 
separate bites is assumed to be impossible). This creates an environment which departs 
from standard population genetics’ models, namely that mating can only occur between 
the small number of different parasite clones within a blood meal. A crucial difference 
between areas of high and low malaria transmission is the MOI: repeated sequential 
infection in areas of high transmission intensity leads to the average number of different 
clones being higher, so mosquitoes frequently ingest unrelated parasites leading to lower 
levels of selfing and inbreeding (Anderson et al., 2000a). MOI is thus a proxy for trans­
mission intensity because higher transmission increases MOI due to repeated sequential 
infection.
We track the spread of resistance over a time-scale of 200 parasite generations. Each 
generation encompasses a P. falciparum life cycle — mosquito-human-mosquito - which 
is likely to be around 5 per year so the simulation lasts 40 years which should encom­
pass all the timescales likely to be considered in long-term planning. We simulate the 
genotype of each infection assuming that all loci are physically unlinked, a realistic as­
sumption for loci known to encode P. falciparum drug resistance (Osman et al., 2007). 
We also make the simplifying assumption that there is no cross resistance among drugs
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(i.e. a single mutation cannot encode resistance to more than one drug), but note that 
this is not applicable to all known cases (Price et ah, 2004). Each loci can have two 
alleles: resistant and sensitive. Resistant alleles will incur a fitness penalty if they are 
not required for survival (i.e. in untreated hosts, in hosts treated with a drug for which 
the mutation cannot encode resistance or in cases where the epistasis mode does not 
require all mutations). Genotypes with multiple mutations incur a multiplicative fitness 
penalty. More than one locus can be involved in resistance to a single drug. Importantly, 
where more than one locus encodes resistance to a single drug, we investigate different 
epistasis modes among loci (Antao, 2010): Duplicate Gene Function (DGF) where a 
resistant allele at any locus is sufficient to confer resistance to a drug; Full Epistasis 
(FE) where resistant alleles have to be present at all loci to confer resistance; Asym­
metrical Epistasis where one locus is more important (for example SP resistance where 
mutations in dhfr have a more substantial role than dhps (Olliaro, 2001)). Full epistasis 
is deemed a “strong” mode as it requires all mutations for resistance, conversely DGF 
and Asymmetrical Epistasis are called “weak”. Parasite multi-locus genotypes can vary 
from sensitive to all drugs to resistant to all drug treatments available and having all 
mutations (multi-resistant).
Infections are assumed to have equal infectivity and mate at random inside the 
mosquito so that if there are n clones in a human then selfing rate is ~ and outcrossing 
rate 1 — and competitive release is assumed to occur. Parasites in infected humans can 
be untreated (an environment where sensitive infections are fitter), treated in humans 
who have little or no host immunity (where a weaker epistasis mode suffices to confer 
resistance) and treated in humans who are semi-immune to infection (requiring the 
strong mode of resistance).
We assume that resistance to all therapies exist at low frequencies (0.1%) at the 
onset of the simulation. The emergence of resistance and its implications on therapy 
effectiveness have been studied elsewhere (Boni et ah, 2008; Pongtavornpinyo et ah, 
2009). Our approach is complementary as we try to understand the spread, rather 
than the origin, of existing resistance. Furthermore resistance to most drugs is now 
widespread, and has probably emerged also for artesunates (Dondorp et ah, 2009) and 
in many cases de novo resistance has arrived to a human population via migration 
(Roper et ah, 2004), not local mutation.
We considered three drug policies: (i) sequential application, modeling the common 
antimalarial deployment strategy where a therapy is replaced by another when treatment 
failure becomes too high; (ii) multiple-first line therapies (MFT) where several drugs 
are made available allowing patients and clinicians to randomly choose which one to use 
and (iii) combination therapy where all available drugs are given simultaneously to each 
patient. The combination therapy model is inspired in Tuberculosis policies where all 
available drugs are used in a single patient (Crofton et ah, 1997), and should not be
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confused with Artesunate Combination Therapies (ACTs) where a Artesunate derivative 
is supplied with a single partner drug.
In order to compare policy duration we assume that a sequential policy lasts until 
the last drug is removed from circulation. A drug is replaced as soon as an average of 
10% treatment failure is observed. For MFT and combination therapy we assumed that 
a policy stops being effective as soon as 10% treatment failure is observed. This figure of 
10% was chosen because the World Health Organization (WHO) recommends a change 
of treatment regimen when cure rate falls below 90% (World Health Organization, 2006).
We simulated sequential application, MFT and combination assuming two drugs are 
available and that resistance is encoded in two different loci per drug (i.e a genotype 
consists of four independent loci) using the following set of scenarios:
Full epistasis: Parasites must possess resistant alleles at both loci to survive treatment 
with that drug (for example parasites must have resistance mutations present at 
both dhfr and dhps to survive SP treatment).
DGF: Parasites with resistant alleles at either locus will survive treatment with that 
drug (for example parasites with resistance mutations at either dhfr or dhps will 
survive SP treatment).
Mixed mode: Half of the treated humans have no host immunity and/or take low 
drug doses. Parasites in these humans will be able to survive treatment if they 
have a resistant allele at the most important locus (asymmetrical epistasis); this 
scenario reflects observations in both SP (where dhfr is more important than dhps) 
and CQ (where crt is more important than mdrl) (Antao, 2010). The other half 
of the human population is assumed to be semi-immune and/or take high drug 
doses, therefore only parasites that have resistant alleles at both loci will survive 
treatment (Full epistasis).
For all simulation scenarios we varied the fitness penalty per resistant mutation 
and the amount of drug usage (defined as the percentage of infected humans that were 
treated) both were between 0 and 100% in increments of 2%. Only results with fitness 
penalties below 20% are reported here as large values are not realistic. We simulated 
4 different MOIs: two simple models with MOI fixed at 2 (low transmission) and 4 
(high transmission) and two more realistic scenarios, one modeling low transmission 
where 50% of human hosts had a single infection and the other half had 2 infections and 
another modeling high transmission where MOI followed a Poisson distribution with 
a conditional mean of 2.3 truncated at a maximum MOI of 7 (Hastings, 2006). The 
simpler MOI models qualitatively capture the results of the more complex ones (Antao 
and Hastings (2011b), supplemental information), so we opt to present only the results 
pertaining to the simple MOI distributions. We repeated the above scenarios with 3
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drugs but the results were qualitatively similar to the results with 2 drugs; we therefore 
only present results for 2-drug simulations except when comparing the importance of 
the number of drugs used.
4.2 Results
Table 4.1 summarises the impact of key factors on the spread of drug resistance and 
table 4.2 the fundamental consequences of different drug deployment policies. Below we 
compare the three deployment policies and detail the results for each key factor.
Factor Impact
Drug use t resistance spread
Fitness cost j. resistance spread
MOI
t competition —>• 4- resistance spread 
f recombination —> 4- LD 
t asymptomatic infection —» 4- drug use
LD (r) t resistance spread
(except if DGF) 4- resistance spread
Genetic
mode
4, resistance spread 
(full > mixed > DGF > none)
Compliance t strength of genetic mode
Immunity t strength of genetic mode
Table 4.1: The impact of key factors in the spread of drug resistance. The left side of 
the table lists important factors involved in the spread of drug resistance. The right side 
describes the impact of increasing that factor. The table not only summarises the impact 
of several factors but also demonstrates the complex web of relationships between factors 
and impacts. This table is applicable for realistic frequencies of resistance according to 
World Health Organisation policy, i.e. where resistance is considerably below 50%.
Policy Impact
Combination therapy Longest useful therapeutic life 
Extreme increase in multi-drug resistance
MFT Long useful therapeutic life
Very low multi-drug resistance
Sequential application Medium useful therapeutic life
Low multi-drug resistance
Table 4.2: Summary of the impact of MFT, sequential application and combination 
therapy on useful therapeutic life and the spread of multi-resistant genotypes assuming 
drug usage typical in control scenarios.
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Policy comparison
MFT policies last longer than equivalent sequential policies for low to medium drug 
usage. For higher drug usage, sequential application performs better, but in this case 
the difference between policies is minor (Figure 4.1). The dynamics of genotypes that 
encode resistance to drugs not in use in sequential application is fundamental: when 
a new drug B is introduced into the sequence, it will compete against a mixture of 
parasites that are either sensitive or resistant to drug A, these resistant forms will be 
less competitive as they have mutations that only decrease fitness, thus resistance to 
drug B will spread faster (Boni et ah, 2008). However, a compensatory effect will 
occur with higher drug usage: parasites that are spontaneously resistant to drug B will 
be eliminated at a higher rate when drug A is in use, therefore when the drug B is 
introduced the basal frequency of infections resistant to that drug is highly reduced. 
The relative benefit of MFT against sequential usage is then a balance between these 
two processes.
Combination therapy shows a similar profile to MFT, while lasting slightly longer. 
The fundamental qualitative difference between combination therapy and the other poli­
cies lies on the spread of multi-resistant infections: the frequency of the multi-resistant 
genotype will be small at the end of the useful therapeutic life with MFT and sequential 
application, whereas with combination therapy the multi-resistant genotype will usually 
be above 50%, Figure 4.2 shows the fraction of resistant genotypes which are multi- 
resistant at the end of policy duration for sequential application, MFT and combination 
therapy. These results are intuitively expected as in both MFT and sequential applica­
tion, the multi-resistant genotype is never the most fit in all human hosts because in any 
human this genotype pays fitness costs for carrying resistance mutations that are not 
required for survival in the host; consequently multidrug resistance will only become 
frequent, through random association, when resistance to all drugs is very high. On 
the other hand, with combination therapy the multi-resistant genotype (or genotypes, 
in the case of weaker epistasis modes) is the only one that can resist treatment. As 
multiple resistance is a serious problem with many infectious diseases and the system 
behaviour has been shown to be function dependent (i.e., the behaviour is qualitatively 
different with low and high resistance frequencies (Antao, 2010)), we also made the same 
comparison for a much higher threshold of resistance (50%) before a drug is removed. 
Simulations show that MFT multi-resistant pattern shifts to an intermediate between 
sequential application and combination therapy (Figure 4.3).
Multiplicity of infection and Linkage disequilibrium
Recombination will reduce any statistical association between resistant alleles at different 
loci and the frequency of resistance qualitatively influences the impact of recombination. 
One of the fundamental assumptions in any malaria model of resistance is that the
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Policy duration
Drug usage
Figure 4.1: Impact of policy and MOI on useful therapeutic life; the latter is plotted on 
the Y axis and is defined as the number of parasite generations that elapse before overall 
drug failure rates reach 10%. It is plotted as a function of drug usage (the proportion 
of infections that are treated) on the X-axis. The chart compares combination therapy 
(CT), MFT and sequential (Seq) deployment policies with MOIs of 2 and 4 and with a 
fitness penalty of 10%. MFT and CT perform better than sequential policies at lower 
drug usage and marginally worse with high drug usage. All three deployment policies 
last longer with lower MOIs.
frequency of sensitive alleles is greater than 50% (as WHO polices postulate efficacy 
levels above 90% (World Health Organization, 2006)). If a clone is resistant to one 
drug, a recombination event involving a different clone will probably generate offspring 
that are only resistant to the same drug, as the other clone is probably sensitive (due 
to the assumption of low frequency of resistance). Linkage disequilibrium patterns can 
change with different epistasis modes and drug policies. Figure 4.4 shows the LD (r)
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Figure 4.2: The distributions of multi-resistant genotypes at the end-of-life for MFT, 
sequential application and combination therapies. MFT and sequential application show 
similar patterns i.e. most genotypes are not multi-resistant. Combination therapy is 
qualitatively different as most genotypes at policy end of life are multi-resistant. The 
distribution includes all simulations with a fitness penalty below 20% and drug usage 
below 60%.
for both policies assuming full epistasis or DGF the whole 200 generations simulated. 
Both the signal and magnitude of LD varies with epistasis and policy as it is positive 
in full epistasis for loci involved in resistance to the same drug and negative for DGF. 
From an empirical perspective, all signals and intensities of LD are plausible depending 
on policy and epistasis mode (Antao, 2010). Note that positive LD indicates resistance 
alleles are found together in the same parasite genotypes more often than expected by 
chance, and negative LD indicates that they are associated less often than expected.
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Frequency of multi-resistant genotypes
Figure 4.3: The distributions of multi-resistant genotypes at the end-of-life for MFT, 
sequential application and combination therapies. End of life is assumed to occur at 
50% prevalence (compared to 10% in figure 4.2) but all other parameters, abbreviations 
and simulation procedures are identical between the two figures.
MOI is an important factor in determining the length of effective drug use as all 
policies last longer with lower MOI (assuming resistance is present at the onset of sim­
ulations). For the same frequency of resistance, higher MOI increases the proportion 
of treated humans with one or more resistant clones (the “prevalence” of resistance) 
(Antao, 2010) allowing a higher frequency of resistant genotypes to be transmitted to 
the next generation. However, this effect is countered, in higher MOI settings, by break­
age of LD that will occur in untreated individuals by outcrossing between resistant and 
sensitive infections; and outcrossing increases with higher MOI. The lesser importance 
of breaking LD compared to prevalence in establishing the spread of resistance can be
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intuitively understood if we assume that the fitness penalty for carrying mutations is 
zero. If there is no fitness penalty, competition in untreated individuals is absent and 
in this case untreated environments will tend towards linkage equilibrium. Thus, the 
breaking of association between resistance alleles will only happen in cases where there 
is strong linkage between them. In fact, if linkage was negative (as in DGF, Figure 4.4), 
untreated individuals would contribute to increase the association between resistance 
alleles.
Epistasis
The spread of resistance is faster in environments with weak epistasis modes. Figure 4.5 
exemplifies this as both MFT and sequential application last longer with full epistasis 
than with mixed mode. In fact, the modes of resistance are more important in deter­
mining policy duration than the policies themselves. In mixed mode, the main locus 
is enough to confer resistance in half of the environments treated with a drug so there 
is no need for association with a second locus. This is quantitatively more important 
for high fitness penalties: The second locus encoding resistance to a drug is not needed 
in half of the drug treatments (in contrast to full epistasis where it is always needed), 
therefore it is often deleterious even in the presence of a drug.
Number of drugs used
The number of drugs used does not qualitatively change, from this policy comparison 
(Figures 4.6 and 4.7): using more drugs will increase the useful therapeutic life propor­
tionally. The “tipping point” where the advantage of mutations encoding drug resistance 
increases, allowing increased drug usage without significant resistance spread.
4.3 Discussion
Our results mostly confirm, from a perspective based on parasite population genetics, 
previous results on the possible effectiveness of MFT policies (Boni et al., 2008). MFT 
lasts longer than sequential application with low to medium drug usage. As semi-immune 
individuals are much more common in high MOI/transmission scenarios (as repeated 
infection leads to the development of immunity (Langhorne et al., 2008; Rogerson et al., 
2010)) the expected fraction of untreated individuals will be higher, i.e., drug usage will 
be lower. This observation suggests that MFT might more efficient in high transmission 
settings because lower drug usage benefits MFT policies.
MFT and sequential application show similar patterns of spread for multi-drug re­
sistant genotypes up to levels of resistance assumed in WHO policies. In both policies, 
end-of-life analysis shows the relative low frequency of multi-drug resistant genotypes, 
with MFT showing slightly more favourable patterns. This is in contrast to the end-of-
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life profile of combination therapies. However, if the frequency of resistance increases 
substantially above WHO standards than the MFT of multi-resistance profile shifts 
considerably (Figure 4.3). Therefore a realistic assessment of the ability to maintain re­
sistance within WHO policy limits should be a fundamental decision guideline regarding 
the introduction of MFT.
Our sequential application analysis did not allow the option of re-using a drug af­
ter all possible therapies have been exhausted. Drug rotation, at the end-of-life of a 
sequential strategy, may reduce the frequency of resistance genotypes of the first drug 
used compared to the moment where the drug was removed. This result is compatible 
with the proposal for reintroduction of CQ as a partner drug for Artesunate (Laufer 
et al., 2006): our predictions are consistent with empirical results seen in Malawi where 
CQ resistance is severely depressed after the replacement with SP. This observation is 
highly dependent on the fitness penalty accrued by resistance loci, and these can vary 
from drug to drug. For instance, the loci involved in CQ resistance seem to incur higher 
fitness penalty, than SP resistance loci (Babiker et al., 2009). Therefore the option of 
re-introducing a drug (especially as a partner to an Artesunate based therapy) is highly 
dependent on a per case fitness penalty.
Residual drug levels have little impact on sequential policies because the residual 
and treatment drugs are identical. They do have an effect in MFT policies as parasites 
may have to survive one drug at residual levels, and survive treatment by another drug 
which, as noted in the Introduction, constitutes a type of combination therapy. We 
have not directly modeled this effect for several reasons. The proportion of people with 
residual drug treatment depends on the overall drug use which consists of treatment 
against malaria infection, and of presumptive treatment of people who have malaria 
symptoms (e.g. fever) but are not actually infected. Presumptive treatment is much 
more common in high transmission (high MOI) areas with poor clinical diagnosis so 
higher MOI settings show a positive correlation, and hence confounding, between lower 
therapeutic drug usage (due to immunity) but higher residual drug levels (due to high 
presumptive treatment). Residual drug levels may require weaker epistatic models than 
therapeutic drug use. Recent attempts to improve diagnosis using rapid diagnostic tests 
may greatly reduce presumptive drug use. Finally, different MFT implementations can 
alter the effects of residual drugs: if an MFT implementation can assure that the same 
individual is treated with the same drug over-time (either by tracking each individual 
treatment history or, more pragmatically, by having different therapies at different close 
geographical locations) then the impact of residual drug levels will be much reduced. 
Consequently we prefer an indirect argument of the effects of residual drugs on MFT: 
the difference between MFT and CT was small and CT was generally slightly better 
at maximising therapeutic lifespan (e.g. Figure 4.1) so we conclude, while noting the 
threat of multidrug resistance (Figure 4.2), that the fact that MFT may operationally 
merge into a type of CT would not undermine its deployment and may even act as a
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kind of cost effective way of harnessing the benefits of CT without the financial and 
technical penalties of having to co-formulate drugs into a CT.
As with the fitness penalty (and its consequences on drug reintroduction), several 
assumptions should be scrutinised on a case by case basis. For instance most analyses 
and discussion was made assuming a range of fitness penalties per loci. This was care­
fully scrutinised through comparisons with simulations with no fitness penalty. Other 
assumptions do require future study: (i) if several different ACTs are used then there 
is clearly a partially shared resistance basis (on the Artesunate derivative) and further 
work is needed in modeling drugs with partially shared resistance; (ii) some drugs, no­
tably Chloroquine and Amodiaquine (Sa and Twu, 2010), do share the same resistance 
loci but the mechanism of resistance seems to be different - even opposite and (iii) 
residual drug levels which play a critical role in the emergence and spread of resistance 
(Hastings et al., 2002). It is important that policy makers understand the limitations 
and assumptions of this (and any other) models of resistance. It is also important to 
note that current control and elimination agendas are explicitly aimed at identifying 
and treating all malaria infections (i.e. severely increasing drug usage) (Antao, 2011) 
and that our results regarding useful therapeutic life are partially reversed with high 
drug usage. Nonetheless, the difference at higher drug usage is relatively smaller than 
the difference at low to medium drug usage.
From a practical perspective a distinction should also be made between formal pol­
icy (which currently is sequential application virtually everywhere) and the pragmatic 
realities of different countries and regions. For instance, in several scenarios, while ACTs 
are the de jure policy, the private and informal sectors still distribute CQ and SP (Bate 
et al., 2008), therefore the de facto field reality is indeed MFT.
Compliance with treatment guidelines is fundamental to delay the spread of drug 
resistance. We presented different epistasis modes as modeling varying immunity pro­
files, but epistasis can also reflect treatment compliance (Antao, 2010). Full compliance 
is modeled by strong epistasis (full treatment forces the parasite to have all resistant 
alleles in order to survive) and poor compliance is modeled by weaker epistasis modes. 
Figure 4.5 clearly shows that stronger epistasis (full compliance) allows both policies to 
last longer. Our model provides strong support for the importance of full compliance 
and proper dosaging as spread is clearly slowed.
4.4 Conclusion
Regarding a comparison of policies, our results are mostly consistent with previous 
research. Most notably we confirm MFT to out-perform the standard policy of sequential 
application for realistic model parameters. Our results suggest that the impact of MFT 
on the spread of multiple resistant genotypes is negligible or even slightly better than 
sequential application as long as resistance is in within WHO guidelines. Importantly,
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we do conclude that widespread availability of multiple ACTs through the informal 
sector is not an immediate cause for alarm (although Artemisinin monotherapies or low 
quality drugs should definitely be suppressed) and that countries may reasonably choose 
to deliberately employ a policy of MFT within the public health sector.
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Policy duration
MFT Full 
MFT Mixed 
Seq Full 
Seq Mixed
z 60
Drug usage
Figure 4.5: Impact of policy and epistasis on useful therapeutic life. We plot the policy 
duration on the Y-axis and the drug usage on the X-axis. The chart compares Full 
epistasis with the mixed model for MFT and sequential drug application assuming a 
fitness penalty of 10%. The useful therapeutic life always lasts longer in epidemiological 
settings requiring full epistasis rather than mixed model.
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Policy duration
100
Drug usage
Figure 4.6: Impact of policy and MOI on useful therapeutic life. Three drugs are 
available (compared to two in Figure 1 of the main text) but all other parameters, 
abbreviations and simulation procedures are identical between the two figures. The 
lines start abruptly because for lower drug usage the policies last longer than the 200 
generations simulated.
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Drug usage
Figure 4.7: Impact of policy and epistasis on useful therapeutic life with 3 drugs. Three 
drugs are available (compared to two in Figure 2 of the main text) but all other param­
eters, abbreviations and simulation procedures are identical between the two figures.
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Evolutionary parasitology applied to 
control and elimination policies
Tiago Antao
Huijben et al. (2010) recently suggested that sub-curative antimalarial drug treat­
ment of clinical cases might slow the spread of drug resistance through increased com­
petition between drug resistant and sensitive infections. This was further discussed in 
letters to Trends in Parasitology, Goncalves and Paul (2011) raised important questions 
about the potential use of sub-curative treatment: What is the epidemiological and 
clinical impact of leaving a patient with circulating parasites? How is the correct drug 
sub-clearance level determined? Hastings (2011) added several ethical and operational 
arguments against such a proposal namely that patients treated with sub-curative drug 
levels may have repeated episodes of recurrent malaria and/or succumb to a secondary 
infection after being weakened by the primary malaria episode. However, the basic 
evolutionary argument remains unscathed, in untreated patients, competition between 
resistant and sensitive infections will benefit the latter as resistant mutations are ex­
pected to incur a fitness penalty. The question then arises: is there any way to exploit 
competition between infections with different resistance profiles infecting the same host?
Fortunately the parasite environment that Huijben et al. describes does already 
exist. Asymptomatic parasite carriers, mostly individuals that have acquired immunity 
due to repeated infection in high transmission areas, provide an environment where there 
is no drug pressure as long as they are not treated. In this environment sensitive parasites 
can out-compete resistant ones due to the absence of drug induced selection. Also the 
community-wide pressure against sensitive parasites is lower because less individuals 
need treatment so fewer individuals have low level of drugs, a decisive factor in the 
spread of tolerance and resistance (Hastings et al., 2002).
Elimination attempts, by definition, will have to target all infected humans (Targett 
and Greenwood, 2008), thus finding and treating asymptomatic carriers is a fundamen­
tal part of such efforts. This will jeopardise the reservoirs of sensitive parasites even if
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the treatment used for elimination is different from the standard first-line therapy. In 
this best-case scenario, if the elimination attempt fails, the frequency of resistance will 
probably increase above the pre-intervention frequency as asymptomatic carriers, the 
safe-haven for sensitive parasites, are treated. The worst-case scenario, using the stan­
dard first-line therapy for elimination, will drive a dramatic increase in resistance should 
the elimination attempt not succeed. It is also likely that a failed elimination interven­
tion will have worse consequences, for the spread of resistance, in high-transmission areas 
as a greater proportion of infections are asymptomatic due to semi-immunity conferred 
by repeated infection (Doolan et ah, 2009).
On the other extreme of the policy spectrum (i.e. maximising the number of un­
treated individuals to increase the relative fitness of sensitive parasites), a more radical 
approach to sub-clearance treatment would be to provide only palliative care. This 
would presumably be applied only to uncomplicated malaria cases on a voluntary basis. 
Analogous situations arise in other infectious diseases like influenza (Fiore et ah, 2011) 
where not all individuals are treated with anti-virals. Most unfortunately, malaria is not 
influenza, and the patient condition can deteriorate rapidly with complications like renal 
failure or even cerebral malaria which can manifest suddenly and have a high mortality 
rate (Mishra and Newton, 2009). Clearly, current adjunctive therapy cannot be seen as 
a palliative alternative to replace proper malaria treatment (John et ah, 2010).
The underlying premise that drug resistant parasites are out-competed by sensitive 
parasites in non-treated environments is based in sound evolutionary genetic theory 
which is consistent, for instance, with the observation in Malawi (Laufer et ah, 2006) 
where Chloroquine removal led to a rather rapid disappearance of CQ resistance pre­
sumably due to a fitness penalty of resistance mutations. Strategies to better exploit this 
effect are still not clear but rational public health policy should recognise that policies 
to eliminate and eradicate malaria might conflict with more modest strategies to pursue 
only control. Decision makers that embark on elimination policies should be reasonably 
sure that they will be able to meet the desired outcome as excessive optimism might 
lead to a serious control problem after the failure of well-meaning, but possibly disas­
trous elimination efforts. Therefore, proper risk-analysis encompassing many different 
factors ranging from donors’ ability to maintain funding, transmission intensity, local 
geo-political factors of the intervention area and the ability to conduct proper surveil­
lance and monitoring of an intervention among others is fundamental to assure that any 
elimination attempt will not develop into a difficult to control scenario. If the last man 
standing is indeed the most resistant (Maude et ah, 2009), shouldn’t at least be a Plan 
B in the case we indeed fail to cure him?
Part II
Fst selection detection and 
discovering genes involved in 
drug resistance
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LOSITAN: A workbench to detect 
molecular adaptation based on a
Fg^-outlier method
Tiago Antao, Ana Lopes, Ricardo J Lopes,
Albano Beja-Pereira and Gordon Luikart
Abstract
Background: Testing for selection is becoming one of the most important steps 
in the analysis of multilocus population genetics data sets. Existing applications 
are difficult to use, leaving many non-trivial, error-prone tasks to the user.
Results: Here we present LOSITAN, a selection detection workbench based on 
a well evaluated FgT-outlier detection method. LOSITAN greatly facilitates correct 
approximation of model parameters (e.g., genome-wide average, neutral Fst)> pro­
vides data import and export functions, iterative contour smoothing and generation 
of graphics in a easy to use graphical user interface. LOSITAN is able to use modern 
multi-core processor architectures by locally parallelizing fdist, reducing computa­
tion time by half in current dual core machines and with almost linear performance 
gains in machines with more cores.
Conclusions: LOSITAN makes selection detection feasible to a much wider 
range of users, even for large population genomic datasets, by both providing an 
easy to use interface and essential functionality to complete the whole selection 
detection process.
6.1 Background
Understanding the contribution of selection and molecular adaptation in shaping genome 
wide variation is among the most exciting and widely researched problems with many ap­
plications ranging from human health to conservation of endangered species. Among the 
many selection detection strategies (Nielsen, 2005), Fst outlier approaches are becoming
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widely used (Beaumont, 2005; Vitalis and Couvet, 2001) because they are important not 
only for studying the genetic basis of adaptation but also for eliminating non-neutral 
outlier loci from data sets before computing most population genetic parameters (e.g., 
Fst, Nm, Ne), that require neutral loci (Luikart et al., 2003). This is particularly im­
portant in a time where production of data sets with information from hundreds of loci 
is becoming fairly common.
One such FsT method is described in Beaumont and Nichols (1996); Beaumont 
(2005) (but see also Cavalli-Sforza (1966) and Lewontin and Krakauer (1975)) and is 
implemented in the fdist program and can be used for any codominant genetic molec­
ular markers including microsatellites, Single Nucleotide Polymorphisms (SNPs) and 
aliozymes. This method evaluates the relationship between Fst and He (expected het­
erozygosity) in an island model (Wright, 1931), describing the expected distribution of 
Wright’s inbreeding coefficient Fst vs. He under an island model of migration with 
neutral markers. This distribution is used to identify outlier loci that have excessively 
high or low Fst compared to neutral expectations. Such outlier loci are candidates for 
being subject to selection.
Using fdist can be a challenging task for those not familiarized with command-line 
applications and requires a specific data format not used by other applications (Excoffier 
and Heckel, 2006). Furthermore, several independent runs are usually needed to tune 
parameters (e.g., determine the appropriate average Fst) before a final execution is 
made in a process that is prone to human introduced mistakes. Fdist, not being one of 
the most computationally intensive programs available, can still take up to one hour for 
a single run (especially if smooth contours for confidence intervals are required), and, in 
most cases, multiple runs are needed for parameter tuning. Large population genomic 
datasets can take even longer. In this context, fdist requires experienced computer 
users, and its usage is error prone (e.g., by incorrectly converting data files or not 
approximating average Fst appropriately).
6.2 Implementation
We designed LOSITAN (LOoking for Selection In a TANgled dataset), a selection de­
tection workbench constructed around fdist. LOSITAN is a Java Web Start application 
coded mostly in Jython with a small part in Java, allowing direct execution from the 
web. LOSITAN provides the following features:
1. Easy to use interface (Figure 6.1), directly usable from the web.
2. Data import in Genepop (Raymond and Rousset, 1995) format.
3. Generation of graphics in several formats (PNG, SVG and PDF).
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Figure 6.1: LOSITAN console: Screen shot showing run parameters (bottom panel) 
and a graphical output with the simulated confidence area for neutral loci (middle color 
band) with loci from the original empirical dataset represented as dots. Outliers are 
tagged with labels.
Graphics can be generated in several formats (covering both bitmap and vector 
format styles) and parametrized in many ways (from choosing colours to deciding 
which labels are printed, among others). A completely unedited example of a PNG 
output is presented on Figure 6.2.
4. Data export in a format suitable for import into statistical packages like R (R 
Development Core Team, 2007) or commonly used spreadsheet software.
In case the user desires to further analyze the data or have total flexibility in gener­
ating graphics, LOSITAN makes available both the confidence intervals computed 
and the Fsts and heterozygosities for each locus.
A simple R script is supplied in order to facilitate loading the data into R. Loading 
in spreadsheet software is done simply by importing as a tab delimited file.
5. Choice of which populations and/or loci are studied.
6. Approximating mean neutral Fst (in the real dataset) by removing potential se­
lected loci.
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Figure 6.2: PNG output: Graphical output from LOSITAN in PNG format without any 
post-edition.
The initial mean dataset Fst is often not neutral in the sense that (initially un­
known) selected loci are often included in the computation. LOSITAN can op­
tionally be run once to determine a first candidate subset of selected loci in order 
to remove them from the computation of the neutral Fst- This value will be, in 
most cases, a better approximation of the neutral Fst (Beaumont and Nichols, 
1996). The procedure works as follows: LOSITAN is run a first time, using all 
loci to estimate the mean neutral Fst- After the first run, all loci that are outside 
the desired confidence intervals (e.g. 99% CIs) are removed and the mean neutral 
Fst is computed again using only putative neutral loci that were not removed. A 
second and final run of LOSITAN, using all loci, is then conducted using the last 
computed mean. This procedure lowers the bias on the estimation of the mean 
neutral Fst by removing the most extreme loci from the estimation. Naturally all 
loci will be present in the last run and will have their estimated selection status 
reported.
7. Approximating average simulated Fst to the average value found in the real 
dataset even when the experimental conditions are far from the ones where the 
theoretical formula Fst = 4 v^+i holds (e.g. low number of demes or the usage 
of the stepwise mutation model, common in microsatellite markers).
To be able to (optionally) approximate the average Fst in conditions far from the 
theoretical optimum, LOSITAN starts by running fdist for 10,000 realizations using 
the theoretical value, calculating the average simulated Fst, if the value is too far 
from the real average Fst, LOSITAN uses a bisection approximation algorithm 
running 10,000 realizations for every tentative bisection point. The algorithm
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works by iteratively slicing the interval of possible Fst values (i.e., between 0 and
1) in half at each iteration and choosing the mean of the bounds on each iteration 
(with the exception of the first iteration where one of the extremes is chosen). An 
example is provided to make the approach clearer:
In a certain demographic scenario we want to simulate a neutral Fst of 0.08. The 
algorithm starts by trying 0.08. If the result is higher than desired then 0.0 will 
be tried (creating an absolute lower bound limit), after that 0.04 (0.0 + 0.08) / 2 
will be tried, if the result is too low, 0.06 will be used next (i.e. (0.04 + 0.08) /
2) , the process repeats until the error margin is acceptable.
In practical terms the method was able to converge to the desired value in all cases 
tested (a completely trivial bisection approach is not possible as the method for 
computing Fst is stochastic and results might vary for the same input conditions).
8. Iterative smoothing of confidence interval contours.
Contour smoothing is achieved by running fdist an extra 5,000 realizations. The 
user can request smoothing an unlimited number of times until the result is deemed 
satisfactory.
9. Ability to use multiple CPU cores and processors when running fdist.
To be able to use multiple cores, LOSITAN divides the number of desired simula­
tion repeats among all available cores (although the application detects the number 
of existing cores, the user is able to change the number of simultaneous concurrent 
processes), this is possible because fdist simulation runs are independent, thus 
making parallelization a simple task. Tests show a near linear relationship be­
tween the number of cores used and performance gains, an existing 5-10% penalty 
is due mainly to joining the partial results together. LOSITAN, although being 
directly executable from the web is a client-side application and all computational 
intensive operations occur on the user computer and not on the server.
10. Automatic and transparent download of the latest version of fdist.
We maintain the latest version of the fdist application on the server, which is down­
loaded transparently by the client application whenever there is a new version. At 
the time of this writing the supported version is fdist2.
The interface includes tips for all the less obvious parameters and enforces constraints 
for all the user inputs which the system can infer are not correct.
6.3 Results and Discussion
In a beta test release to users the feedback was generally very positive stressing essen­
tially that the application is easy to use, allows to easily input and output data and
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deal with non-trivial parameter determination like calculating neutral Fst- Most im­
portantly it made users aware of issues in data analysis that they were not aware of. 
For example, users were not aware of how to estimate the genome wide average neutral 
Fst from their empirical data set by removing one or a few strong outlier loci, and the 
recomputing the average Fst- Although LOSITAN helps avoid many pitfalls involved 
with using FsT-outlier approaches in general, it is not able to solve fundamental issues 
regarding these approaches, for instance the non-linear behavior of Fst = m£Nm+i when 
Fst approaches zero can make it difficult to detect low FsT-outliers especially when 
selection is not strong. As such an easy to use application should not be seen by users 
as a excuse to avoid critical reasoning around the the whole selection detection process. 
Feedback from users also allows to chart possible future work, like supporting domi­
nant markers or supporting other selection detection approaches like Vitalis and Couvet 
(2001).
The most important and recurrent request from users pertains the support of large 
amounts of markers (mostly SNPs) that are being generated by next generation sequenc­
ing technologies. When version 1 of LOSITAN was released, typical datasets included 
less than 100 markers whereas now tens of thousands of markers are possible and even 
hundreds of thousands of SNPs are becoming common. LOSITAN version 1 would load 
all the genetic information into memory, thus any dataset bigger than available memory 
would not be readable by the application. LOSITAN version 2, uses an iterative parser 
which reads one individual at time and updates summary information making the ap­
plication usable with virtually unlimited markers. LOSITAN version 2 was tested with 
real datasets of up to 25,000 markers. While LOSITAN has currently no limit, fdist2 is 
limited to around 50,000 markers and, therefore, there is still a practical limit. If future 
users require more than 50,000 markers, changing the hard-coded limit of fdist2 should 
be feasible.
Our solution to use all the available computing power on new multi-core hardware is 
an example of an “embarrassingly simple parallel” computation approach. We contend 
that having a simple approach is a good principle: The point in this application is to 
make all computational power available to the users and not to develop new concurrent 
algorithms. A simple, highly efficient, elegant and less bug-prone approach is what re­
sponds to the users needs, as the objective of this work is not to develop new algorithms, 
but to use them.
6.4 Conclusions
LOSITAN is built along the principles exposed in Kumar and Dudley (2007), namely 
that intuitiveness and user empowerment should be fundamental guidelines for software 
construction targeting biologists. This is done, not only by supplying an easy to use web 
interface for an, otherwise, hard to use application, but also allowing the use of widely
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utilized population genetic data formats, automating the tuning of nuisance parameters 
and lowering the computational costs on modern hardware. In addition, strong emphasis 
is put on trying to avoid errors on the usage of the software either by both enforcing 
constraints and giving suggestions on less obvious features. This will lower the barriers 
to usage of the underlying application, allowing for a wider user base which will be 
able to concentrate more on the biological problems and less on unnecessary application 
complexity.
We are in the dawn of the era of multi-core computing. The vast majority of existing 
software cannot make use of the extra computational power made available on new ma­
chines. Our approach, based on partitioning a computational intensive task into smaller 
ones, can be used to leverage the extra computational power even without changing 
existing code on applications which can be broken into smaller independent running 
units. This partitioning approach can be performed in some cases by users on existing 
software or by programmers in new applications that take advantage of multiple cores. 
With the current trend of supplying many more cores with new computers, strategies 
like the one presented here will be mandatory in order to take full advantage of all the 
existing processing power. LOSITAN is one of the first of many applications to explore 
the multi-core programming paradigm.
Future planned developments will include addition of other F-outlier methods and 
simulation facilities for explore the effects of different demographic scenarios on Fst 
variance and the detection of outliers.
All the code to handle GenePop and fdist file formats and applications was also 
donated to the Biopython project and is publicly available starting from version 1.44.
6.5 Availability and requirements
Project name LOSITAN
Project home page http://popgen.eu/soft/lositan. Development site: http: 
//code.google.com/p/lositan/
Operating systems Platform independent 
Programming language Java and Jython
Other requirements Browser with JavaWebStart to run over the internet (software 
can be run locally).
Windows: At least Windows 2000 and Java 1.6.
Mac OS X: 10.4 (Tiger) and Java 1.5 (Most current 10.4 installations will require a 
freely available Java update).
Linux: Java 1.6 and the free GNU G compiler.
License GNU GPL
Any restrictions to use by non-academics None
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Mcheza: A workbench to detect selection
using dominant markers
Tiago Antao and Mark A. Beaumont 
joint-first authorship
Abstract
Motivation: Dominant markers (DArTk and AFLPs) are commonly used for 
genetic analysis in the fields of evolutionary genetics, ecology and conservation of 
genetic resources. The recent prominence of these markers has coincided with re­
newed interest in detecting the effects of local selection and adaptation at the level 
of the genome.
Results: We present Mcheza, an application for detecting loci under selection 
based on a well evaluated FgT-ontlier method. The application allows robust esti­
mates to be made of model parameters (e.g., genome-wide average, neutral Fst)i 
provides data import and export fmictions, iterative contour smoothing and gen­
eration of graphics in an easy to use graphical user interface with a computation 
engine that supports multi-core processors for enhanced performance. Mcheza also 
provides functionality to mitigate common analytical errors when scanning for loci 
under selection.
Availability: Mcheza is freely available under GPL version 3 from http:// 
popgen.eu/soft/mcheza.
7.1 Introduction
Non-specific amplification methods such as Diversity Arrays Technology (DArT) mark­
ers and amplified fragment length polymorphism (AFLP), are commonly used for anal­
ysis of within-species variation because they allow the rapid acquisition of substantial 
genetic information, at relatively low cost. Although other alternative sequencing tech­
niques have since been developed, DArTs and AFLPs are still widely used in the fields of 
evolutionary genetics, ecology and conservation. One of the most important applications
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of these dominant markers is in detecting the effects of selection and local adaptation 
at the level of the genome, in areas ranging from parasitology to conservation genetics.
There are two current approaches to detect selection: “classical” FsT-outiier ap­
proaches (reviewed in Storz, 2005), based on the distribution of summary statistics; and 
those based on likelihood (such as Beaumont and Balding, 2004; Foil and Gaggiotti, 
2008). The original FgT-outlier methods do not account for dominant markers such 
DArTs or AFLPs. These markers have two phenotypes detectable at each locus: one 
allele (the plus-allele) is amplifiable, whereas the other (the null-allele) is not. Het­
erozygous genotypes cannot be directly distinguished from homozygotes making the 
estimation of allele frequencies non-trivial.
A widely used FsT-outlier method (Perez-Figueroa et al., 2010) for detecting se­
lection with dominant markers is implemented in the package DFDIST. DFDIST is a 
modification of the FDIST program (Beaumont and Nichols, 1996) to allow for dominant 
markers, and implements the method of Zhivotovsky (1999) to estimate allele frequen­
cies. Briefly, coalescent simulations are used to generate a null sampling distribution 
of estimates of Fst based upon neutral expectations. The performance of the method 
has been examined, using data simulated with known levels of selection, in Caballero 
et al. (2008) and Perez-Figueroa et al. (2010). DFDIST has a complicated text-based 
interface that makes it difficult to use correctly. For example the tuning of parameters 
for the coalescent simulations is non-trivial, and the input dataset has to be formatted 
in a non-standard way. We describe Mcheza, a new application based on DFDIST, with 
a graphical user interface allowing easier configuration of some non-trivial parameters.
7.2 Software implementation
The Mcheza architecture is composed of two parts: the front-end implemented in Jython 
and the DFDIST back-end implemented in C. The front-end provides an interface similar 
to LOSITAN (Antao et al., 2008) (A selection workbench based on the analogous method 
for co-dominant markers). The interface provides the following functionality on top of 
DFDIST:
1. Estimation of the mean neutral Fst, while taking into account loci that might 
be under selection. While DFDIST requires an estimate of the neutral FgT, an 
empirical dataset will probably include loci under selection. Mcheza provides a 
mechanism similar to that in LOSITAN for estimating the neutral Fst based on 
removal of loci that are potentially under selection.
2. An improved method for ensuring that the simulated distribution of Fst has a 
mean that is close to the required value. DFDIST is only capable of providing a 
reliable approximation when close to theoretical conditions (i.e. when simulating
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a large number of populations). The Mcheza interface provides a correction that 
accurately approximates FgT even when the number of demes is very low.
3. Mcheza provides additional features in comparison with LOSITAN by supporting 
very large datasets: while LOSITAN is only able to support hundreds of loci 
and hundreds of individuals, Mcheza has been tested using real datasets with 
25.000 loci. Support for very large datasets is, as expected, computationally more 
intensive.
4. Mcheza also introduces support for multi-test correction based on false discovery 
rates (FDR) (Benjamini and Hochberg, 1995), as implemented in Chiurugwi et al. 
(2010). Without such a correction there is a danger in over-estimating the pro­
portion of loci that are under selection (Beaumont, 2008; Perez-Figueroa et ah, 
2010).
5. A multi-core aware version of DFDIST with computational performance gains that 
are near linear with the number of cores.
6. An easy-to-use interface including the ability to import data in the standard 
Genepop format (Rousset, 2008), generation of charts, export in standard for­
mats including R (R Development Core Team, 2007) and spreadsheets, iterative 
smoothing of confidence contours, choice of population and loci among other fea­
tures.
The application, based on the Java Web Start technology, requires only a browser 
with a modern version of Java installed (on Linux the GNU C compiler is also required). 
The Java code will detect the operating system and choose the correct DFDIST imple­
mentation.
The use of the Jython programming language allows the use of Biopython (Cock 
et ah, 2009) which provides a parser for Genepop files. Our Python code to interact 
with DFDIST is incorporated in the Biopython population genetics module allowing 
for bioinformatics programmers to directly interface with the DFDIST core using the 
Python programming language.
7.3 Discussion
A fundamental consideration in the design of Mcheza is supporting the user by correctly 
computing important non-trivial parameters that are needed to properly calculate can­
didate loci for selection. Erroneous usage of population genetics applications can easily 
produce results that seem correct but are, in effect wrong.
While Mcheza tries to minimise usage errors, the user should be aware of potential 
limits of the underlying method. Potential users are advised to read Caballero et al.
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(2008), Perez-Figueroa et al. (2010) and Excoffier et al. (2009) where several scenar­
ios where DFDIST is less applicable are clearly explained. In particular, the Bayesian 
method of Foil and Gaggiotti (2008), implemented in the program BayeScan is an impor­
tant alternative, with which results should be compared. By improving the estimation 
of the neutral mean Fg-p when the number of demes is low, Mcheza addresses situations 
where DFDIST is known to perform less well (Perez-Figueroa et al., 2010).
In summary Mcheza tries to provide an intuitive interface, which includes intelligent 
suggestions to the user with regards to correct usage of software, while enforcing model 
constraints and providing necessary corrections (e.g. FDR support). It is hoped that 
this approach will lower barriers to its use, allowing researchers to concentrate more 
on the biological problems (including the theoretical assumptions and limitations of 
underlying models) and less on unnecessary software complexity.
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interPopula: a Python API to access the
HapMap Project dataset
Tiago Antao 
Abstract
Background: The HapMap project is a publicly available catalogue of common 
genetic variants that occur in humans, currently including several million SNPs 
across 1115 individuals spanning 11 different populations. This important database 
does not provide any programmatic access to the dataset, furthermore no standard 
relational database interface is provided.
Results: interPopula is a Python API to access the HapMap dataset. inter­
Popula provides integration facilities with both the Python ecology of software (e.g. 
Biopython and matplotlib) and other relevant hmnan population datasets (e.g. En- 
sembl gene annotation and UCSC Known Genes). A set of guidelines and code 
examples to address possible inconsistencies across heterogeneous data sources is 
also provided.
Conclusions: interPopula straightforward and flexible Python API facilitates 
the construction of scripts and applications that require access to the HapMap 
dataset.
8.1 Background
The HapMap project (International HapMap Consortium, 2007) (http://hapmap.ncbi. 
nlm.nih.gov/) is an effort to identify and catalogue genetic similarities and differ­
ences in humans. The project makes information available on single nucleotide poly­
morphisms (SNPs), and it more recently added information on copy number variation 
(CNV). HapMap phase 3 includes data on 1115 individuals (around 1.5 million SNPs 
per individual) spanning 11 populations while phase 2 included only 4 populations (270 
individuals) but more than 3.5 million SNPs per individual. This dataset can be useful 
in a multitude of situations from finding genes that affect human health to evolutionary
69
70 CHAPTERS. INTERPOPULA
research about the human species or for genome-wide association studies. All of the 
information generated is released into the public domain and can be downloaded with 
minimal constraints.
The HapMap project provides access to the data in bulk form (via FTP download), 
a web interface (Thorisson et al., 2005) which includes a genome browser (Stein et al., 
2002) and the data mining application HapMart based on Biomart (Smedley et al, 
2009). Programmatic and relational database interfaces are not offered though some 
API support is implemented by external parties such as a generic Perl API for variation 
datasets in Ensembl (Rios et al., 2010), BioPerl’s Bio::PopGen module (Stajich et al., 
2002) or the GGtools package (Carey et al., 2007) for R/Bioconductor. Most existing 
libraries support only a subset of features (e.g. parsing of HapMap file formats or creat­
ing a local database) making the construction of scripts and applications more complex 
as basic data manipulation functionality must be built as least partially. Furthermore, 
there is no known Python library supporting HapMap data.
8.2 Implementation
interPopula provides a Python API to access the HapMap dataset. Interfaces to all 
HapMap phases are supported including phase 2 data with fewer populations but more 
SNPs genotyped per individual and phase 3 covering more populations. interPopula 
provides access to frequency, genotype, linkage disequilibrium and phasing datasets. 
The recent CNV dataset is also supported along with family relationships for the 5 
populations where sampling was performed for family trios (mother, father and one 
offspring).
Support for annotation information that is commonly needed to process HapMap 
data is also provided through an API to both the UCSC Known Genes dataset (Hsu 
et al., 2006) from the UCSC genome browser database (Rhead et al., 2010) and the 
Ensembl gene annotation database (Curwen et al., 2004).
The API was constructed according to the following design guidelines:
1. The API is straightforward and self-contained. The core API requires only a 
Python interpreter, has no extra dependencies and minimal administrative over­
head.
2. Downloaded data is stored on an SQL database for faster access. All data is stored 
using SQLite (SQLite Development team, 2010) which is natively supported in 
Python thus lowering the maintenance costs of the system. interPopula can also be 
connected to enterprise-grade databases which support multiple users, concurrent 
usage and large datasets for which the standard sqlite backend might not be enough 
(a PostgreSQL example is provided).
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3. Data management (i.e. downloading from the HapMap site and local database 
construction) is fully automated: the required data subset is downloaded on de­
mand only once and stored locally, reducing the load on both the client and server.
4. While SQL interfaces are made available from both the UGSC and Ensembl 
projects for their annotation databases, interPopula uses the same implementa­
tion strategy for the HapMap dataset: files are intelligently downloaded and locally 
stored. This provides a consistent interface to these two datasets which provide 
important annotation information frequently used to process HapMap data.
5. The framework is extensible and designed to be easily integrated with other Python 
tools and external databases. The web site provides several examples of integration 
with standard tools used in Python for bioinformatics such as Biopython (Cock 
et ah, 2009), NumPy (Oliphant, 2006) and matplotlib (Hunter, 2007).
6. Integration with Biopython allows for access to the Entrez SNP database and 
the population genetics tools supported by Biopython such as Genepop (Rousset, 
2008) allowing automated analysis of datasets.
7. Facilities to export HapMap data to Genepop format are provided enabling (non- 
automated) analysis of the HapMap dataset with the plethora of population ge­
netics software which support this format. Data export can also be use to initialize 
population genetics simulators like the Python-based simuPOP (Peng and Kim- 
mel, 2005) allowing computational simulations to be initialised with real datasets.
8. A large set of scripts is included, serving both as utilities to analyse the data, as 
well as examples of database and external tool integration. Currently we provide 
examples of integration with Entrez databases (nucleotide and SNP), the Genepop 
population genetics suite and charting libraries.
9. A set of guidelines and scripts was developed in order to facilitate a consistent view 
across heterogeneous databases. HapMap, Ensembl, UCSC Known Gene and the 
Entrez databases might not be fully consistent among themselves and, if care is 
not taken, database integration efforts might lead to erroneous results. The main 
pitfall is the usage of different NCBI reference builds across different databases, 
most notably HapMap is still based on build 36 whereas other databases either 
support multiple builds or only the most recent build 37.
10. A robust open-source software development process is put in place: a full public 
web based platform (hosted on Launchpad) is used to maintain the code infras­
tructure and unit tests approach 100% coverage.
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8.3 Results
interPopula can be used to create a wide range of applications and scripts based on the 
HapMap dataset. The most commonly expected usage pattern will be for genome wide 
association studies, though the example presented here will be of a different nature.
As an example of usage, we present a population comparison of all the genotyped 
SNPs for a gene. We will plot the Fst statistic for all Lactase SNPs between two 
HapMap populations: Utah residents with Northern and Western European ancestry 
(CEU) and Yoruban in Ibadan, Nigeria (YRI). These populations are known to differ in 
their tolerance to lactose (Tishkoff et al., 2007). This example uses genotype information 
from HapMap and also demonstrates the integration facilities with UCSC Known Genes 
(to retrieve gene position and exon data), matplotlib (used for plotting), Biopython and 
Genepop (used to calculate Fst)-
This example, which is quite complex in terms of integration between several databases 
and tools can be broken down into the following steps:
1. Load the Known Genes database. The version pertaining build 36 should be loaded 
to assure consistency with HapMap.
2. Determine relevant information about Lactase from Known Genes. The following 
information is needed: The chromosome on which it is located, the start and end 
positions in the chromosome and all exon positions.
3. Load HapMap genotype information for the CEU and YRI populations for the 
relevant chromosome.
4. Retrieve all the HapMap SNP ids between the start and end positions in the 
chromosome.
5. Export a Genepop formatted file with two populations including all HapMap SNPs 
for Lactase.
6. Call the Genepop application via Biopython to calculate the Fst for all markers.
7. Plot the calculated Fsts along with the exon positions.
The result of this example is shown in Figure 8.1. The X-axis reports the position 
along chromosome 2, Fst in on the Y-axis, the dots represent the Fst values for existing 
SNPs on the HapMap database and the red boxes are the exon positions (17 in the case 
of Lactase). Interpreting the results of this specific application of interPopula is beyond 
the scope of this manuscript but at least two different interpretations are possible: (i) 
SNPs where Fst is above approximately 0.45 are candidates for positive selection (as 
around 95% of Fst values for humans are below 0.45 (Akey et al, 2002)) or (ii) the Fst 
statistic is noisy when applied to a single marker (Kelley et al., 2006) .
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Figure 8.1: Fst for Lactase between 2 HapMap populations: Fst between CEU and 
YRI populations for all Lactase SNPs on the HapMap database. The X-axis reports the 
position on chromosome 2 (the value on the lower right is the absolute offset from the 
beginning of the chromosome), the Y-axis the Fgx value. The dots represent the Fst val­
ues for existing SNPs on the HapMap database. The red boxes represent exon positions. 
To construct this chart HapMap frequency data and the UCSC Known Genes database 
were consulted. Biopython and Genepop were used to compute the Fst statistic.
The above example was constructed using the UCSC Known Genes database but 
the programmer can alternatively use the Ensembl gene annotation database instead.
This example (script IGFstGene.py in the distribution), along with more than 20 
others including data export, connection to enterprise-grade databases, analysis of the 
distribution of the number of exons per gene, the distribution of genes per chromosome 
are made available with interPopula.
In order to illustrate interPopula’s basic API, Figure 8.2 shows a commented script 
which provides useful functionality. In this example the HapMap frequency database is 
consulted to report the frequency of both alleles for each SNP within a certain chromo­
some interval. The code example is less than one page in length and there are only 4 
API calls to achieve the complete functionality. This is one case illustrating the ease
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of use of the API. All scripts provided with interPopula are documented to the level of 
the example presented and automated documentation covering the full API is extracted 
from the source using epydoc (http://epydoc.sourceforge.net/).
The part of the API devoted to both UCSC Known Genes and the Ensembl gene an­
notation database can be used stand-alone to access both databases, i.e., it can be used 
for application and scripts that have no relationship with the HapMap data. interPop- 
ula’s UCSC and Ensembl APIs can be used to access also non-human data as genome 
annotations are available for other species. This is especially useful with the Ensembl 
dataset as it makes available gene annotation information for many other species. Users 
should note that the quality of the datasets for other species varies as more effort is put 
in the curation of human data (e.g. while for humans the chromosome information is 
normally the chromosome number, for cats - Felis catus - it is mostly scaffold data). 
Stand-alone example script examples are provided for both datasets.
Future development efforts for interPopula will focus on supporting large datasets. 
As sequencing costs continue to decrease and the sequencing of complete genomes be­
comes commonplace it is clear that the backend infrastructure will have to be redesigned 
to support the large amounts of data generated by such efforts. In this context, sup­
porting the 1000 genomes project (The 1000 genomes project team, 2010) is a natural 
extension for interPopula as many of the samples used in this project come from the 
HapMap dataset. While the API for UCSC and Ensembl extensions provides access 
to other species data, the main focus of interPopula will remain providing robust and 
well-maintained APIs for publicly available human genomic datasets which lack a stan­
dardized Python API or relational interface.
8.4 Conclusions
interPopula is a flexible, straightforward Python API to the HapMap project. It strives 
to integrate with both common Python bioinformatics and scientific libraries and other 
genomic databases that are commonly used in conjunction with the HapMap dataset. 
interPopula makes HapMap data processing possible inside Python, thus opening the 
possibility for the development of a plethora of interesting applications and scripts that 
make use of this important resource for human population genomics studies.
8.5 Availability and requirements
Project name interPopula
Project home page http: //popgen. eu/sof t/interPop/. Development site: https 
//launchpad.net/interpopula
Operating systems Platform independent 
Programming language Python
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Other requirements Optionally NuraPy, Biopython, Genepop and matplotlib 
License GNU GPL version 3
Any restrictions to use by non-academics None
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tram interPopula import Config
from interPopula.HapMap.Frequency import Frequency
^configuration directory 
Config. dataDir = ,,.M
#tfan Chinese Lactase information pop = "CHB" 
chr = 2
startChr = 136261855 
endChr = 136311220
#Lets get the Frequency information 
freqDB = Frequency ("2010-05jhaselll")
# We require a chromosome and population 
freqDB.requireChrPop(chr, pop)
# We need to get the RSIds for the interval
RSs = freqDB.getRSsForlnterval(chr, startChr, endChr)
print "rsid allele 1 freqAIlelel allele2 freqAllele2" for rs in RSs:
#We get frequency information 
freqSNP = freqDB.getPopSNPs(pop, rs)
#al retrives allele 1 (A,C,T,G), a2 does the same for 2 
al = freqSNP[5]
a2 = freqSNP[6]
#freguency of al homozygotes 
alal = freqSNP[7]
^frequency of a2 homozygotes 
a2a2 = freqSNP[8]
#freguency of heterozygotes 
ala2 = freqSNP[9]
#gets the frequency of allele 1
fal = (2.0*alal+ala2)/(2*alal + 2*a2a2 + 2*ala2)
print rs, al, fal, a2, 1 - fal
^example output
#rsid allelel freqAIlelel allele2 freqAllele2)
#730005 C 0.727941176471 T 0.272058823529 
#872151 C 0.658088235294 T 0.341911764706 
#1042712 C 0.36496350365 G 0.63503649635 
#[. . .]
Figure 8.2; Example code to print the frequency of HapMap SNPs: This example de­
scribes how to consult the HapMap frequency database to retrieve the allele frequencies 
for a set of SNPs in section of a chromosome.
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Detecting F^-outliers and selection 
requires genotyping multiple SNPs per 
gene: lessons from empirical data
Tiago Antao and Gordon Luikart 
Abstract
Single nucleotide polymorphisms (SNPs) are increasingly used to identify genes 
under selection using FgT-outlier tests. However, researchers often genotype only a 
few SNPs per gene. We quantify the sensitivity of using only a few SNPs in a gene 
to identify high Fg-r-outlier genes using large empirical data sets from humans. We 
find that genotyping less than four random SNPs generally gives low power (<80%) 
to detect genes that are known to be under directional selection, because of high 
variation in Fst among SNPs. These results held even for genes with the largest 
proportion of high-FgT SNPs. For example, alleles in the lactose tolerance gene 
have been under strong selection in humans in Northern Europe. However, only 15 
of 61 SNPs across the gene show excessively high Fst (>0.45). Inferring haplotypes 
using 4-8 random SNPs seldom increased the power to detect high FgT-outliers. 
We recommend genotyping >3 SNPs per gene to have a reasonable probability of 
identifying high FsT-outlier genes. Genotyping >3 SNPs per gene will not substan­
tially increase the false positive rate. Importantly, our results suggest that common 
SNP genotyping strategies (e.g. SNP chips, RADs, exon capture) often have too 
few SNPs per gene region to reliably detect selection.
Keywords: Statistical power, Fst, HapMap, selection, molecular adaptation, 
single nucleotide polymorphisms, candidate genes.
9.1 Introduction
“The problem is that our knowledge about false negatives is even more rudi­
mentary than about false positives. For panmictic populations, the power of
77
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many tests to detect selection is known to be rather low. For a structured 
population, this information is basically missing.”
Hermisson (2009)
Many genome scans and candidate gene studies that test for natural selection use 
only one or a few SNPs per locus (along with tests for FsT-outliers) because it is costly 
to discover and genotype many SNPs per locus (Narum and Hess, 2011; Bourret et ah, 
2011). Unfortunately, high variation in Fst and weak linkage disequilibrium among 
SNPs in a gene could lead to low power to detect Fsx-outliers, even following a strong 
selective sweep driving a certain haplotype or SNP(s) to high frequency in a local pop­
ulation.
Computational simulations are the most common approach to research the perfor­
mance of methods to detect selection (see e.g. Beaumont and Balding, 2004; Vitalis 
et al., 2003). Use of computational simulations, instead of empirical data, is helpful 
because for most genomes and populations little is known about which genes are under 
selection, where complete understanding of selection exists for simulated populations. 
Unfortunately computational simulations have limitations such as the use of simplifying 
assumptions about demography, genomic structure, recombination rates, and patterns 
and strength of selection.
For some species (e.g humans or pathogens such as Plasmodium falciparum) there 
have been extensive genome and population studies and several genes are known to be 
under selection. In some cases the mode of action of the gene and the mutations that 
affect protein function are also known. If the function, relevant mutations and/or mode 
of action of a gene are known then it becomes possible to evaluate a selection detection 
method against empirical data data: If we know that a certain locus is under directional 
selection, what is the Fst for individual SNPs and haplotypes? Does Fst indicate 
directional selection? How many SNPs are needed to detect a signal of directional 
selection?
If large genome-wide datasets are available with reliable annotation, we can also 
search for all genes that have the largest proportion of SNPs with high Fst and compute 
the probability of detecting such a gene when only using a small number of SNPs. We 
can then answer the question: How many SNPs must we genotype in order to have high 
power (above 80%) to detect a high Fst locus?
Many species have much less information available than humans, at several levels: (i) 
There is no assembled genome reference sequence; (ii) gene function is mostly unknown 
or (hi) most studies lack the resources to genotype thousands of SNPs in thousands of 
genes. Here we use the information from the human HapMap project (International 
HapMap Consortium, 2007) which includes millions of genotyped SNPs and also avail­
able information about several human genes known to be under directional selection 
(e.g. involved in skin pigmentation, lactase persistence or protection against malaria).
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We then “sample” from the HapMap dataset using only a few SNPs per gene (from one 
to eight, typical of studies in many other species) and ignoring any information about 
gene function and location. We then compare our findings by searching “blindly” with 
the known information about existing genes. Can we find genes that are known to be 
under selection using less information (few SNPs and no information about gene func­
tion)? This question is important for non-model species, and can also be useful with 
model taxa, as studies genotyping small numbers of markers are still common.
The main question that we address in this paper can be broadly expressed as: “If 
there is a gene under selection, (or with many high Fgn SNPs) how many SNPs must 
we genotype in order to detect it?” We are thus concerned with lowering the number of 
“false negatives”, a rarely addressed question with FgT-outlier approaches (Hermisson, 
2009). Here we evaluate and propose genotyping strategies to help researchers detect 
directional selection and avoid “false negatives”. We also briefly address the impact of 
our proposals on the false positive rate (i.e. erroneously concluding a low-Fgx locus 
(e.g. neutral locus) has exceptionally high-FsT)- This study has applications to current 
research in model and non-model species, namely with:
1. Limited genome scans where approximately 100-1000 SNPs are sampled to detect 
selection in genes (Narum and Hess, 2011; Bourret et ah, 2011).
2. Candidate gene studies where tens-to-hundreds of genes are genotyped (using SNPs 
discovered or genotyped with techniques such as exon capture and next generation 
sequencing (Cosart et al., In press)).
9.2 Methods
We used HapMap Project Phase II+III data files (release 28) (International HapMap 
Consortium, 2007; Altshuler et al., 2010) for SNP analysis. Two populations were used: 
Utah residents with ancestry from northern and western Europe (CEU) and Yoruban in 
Ibadan, Nigeria (YRI). We removed offspring from the CEU and YRI samples and anal­
ysed only the data from 60 unrelated parents for each population. We used haplotype 
phase estimation performed using parent-offspring trios and imputation (Howie et al., 
2009) by the HapMap consortium. In total, the numbers of polymorphic SNPs analysed 
for each population were 279,448 and 155,772 for chromosomes 2 and 12 respectively 
plus all SNPs for studied genes from other chromosomes (Table 9.1). All HapMap data 
used is based on NCBI genome build #36, thus all physical positions reported will be 
related to that build. To obtain human gene information (genomic location, number, 
position and size of exons) we used the UCSC Known Genes database (Hsu et al., 2006) 
(if different gene annotations were available for the same gene, we use the one which 
the largest gene size). Fgx was calculated according to Weir and Cockerham (1984) 
as implemented in Genepop (Rousset, 2008). Fgx was calculated for individual SNPs
80 CHAPTER 9. DETECTING FSt-OUTLIERS
and for haplotypes across each gene (blocks). Automated downloading and processing 
of HapMap data was done using interPopula (Antao, 2010). For automated bulk calcu­
lation of FSt we used Biopython (Cock et al., 2009) to control Genepop and parse its 
output.
We studied the Fst for individual SNPs and haplotypes for 5 genes that are known 
to have been under directional selection (see Tables 9.1 and 9.2). For chromosome 2, 
we also identified the 5 genes (with >20 SNPs genotyped) with the highest proportion 
of Fst SNPs above 0.45 (hereby termed high-FST SNPs) and again studied individual 
SNP and haplotype Fst- We computed for all genes the mean, median and maximum 
SNP Fst- We also computed the probability of finding a SNP with Fst above 0.45 
when genotyping sets of 2, 4 or 8 SNPs randomly sampled (without replacement within 
a sampled set).
We used the haplotype information made available by the HapMap project and 
computed haplotypes with 2, 4 and 8 SNPs. SNPs were randomly chosen not using any 
existing information about tag SNPs (as tag information is normally not available for 
non-model species). We then also computed FgT using haplotype reconstructions for 
each set of 2, 4 and 8 randomly sampled sets of SNPs.
To quantify the false positive rate, we computed the probability of detecting at least 
one high-FsT SNP using 1, 2, 4 and 8 SNPs in the following cases: (i) random sample of 
SNPs across a whole chromosome (using chromosomes 2 and 12), (ii) random samples 
of SNPs inside a 150 kb interval (from chromosome 2 or 12); and (iii) random samples 
of SNPs inside genes retrieved from the UCSC Known Gene database for chromosomes 
2 and 12.
9.3 Results
Among the 5 human candidate adaptive genes under directional selection that we stud­
ied, all have at least one SNP with Fst above 0.45 (Figure 9.1). The mean number of 
SNPs with Fst above 0.45 is 18.9%. Among the 5 high-FgT genes that we studied all 
except one have less than 50% SNPs with a FSt above 0.45 (mean 35.7%).
When considering only SNPs with heterozygosity above 0.2 this pattern remains 
unchanged, though the frequency of SNPs with Fst above 0.45 increases slightly (from 
a mean of 24.1% for both classes to 39.3% — Table 9.3). Genotyping 2 random SNPs 
will increase the probability of detecting at least one high FSt SNP above 50% for most 
genes. Power above 80% will require 4 to 8 SNPs per gene to detect at least one SNP 
with Fst above 0.45.
For the five putative genes under selection, the probabilities are slightly lower than 
for the five high Fst genes: two SNPs are rarely enough to have probability above 50% 
and in most cases 8 SNPs are required to have power above 80%.
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Gene
symbol
Chromos.
number
Start
position
Length 
of gene
(kb)
Number 
of exons
Length 
of exons 
(kb)
Candidate genes under directional selection
MDM4 1 202752133 33842 10 2027
LOT 2 136261884 49336 17 6274
KITLG 12 87410697 87672 10 5434
OCA2 15 25673615 344438 24 3140
SLC24A5 15 46200460 21421 9 1617
High-Fgx genes
ANTXRl 2 69093992 133000 13 2125
CAB39 2 231285908 108123 9 3718
CAD 2 27293761 26397 44 7108
CLASP1 2 121811824 311698 39 8086
MAP4K3 2 39329925 187798 34 4113
Table 9.2: Summary information for all 10 genes used. The first five genes are known 
to be under directional selection. The last five have the largest proportion of SNPs 
(chromosome 2) with Fst above 0.45. The table includes the symbol name, chromo­
some number, start position in relation to NCBI human genome build #36, gene length 
(introns and exons), number of exons and length of all exons together.
For long genes (with total length - exons and introns together - of at least 100 kb) 
it is possible that only certain segments of the gene have SNPs with substantially high 
Fst’s. For example the ANTXRl gene has 60% of all SNPs with an FSt > 0.45 in the 
first 25% stretch (5’ end) of the gene, but this number drops to 0% in the last 25% (3’ 
end; Table 9.3 and Figure 9.2). Similarly, the OCA2 gene has 0% of SNPs with high-FST 
in the start (5’) stretch.
The probability of finding a high-FsT SNP on chromosome 2 while sampling 1, 2, 
4 and 8 SNPs in random 150 kb length zones is respectively 3.6, 6.8, 11.8 and 22.8% 
(Table 9.3). Sampling known genes (including introns) has similar probabilities of 3.6, 
6.8, 11.6 and 18.7% respectively. If SNPs are chosen completely at random from the 
entire chromosome 2 (not within a subregion) then the probability of finding a high Fst 
SNP is respectively 6.4, 12.4, 23.3 and 41%. Again, using SNPs where heterozygosity 
is above 0.20 increases the probability of finding a high Fst SNP. We repeated this 
analysis for chromosome 12 and results were qualitatively similar.
Haplotype reconstruction (Figure 9.3) suggests that using 4-8 SNPs will make Fst 
converge to a single value per gene. This happens even when randomly choosing SNPs 
to construct haplotypes. The genes under selection or the genes with a high proportion 
of high Fst SNP tend to have an haplotype Fst above putative neutral genes, but this 
value of haplotype Fst is still often below 0.45.
Finally, we verified our results by comparing overall Fst for chromosome 2. While 
we know of no studying reporting pair-wise Fst between YRI and CEU populations, our 
results are comparable to other reports (see e.g. Amato et al,, 2009): We used 120684
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Fst distribution for 10 genes
Figure 9.1: The Fst distribution for all SNPs in the 5 genes under directional selection 
and 5 genes in chromosome 2 with the highest proportion of SNPs with FSt above 0.45. 
Bottom and top edges of boxes are the 25% and 75% percentiles of the distribution. The 
horizontal bar in each box is the median (i.e. 50% percentile). The whiskers extend to 
the most extreme data point below 1.5 times the inter-quartile range from the box.
SNPs and obtained a median FSt of 0.0712, mean 0.1181. The 0.45 point is the 96.4% 
percentile and 0.494 is the 97.5% percentile (for 95% confidence intervals).
9.4 Discussion
Our most important result is that genotyping only one or few SNPs per locus is often 
insufficient to detect high Fst and directional selection associated with local adaptation
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or speciation (Beaumont, 2005). We first discuss this problem of “false negatives” (i.e. 
failure to detect selection).
SNP sampling and false negative rates
Sampling a single random SNP is rarely enough to detect a high Fst gene. Even in the 
case where, by definition, the gene has a high proportion of high Fgx SNPs, genotyping 
only one random SNP will give at most 56.1% probability of detecting Fst above 0.45 
(Table 9.3). Most high Fgx genes might often require at least 4 SNPs to have power 
near 80%. Genes that are known to be under selection will often require up to 8 SNPs 
in order to have power above 80% . As expected (Allendorf and Seeb, 2000) using SNPs 
with expected heterozygosity above 0.2 slightly improves, in most cases, the power to 
detect High Fst genes.
Our results suggest that current sampling strategies (with only 1 or 2 SNPs per gene) 
with many non-model species are insufficient to detect genes with high-Fsx SNPs. Even 
with 4 SNPs sampled (genotyped), some high-Fst genes likely would not be detected at 
80% power.
It is not clear if Fst can reliably detect selection when genotyping less than 8 (or 
even more) SNPs when directional selection is relatively weak. For instance research 
from (Atwal et al., 2009) suggests that the MDM4 gene is only under selection on CEU 
populations and our results suggest detection would be improbable (59.0-69.7%) with 
even 8 SNPs.
If genes are long (e.g. >100-200kb), having different set of SNPs targeting dif­
ferent parts of the gene should increase the power to detect High-FsT areas. As the 
cases of ANTXR1 and OCA2 demonstrate that high Fst gene subsegments might be 
concentrated in some specific part of a gene. This effect can be explained with two com­
plementary observations: long genes will have a higher probability of spanning areas 
with in-between recombination hotspots and if the selection effect is ancient recombina­
tion will potentially lower Fst in parts of the gene distant from the actual area under 
selection.
Haplotype inference
Haplotype inference tends to converge to a central value per gene as the number of 
SNPs used is increased (Figure 9.3), even with a random choice of SNPs. Genes with 
high-FsT or under selection tend to converge to higher values than other genes, though 
not to values above the 0.45 cut for SNPs. Nonetheless is seems clear that a rank 
based on haplotype Fst is possible: the higher the haplotype Fst, the greater the 
probability of being a gene under selection or with high-FsT- Haplotype reconstruction 
is, unfortunately problematic with most species: The YRI and CEU populations of the 
HapMap dataset are a best case scenario as pedigree information (mother, father and
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offspring) is available and was used to perform haplotype reconstruction. Most other 
datasets (including human datasets) will not have as much information to do haplotype 
reconstruction and thus such as option will probably not be available in many studies.
False positive rates
While it is not possible to completely characterise the false positive rate (as the neutrality 
status of all segments of genome is not known) it is possible to quantify the probabilities 
of: (i) detecting 1, 2, 4, 8 SNPs with high-FsT by random sampling; (ii) detecting 
high-FsT SNPs in a 150 kb block and (iii) finding high-FsT SNPs in all genes. These 
quantifications will be over-estimates of the false positive rate (as they will also include 
parts of the genome that are either under selection or strongly linked to areas under 
selection).
Finding 1, 2, 4 and 8 SNPs with High-FsT by randomly sampling shows qualitatively 
different results when scanning 150 kb spans of chromosomes and, genotyping SNPs in 
known genes. Indeed, when using 8 SNPs the “false positive rate” will more than double 
when comparing totally random scans to inside-gene scans. This suggests that FgT is 
not distributed randomly and that high Fst SNPs tend to cluster together (as found, 
using a different method, in Akey et al. (2002)), this is further confirmed as a smaller 
window (150 kb) has less probability of finding a high SNP Fst than a longer window 
(1.5 mb), especially when 8 SNPs are used. Both non-random genotyping strategies 
suggest that with 4 to 8 SNPs between 10 and 40% of all observations would report 
back a high-FgT location. Discounting real observations of selection, the false positive 
rate will probably be still above 5% with 4 SNPs and probably above 15% with 8 SNPs. 
Even so, with an average coverage of 8 SNPs or less per gene, and assuming that the 
highest Fst SNP found as a representative for the gene, Fst might be a reasonable 
strategy in the face of the low information available to detect genes under directional 
selection.
Gene targeted approaches are thus beneficial to detect selection because the false 
positive rate is lower in genes than in random SNPs or even chromosome segments 
and selection is often directed at genes. Furthermore, gene targeted SNP discovery is 
increasingly feasible in non-model species (Cosart et al., In press).
SNP genotyping and discovery
This research questions the usefulness of increasingly available high density SNP chips 
(micro-arrays) for detecting selection when the SNPs are evenly distributed across the 
genome. For instance, the cow 54k SNP chip design of Matukumalli et al. (2009) with 
a minimum gap of 22.5 kb between SNPs would often be insufficient because <4 SNPs 
would occur in many genes (e.g. in 4 out of the 10 studied genes we studied here), SNP 
chips with shorter gaps between SNPs (e.g. <10 kb between SNPs) could be developed
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to increase the power to detect selection. For chip design, SNPs in genes could also 
be favoured to allow a gene-targeted approach to increase the probability of detecting 
selection.
Exon capture provides an ideal SNP discovery and genotyping technology for detect­
ing selection using either a candidate gene approach or a genome wide scan approach 
using gene-targeted SNPs (Hodges et al., 2007). For example, exon capture micro-arrays 
can be designed to allow for next generation sequencing of a few exons from each of tens 
to thousands of genes (Cosart et al., In press). This would allow genotyping of 4 to 8 
SNPs per gene if at least approximately 2 kb were sequenced per gene (assuming one 
ore more SNPs per 500 bp as is common in natural populations (Morin et al., 2004; 
Hohenlohe et al., 2010). Exon capture also allows targeted sequencing of 3’ and 5’ exons 
(Cosart et al., In press), which helps avoid missing selection signatures occurring at only 
one end of a gene as in ANTXR1 (Figure 9.2 c).
Limitations
Our analysis is subject to limitations. First, we only considered pair-wise Fst as we 
only include two populations in our study.
Secondly, calculating the false positive rate across entire chromosomes or gene sets 
is not trivial as the selection status of most genes is not known. Therefore we can only 
provide the probability of finding high-FsT SNPs using different sampling strategies and 
from there conduct an informed assessment of the possible false positive rate of different 
genotyping strategies.
Our work is highly dependent on the quality of both the Known Gene and the 
HapMap databases. The HapMap project dataset is known to suffer from ascertainment 
bias (Clark et al., 2005) and, for association tests between SNPs and complex disorders 
the power should be slightly eroded. This problem can be addressed with the complete 
sequencing of genomes (e.g., the 1000 genomes project http://www.1000genomes.org/). 
Most importantly, the Know Genes database included in some cases and for the same 
gene different alternatives for gene size and exon number and position. Manual inspec­
tion suggested that differences were minor in most cases and that the quality of the 
curation for this dataset is, and will be for the foreseeable future much better than 
similar information for non-model species (if it is available at all).
Here we focused on two distinct problems: (i) the ability to detect high-FsT genes 
when they exist and (ii) detection of high-FgT SNPs in genes that are under selection. 
For point (i), it is clear that we used only a small subset of genes (5), but such a lim­
ited subset is enough to address the fundamental question that even for genes with a 
high percentage of high-FgT SNPs, detection clearly requires more SNPs than is com­
monly used for non-model species and limited genome wide scans and candidate gene 
approaches. For point (ii), it is less clear what has been the actual mode(s), timing, and
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strength of selection on the genes studied, therefore it is not completely clear what the 
impact of selection on Fgx would be other than there was probably directional selection 
occurring.
Some limitations are self-imposed. The purpose of this study is to use an empirical 
dataset for which there is both many markers and knowledge of demographic history and 
selection status of many genes in order to develop understanding and recommendations 
applicable to species where much less information is available. Therefore we sometimes 
self-imposed limitations like assuming that nothing is known e.g. about gene locations 
across the genome or the function of an SNP (intron or exon based, synonymous or 
non-synonymous).
9.5 Conclusions and recommendations
Due to the high number of SNPs required to have reasonable power and the relatively 
high false positive rate, it is difficult to provide clear quantitative guidelines as to geno- 
typing SNPs to detect molecular signatures of adaptive differentiation between popula­
tions. Nonetheless a few helpful guidelines can be made:
1. Power to detect selection is usually low with less than 4 SNPs per gene, because 
variance in Fst among SNPs is generally high within a gene. Therefore we rec­
ommend the analysis of at least 4 SNPs per gene.
2. Targeting genes or gene rich areas is a more reasonable strategy than a completely 
random genomic scan using only hundreds or a few thousand SNPs to avoid failure 
to detect high Fst SNPs.
3. Each individual researcher will require balancing between failing to detect selection 
signals and detection of false positive signals. Depending on the research project, 
different false positive and negative rates might be acceptable.
4. All the information available should be used. If known, gene position, gene function 
and mutations relevant to protein conformation should be used.
5. For long genes, genotyping sets of SNPs at the ends may increase the probability 
of finding high-FsT SNPs because recombination and drift could prevent selection 
from driving up Fst at both distant ends of genes.
6. Design of high density SNP chips or assays should include several SNPs per gene. 
Researchers using existing SNP assays should verify the distance between SNPs 
(e.g. at least <20 kb in gene-rich areas) when using a candidate gene approach or 
genome-wide scan.
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Assessing selection for drug resistant 
malaria: Can temporal Fg-p help?
Tiago Antao, Gordon Luikart and Ian M. Hastings 
Abstract
Plasmodium falciparum malaria is treated by antimalarial drugs which select 
for drug resistant Plasmodium parasites. Detecting which genes encode resistance 
can provide fundamental insights to help manage and monitor the spread and the 
burden of drug resistant P. falciparum. Fst outlier tests are commonly used to find 
genes under selection and applied to the case of P. falciparum: where samples from 
the same population are compared over time to test for an increase in temporal 
Fst (at resistance genes) following antimalarial treatment of a host population.
We use computational simulations to evaluate the performance of temporal Fst to 
detect genes under selection in Plasmodium. Our results suggest temporal Fst is 
more powerful in low transmission areas as long as the time between samples is 
low (<20 P. falciparum generations). Temporal Fst cannot reliably detect genes 
under selection with small changes in prevalence (<10%) between samples. For 
example, temporal Fst might not be the best strategy to find Artemisinin related 
resistance genes as the current prevalence of Artemisinin resistance is still low. 
Temporal Fst is applicable in epidemiological scenarios where a large change in 
frequency of resistance is expected to occur, e.g., when a drug is removed or applied 
at high intensity. Empirical studies would also benefit from increasing sample sizes 
of individuals and loci, which is now feasible with new genomic technologies.
Keywords: malaria, selection, Fst, drug resistance, population genomics, infectious 
diseases, genetic monitoring
10.1 Introduction
Malaria is a major public health concern for the one third of the global human population 
estimated to be exposed to the most virulent parasite species, Plasmodium falciparum.
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Estimated numbers of clinical episodes of P. falciparum malaria range from 300 to 
660 million per annum (Snow et al., 2005). There is no effective vaccine for this species. 
Infection is controlled by insecticides targeted at vector mosquito species, and treatment 
by antimalarial drugs. As might be expected, drug-resistance rapidly evolved and spread 
(Olliaro, 2005).
Determining which genes are involved in drug resistance is thus fundamental both 
for control and elimination efforts and has been successfully done for older drugs like 
Chloroquine or SP (Olliaro, 2001) though the mechanisms of resistance in the newest 
class, the Artemisinins still eludes us (Rogers et al., 2009; Dondorp et al., 2009). Even 
for older therapies, there are still doubts that all genes involved in drug resistance have 
been identified. Genes involved in drug resistance have asymmetrical importance, for 
instance, the crt gene is more important that the mdr gene in conferring resistance to 
Chloroquine and the same observation was made for dhfr and dhps with regards to SP 
resistance.
There are several strategies to detect genes under selection, among them multilo­
cus comparisons. The Lewontin-Krakauer test (and more recent versions) utilises the 
variance in Fst estimates from multiple independent loci to determine if non-neutral 
markers are present: Loci that undergo different directional selection in some popula­
tions are expected to show larger allele frequency differences among populations. Fst 
studies and subsequent selection tests are commonly done over many species and P. fal­
ciparum is not an exception (e.g. Escalante et ah, 2001; Iwagami et al., 2009; Anderson, 
2004).
Multilocus selection tests are normally conducted comparing different populations, 
but they can be applied to one population, sampled over time (for examples with P. 
falciparum (see e.g. Abdel-Muhsin et al, 2003; Chenet et al., 2008; Gatei et al., 2010). 
These tests can be used to detect the impact of many artificial interventions ranging from 
the deployment and removal of new drugs (Abdel-Muhsin et al., 2003) to the impact of 
usage of insecticide treated bednets (Gatei et al., 2010).
Here we conduct computational simulations of the spread of drug resistant malaria to 
understand how temporal Fst signals are influenced at drug resistant loci. Some of the 
questions we address are: “What increase in prevalence is required before directional 
selection can be detected?”, “Is the Fst signal similar at loci with asymmetrical (or 
unequal) contribution to resistance (e.g. comparing dhfr with dhps, the loci involved 
in SP resistance)?”, “When can selection tests based on Fst be used to find the genes 
responsible to Artemisinin resistance?”, “Are Fst tests more informative in areas of low­
er high-transmission?”, “Can Fst be informative with seasonal population fluctuations 
(like the ones imposed in areas with wet and dry seasons)?”, “Are commonly used 
sampling strategies enough to provide a reliable estimate of Fst?”
The World Health Organisation (WHO) recommends a change in antimalarial treat­
ment if the total treatment failure proportion is equal or above 10% (World Health
10.2. METHODS 93
Organization, 2006). This suggests that any simulations of P. falciparum drug resis­
tance should concentrate on frequencies of resistance that span a range from zero up 
to 10% failure rate. We will assume that the treatment failure rate will be equal to 
the prevalence of resistance (i.e. the proportion of humans that harbour resistant in­
fections). The prevalence of resistance is defined as the number of individuals that 
harbour resistant infections. An important parameter in P. falciparum biology is thus 
the Multiplicity Of Infection (MOI), i.e. the number of different infections that a human 
host carries. It should clear that prevalence resistance should not be confused with the 
frequency of resistance as individuals might have more than one simultaneous infection, 
so for any given frequency, prevalence increases with MOI.
As P. falciparum parasites only reproduce sexually inside the mosquito vector, mat­
ing opportunities are limited to the parasites ingested in the last blood meal (mosquitoes 
feed approximately every three days so mating between parasites in blood meals obtained 
in separate bites is assumed to be impossible) thus the MOI is one of the fundamental 
factors influencing inbreeding. Selling (mating with a genetically identical parasite) is 
possible. The MOI is a proxy for transmission intensity: due to repeated sequential 
infection typical in high transmission areas, infected individuals will have a higher MOI 
than in low transmission areas. Higher transmission areas will thus have lower parasite 
inbreeding (e.g. selfing) levels.
10.2 Methods
We preformed two different kinds of simulations: One approach used a simulator of 
malaria epidemiology and population genetics to study genes under selection due to 
drug pressure. This simulation exercise is intended to estimate the plausible values of 
temporal Fst with varying prevalence and frequency of resistance.
A second set of simulations used a standard forward-time population genetics simu­
lator, in order to establish the expected null distribution of temporal Fst with neutral 
markers. This simulation exercise is intended to answer a different set of questions, 
namely what is the impact of sampling strategies on the estimation of neutral temporal 
Fst-
Simulation of genes involved in drug resistance
We simulated data using ogaraK (Antao and Hastings, 2011a), a population genetics 
simulator of the spread of drug resistant P. falciparum using an infinite population 
size model. OgaraK is able to simulate the non-standard biological features on P. 
falciparum biology, namely: (i) a genome that is haploid (with asexual reproduction) 
but with a brief diploid (sexual) phase inside the mosquito vector; (ii) mating options 
inside the mosquito are limited and dependent on MOI (see below) and (iii) infections,
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not individual parasites are simulated due to the very large number of individuals (up 
to 1012 in a single human host). A formal description of the model and application 
is available in Hastings (2006); Antao and Hastings (2011a,b). Here we present the 
fundamental concepts and parameters related to this study.
Parasite resistance is modeled using 2 loci that encode drug resistance (for a more 
general model with different number of loci see Antao and Hastings (2011b)). Each 
locus has 2 alleles (sensitive and resistant). Resistance to drug treatment might require 
both loci being resistant (full epistasis); or only a single locus being resistant (duplicate 
gene function) or one specific locus (of the 2) being necessary and sufficient to confer 
resistance (asymmetrical epistasis). Asymmetrical epistasis is based on Chloroquine and 
SP resistance where two loci were identified in resistance but one loci is more important 
than the other (crt is more important than mdr in Chloroquine resistance and dhfr is 
more important than dhps in SP resistance). Resistance alleles incur a fitness penalty in 
the absence of the drug and all mutations are assumed to have the same fitness penalty. 
Genotypes with multiple mutations suffer a multiplicative fitness penalty.
The mode of resistance required depends on the human: (i) in untreated humans 
all parasites survive drug treatment; (ii) in humans with no immunity or with poor 
treatment compliance a weak mode of resistance (i.e. asymmetry or DGF) is enough 
for a infection to survive treatment and (iii) in semi-immune humans with complete 
treatment compliance only the strong mode (full epistasis) is enough to confer resistance.
Assuming the resistance modes above we simulated three different scenarios:
Simple Full Epistasis: All parasites in untreated individuals survive. Parasites in 
treated humans require both alleles to be resistant.
Simple DGF: All parasites in untreated individuals survive. Parasites in treated hu­
mans require only one allele to be resistant.
Mixed mode: All parasites in untreated individuals survive. Treated humans are split 
in two groups of equal size: The first group, representing individuals with no im­
munity and/or insufficient drug doses will allow parasites to survive with fl.symmp.t- 
rical epistasis (i.e. the most important resistant locus is necessary and sufficient to 
confer resistance). The second group, representing individuals with semi-immunity 
and/or sufficient drug treatment will allow only parasites with both resistant alleles 
(full epistasis), to survive.
In simple modes, the parasite genotype is enough to determine the survival to drug 
treatment, whereas in mixed mode, the environment (human immunity status and/or 
treatment compliance) is also a factor.
For all simulation scenarios we varied the fitness penalty per resistant mutation 
and the amount of drug usage (defined as the percentage of infected people that is
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treated) between 0 and 20% in increments of 2%. We simulated 5 different MO Is: three 
simple models with MOI fixed at 1 and 2 (low transmission) and 4 (high transmission) 
and two more realistic scenarios, one modeling low transmission where 50% of human 
hosts had a single infection and the other half had 2 infections and another modeling 
high transmission where MOI followed a Poisson distribution with a conditional mean 
of 2.3 truncated at a maximum MOI of 7 Hastings (2006). The simpler MOI models 
qualitatively capture the results of the more complex ones therefore we will present 
all results with fixed MOIs. Initial frequency of resistance was set at 0.1% for each 
resistance allele and no linkage disequilibrium among resistance loci.
Linkage disequilibrium (LD), the non-random association of resistance alleles at 
different loci, has been shown to be a critical factor influencing the rate of spread of 
resistance (Dye and Williams, 1997). Here we use r as a measure of LD as the signal 
of r gives important information about the type of association encountered: a positive 
r means that resistance alleles at different loci are more likely to be associated than 
expected by random association, whereas a negative value suggests that resistance alleles 
are less associated than expected.
While we have complete information about the parasite population, in order to 
present a more realistic estimate of Fst> we sample 100 haploid individuals and use 
Cockerham and Wier’s 6 (Weir and Cockerham, 1984) implemented in Genepop (Rous- 
set, 2008). In order to do the many thousands of evaluations needed we used the 
Bio.PopGen module of Biopython (Cock et al., 2009) to automatise the Fst estimator 
calculation. We assume that we can trivially infer haplotypes as such information is 
available from simulated data, but we notice that, in real settings haplotype inference 
is not trivial when MOI >1.
We considered that resistance existed at the onset of the simulation (i.e. this study 
is not concerned with de novo emergence of resistance) with a starting frequency of 0.1% 
and ran simulations for 100 generations (approximately 20 years for P. falciparum).
Simulation of neutral markers
We conducted simulations using the forward-time, individual based simulator simuPOP 
(Peng and Kimmel, 2005). Simulations were performed using a Wright-Fisher model 
with separate sexes, random mating (average sex ratio of 1) and discrete, non-overlapping 
generations. We simulated constant size populations with an Ne of 1,000, 5,000 and 
20,000, in line with estimations of Ne for low-, medium- and high-transmission areas 
respectively (Anderson et al., 2000a). Each demographic scenario was replicated 1,000 
times. Simulations had a burn-in phase of at least 10 generations in order to approx­
imate mean observed heterozygosity with realistic values (below 0.8) and lasted 100 
generation. Longer burn-in periods were also tested, but results were qualitatively un­
changed. The genome simulated included 100 neutral, independent microsatellite loci
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initialised with a Dirichelet distribution (10 initial alleles per locus exhibiting a mean 
of 8 after burn-in) and no mutation rate. As with the simulations of loci involved in 
drug resistance, simulation data was saved in the Genepop (Rousset, 2008) format and 
automatically processed using Biopython (Cock et al., 2009).
10.3 Results
Simulation of genes involved in drug resistance
The frequency of resistance alleles is not clearly related with the frequency of resistance 
(phenotype) and is dependent on MOI and epistasis mode (similar results were obtained 
in Antao and Hastings (2011b)). While for full epistasis there is a direct relationship 
between allele frequency and resistance phenotype (i.e., the increase in frequency of the 
haplotype with all resistance alleles is parallel to the increase in frequency of individual 
resistance alleles — Figure 10.1), the pattern is different for the other two scenarios: in 
mixed mode, the most important locus, as expected, is fundamental in determining the 
increase in resistance phenotypes. Indeed, any temporal Fst signal for the least impor­
tant locus is delayed when compared with the spread of resistance phenotypes. With 
DGF the direct relationship between resistant allele frequency and resistance phenotype 
is even weaker: it is possible that resistant alleles stabilise at intermediate frequencies 
whereas the resistance phenotype approaches fixation through an increase in absolute 
value of linkage disequilibrium (in the case of DGF and using r as a measure, r is 
increasingly negative).
To understand the epidemiologically relevant allele frequencies it is necessary to 
establish a relationship between prevalence and frequency due to WHO policy recom­
mendations being based on prevalence, not frequency. The prevalence is given by:
1 - (1 - R)% (10.1)
Where R is the frequency of resistance and i is the MOI. This simplified formula 
is easier to compute with Full Epistasis and DGF (not mixed mode) and using a fixed 
MOI.
MOI has a considerable impact on prevalence for very low frequency of resistance: 
For very low frequencies, the prevalence is approximately MOI times larger than the 
frequency (Figure 10.2). The relative impact of MOI on prevalence is highly reduced as 
frequency increases.
As per Antao and Hastings (2011b) R = Fiti for full epistasis, where Fq.o is the 
frequency of the haplotype with no resistant alleles, Fito the frequency of the haplotype 
where the first loci is resistant and the second sensitive, Fq,! the frequency of the hap­
lotype where the first loci is sensitive and the second resistant and F^i is the frequency
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Figure 10.1: Summaxy statistics for simulations using the three epistasis modes. Each 
column documents a different epistasis mode over time (generations since the start of 
the simulation). The first row shows haplotype frequency (Lighter tones of grey indicate 
an increasing number of resistance alleles in the haplotype). The second row shows allele 
frequency, in the case of symmetrical modes (full epistasis and duplicate gene function 
- DGF) the frequency for both alleles is equal, but in mixed mode the frequency of the 
most important gene increases before the frequency of the least important gene. The 
third row also shows LD (r - grey line) between loci involved in drug resistance. The 
drug treatment rate is 20% and the fitness penalty 5%.
of the haplotype having all resistant alleles. F\^, is thus, assuming full epistasis, the 
only resistant haplotype (the two resistant alleles are required).
For DGF, the frequency of resistance is +Fo,i +Fi,o, as it is enough to have only 
one resistant allele to survive treatment. For mixed mode, the calculation is slightly 
more complex and an intermediate value is expected as in some cases (treated non- 
immune humans and/or with poor drug compliance) a single mutation Fi,o (but not 
Fo,i) is enough to confer resistance, whereas in others (semi-immune humans and/or 
proper drug compliance) both mutations are required, thus assuming equal proportions 
of individuals in both groups, R = it is now trivial, to determine
the relationship between the frequency of resistance of a single locus and prevalence 
(knowing MOI and LD).
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Relationship between prevalence and frequency of resistance
Frequency
Figure 10.2: The ratio between frequency of resistance and its prevalence as a function 
of the multiplicity of infection (MOI). For the same frequency, higher MOI entails higher 
frequency. Most importantly, the ratio between prevalence and frequency clearly shows 
that MOI is a much more important factor, in terms of prevalence, at lower frequencies.
With the above calculation we can now study pairwise Fst between time samples 
and know the difference in prevalence and frequency in those samples. Figure 10.3 shows 
pairwise Fst between samples where prevalence varies between 0 and 20%. Full epistasis 
shows an higher Fst than DGF for the same MOI and difference in prevalence: a smaller 
frequency of resistance alleles is required with DGF to confer resistance (as long as LD 
- r - is negative) because either gene is enough to confer resistance, therefore for the 
same prevalence Fst is lower in DGF due to lower frequency.
The second factor influencing temporal Fst is the MOI: an higher MOI will imply 
lower Fst- This happens because with lower MOI a higher frequency is needed to attain 
the same prevalence (especially at low prevalences - Figure 10.2).
When sampling the generation with resistance near 0% and for differences of preva­
lence of up to 10%, Fst is only slightly above 0.1 with Full Epistasis and a MOI of 1, 
and only near 10% prevalence. For all other modes Fst is between 0.0 and 0.1. Even 
at 20% difference in prevalence many simulation results fall below 0.1.
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If the initial generation for temporal Fst has higher prevalence than the signal is 
further reduced. The reduction in Fst is not just proportional to the prevalence of the 
first sample but slightly above (Figure 10.3). For example the temporal Fst between 
prevalence 0 and 10% is larger than between 1 and 11% which is much larger than 
between 5 and 15%.
Simulation of neutral markers
For multilocus selection tests based on Fst? the distribution of neutral loci is funda­
mental to make inferences about locus potentially under selection. Directional selection 
is expected to increase the Fst of selected genes, therefore we will study the upper con­
fidence interval of the distribution of neutral loci, because most tests assume precisely 
that directional selection loci is indicated by an Fst above most (typically 95 or 99%) 
neutral loci.
Neutral temporal Fst will increase over time due to drift. Figure 10.4 shows the 
behaviour of the upper confidence interval (95 and 99%), the mean and median values 
have the same behaviour (results not shown). The increase in Fst is influenced by the 
population size: the larger the population size, the lower the increase in Fst- This 
relationship is mostly due to drift: smaller populations (i.e. lower transmission areas) 
will have higher drift, thus increasing the difference between samples over time.
Relationship between prevalence and Fst
• Full Eplstasis - MOI1 
o o Duplicate Gene Function - MOI 1 
*—* Full Eplstasis - MOI 4 
v v Duplicate Gene Function - MOI 4
Prevalence
Figure 10.3: The relationship between prevalence, epistasis mode, multiplicity of in­
fection (MOI) and temporal Fst- The figure shows the pair-wise Fst where the first 
sample is, from left to right: generation 0 (approximately 0% prevalence as frequency 
is at the initial 0.1%), 1% prevalence and 5% prevalence. Two MOIs (1 and 4) and two 
epistasis modes (full epistasis and duplicate gene function) are considered. The drug 
treatment rate is 20% and the fitness penalty 5%.
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Figure 10.4: The upper confidence interval of temporal Fst for neutral markers. Three 
different simulations with constant Nc are presented (1000, 5000 and 20000) representing 
values for different malaria transmission intensities. Sample sizes varies from 15 to 50 
individuals (equivalent to 30 to 100 haploid P. falciparum clones) and is representative 
of several empirical Fst studies. 95 and 99 confidence intervals are presented. Only 
the upper confidence interval is presented as this is the relevant interval for directional 
selection (which is expected to raise Fst-
Sample size is a fundamental parameter influencing the confidence interval around 
estimated Fst- 15 samples (30 haploid samples) will have roughly four times higher Fst 
than 50 samples (100 haploid samples) if comparing samples that are close temporally 
(i.e. below 10 generations of separation). This effect will reduce over time, but even 
with an interval of 100 generations, the estimation using a smaller sample will be 60% 
higher for a population size of 1,000 and, due to less drift, 3 times more for a population 
size of 20,000.
10.4 Discussion
Fst estimation cannot reliably identify loci involved in drug resistance under selection 
assuming epidemiological scenarios with gradual change. The WHO recommends that 
first-line therapies should be removed after 10% clinical failure rates. Assuming that 
clinical failure is well approximated by prevalence of resistance, sampling two time points 
below 10% of prevalence will yield, in most cases temporal Fst below 0.1 consistent with 
locus neutrality. Indeed a signal of apparent balancing selection could even appear if 
either the generation interval is too short and/or the sample size is insufficient (while 
wre did not simulate balancing selection, it is quite clear that simulated Fst °f genes 
involved in drug resistance can be very low). This applies to all situations where very 
gradual change is frequency of resistance occurs, including control interventions that 
might strongly reduce parasite numbers but do not target specifically resistance loci.
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“Gradual” here is a relative definition: even strong selective sweeps are termed “gradual” 
when compared with changes imposed by seasonality (see below).
More specifically, as the initial spread of drug resistance is predicted to be very slow 
on an arithmetic scale, temporal Fst will not be a good statistic to detect any loci 
under selection in the initial phases after emergence of drug resistance. This result is 
particularly important in the current context where resistance to artesunates is starting 
to spread: while the genes that are involved in artesunate resistance are not known, 
temporal genome-wide Fst scans will probably not provide a useful way to find such 
genes, at least at an early stage.
Fst can provide a reliable signal if the frequency change in resistance alleles is large 
(above 10%) and fast (e.g. within a year). Such patterns can be observed, e.g., in 
seasonality studies (Abdel-Muhsin et al., 2003; Babiker et ah, 2005) for genes involved 
in drug resistance. This suggests that seasonality induced changes in the frequency in 
drug resistance (with the inherent changes in transmission intensity and, especially, drug 
treatment rate) can serve as a good scenario to better understand the dynamics of drug 
resistance and to better understand, if drug treatment is removed, if alleles involved in 
drug resistance do entail a fitness penalty for parasites in absence of drug pressure.
Sample size highly influences estimated Fst- Common sample sizes used with P. 
falciparum (see e.g. Abdel-Muhsin et al., 2003; Chenet et al., 2008; Gatei et al., 2010) 
vary between 30 and 70 haploid (i.e. equivalent to 15 and 35 diploid) samples per 
unit of time. The time span in empirical studies varies from a couple of generations 
(studies involving seasonality) up to 40 generations (roughly 8 years assuming 5 parasite 
generations per year). Researchers should be particularly careful in interpreting Fst 
with small samples (below 60 haploid individuals) and large time-spans: Our results 
suggest (in consonance with previous research (Kalinowski and Waples, 2002)) that low 
sample sizes will severely increase the variance with (neutral) loci that have low Fst? 
furthermore drift will increase the size of the confidence interval over time. Even with 
studies spanning small time spans (a single generation), small sample sizes (which have 
been used in recent empirical studies) can account for a temporal Fst of 0.08, whereas a 
larger sample size would decrease the confidence interval to 0.02. Loci involved in drug 
resistance would thus be inside the confidence interval for neutrality and could not be 
distinguished from neutral loci.
The estimates of temporal Fst are dependent on the frequency of resistance of the 
first time sample: If the first sample is taken when prevalence/frequency is minimal, 
it maximises the value of Fst- Most samples are normally taken after frequency has 
attained observable values, therefore the estimated temporal Fst will normally be lower. 
This does not depend only on the difference of prevalence between samples but on the 
initial value itself: the lower the frequency, the higher the temporal Fst- At an extreme 
if the two samples are taken during a stabilisation period, it is possible that temporal 
Fst will be interpreted as balancing selection. During stabilisation, balancing selection
102 CHAPTER 10. TEMPORAL FSt
is indeed occurring - so the result is not in error - but the Fst signal obtained will be 
useless to find genes involved in drug resistance.
Temporal Fst for drug resistance genes will be slightly higher in low-transmission 
settings, therefore it should be easier to differentiate from neutral loci. But, as drift is 
expected to be higher in low-transmission (smaller population) areas, if the time span 
between samples is large, them the Fst of neutral loci will increase at a faster pace than 
in high-transmission areas.
We considered the optimal situation where we always know haplotype frequencies. 
In particular a problem with particular importance in high-transmission areas comes 
from not being easy to establish which combinations of alleles, genotyped from a human 
with multiple infections, correspond to each infection. For example, a patient might 
be infected with two infections, one resistant at only one gene and another resistant 
at the other gene. In this case it is not easy to discriminate the situation above from 
one where a patient has one infection that is totally sensitive (no resistant alleles) and 
another totally resistant. This problem increases in complexity with MOI (it is not a 
problem when MOI is 1, i.e., there is a single infection). Thus, with higher MOIs it 
might not be always possible to infer haplotype frequencies from allele frequencies.
Mathematical models of malaria epidemiology and drug resistance consistently pre­
dict that once drug resistance arises, it spreads rapidly to 100% (Curtis and Otoo 
(1986), Cross and Singer (1991), Dye and Williams (1997), Hastings (1997), Hastings 
and D!Alessandro (2000)). This expectation, did not found support in field evidence 
which has shown, at least in some cases, that resistance may stabilise at levels well be­
low 100% (Plowe et al., 2004; Babiker et ah, 2005; Ursing et ah, 2007). Hastings (2006) 
proposed that intense competition between separate P. falciparum clones co-infecting 
the same human can explain this observation. Antao and Hastings (2011b) suggested 
that epistasis between genes involved drug resistance would also be necessary to explain 
stabilisation at intermediate frequencies, since the results in Hastings (2006) would only 
happen in a very small part of the parameter space (i.e. they would be a mathemat­
ical rarity). Our research here suggests that the explanation in Antao and Hastings 
(2011b) might also be insufficient, because while Antao and Hastings (2011b) predicts 
stabilisation at intermediate frequencies of resistance alleles in many scenarios, the re­
sistance phenotype would still approach fixation. This effect can be observed on Figure 
10.1 (DGF) where haplotypes conferring resistance (top right panel) approach fixation 
whereas allele frequency is stabilising at intermediate frequencies. Our results suggest 
that existing explanations for the widely observed effect of stabilisation of resistance at 
intermediate frequencies should be revisited.
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10.5 Conclusion
In the case of malaria epidemiology, temporal FgT-outlier approaches to detect selection 
can be an effective tool only in very limited circumstances. It is not clear, for instance, 
that it will be useful in search for genes involved in artesunate resistance, especially 
during the initial phase of resistance spread. On the other hand, we see a strong signal 
of selection in some P. falciparum studies with varying transmission intensities (and 
parallel variation in drug usage rates) over the year induced by wet-dry season variability. 
This suggests that mutations related to drug resistance might indeed pay a considerable 
fitness cost or, at least, that scenarios involving seasonality such be further researched 
as the epidemiological and evolutionary forces present might shed considerable light 
regarding the spread of drug resistance.
In cases where temporal FsT-outlier detection might be applicable, researchers should 
be careful with the sample sized used: at least 50 haploid samples should be used. In 
low transmission cases, a long time span between samples might increase the size of the 
confidence interval for neutral loci, whereas in high transmission scenarios haplotype 
inference will be non-trivial. If such guidelines are observed, FgT-outlier approaches 
might provide important information regarding genes involved in P. falciparum drug 
resistance.
Part III
Estimating effective population 
size and assessing the success of 
control and elimination measures
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Early detection of population declines: 
High power of genetic monitoring using 
effective population size estimators
Tiago Antao, Andres Perez-Figueroa, Gordon Luikart 
Abstract
Early detection of population declines is essential to prevent extinctions and to 
ensure sustainable harvest. We evaluated the performance of two Ne estimators 
to detect population declines: the two-sample temporal method and a one-sample 
method based on linkage disequilibrium (LD). We used simulated data representing 
a wide range of population sizes, sample sizes, and number of loci. Both methods 
usually detect a population decline only one generation after it occurs if Ne drops 
to less than approximately 100, and 40 microsatellite loci and 50 individuals are 
sampled. However, the LD method often out performed the temporal method by 
allowing earlier detection of less severe population declines (Ne approximately 200). 
Power for early detection increased more rapidly with the number of individuals 
sampled than with the number of loci genotyped, primarily for the LD method. 
The number of samples available is therefore an important criterion when choosing 
between the LD and temporal methods. We provide guidelines regarding design 
of studies targeted at monitoring for population declines. We also report that 40 
SNP (single nucleotide polymorphism) markers give slightly lower precision than 
10 microsatellite markers. Our results suggest that conservation management and 
monitoring strategies can reliably use genetic based methods for early detection of 
population declines.
11.1 Introduction
Managers of threatened populations face the challenge of early and reliable detection of 
population declines. Maintenance of large populations and associated genetic variation
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is important not only to avoid population extinction but also because loss of genetic vari­
ation affects the adaptation capability of a population. Timely detection of populations 
that have suffered a decline will allow for a broader and more efficient range of manage­
ment actions (e.g., monitoring, transplanting, habitat restoration, disease control, etc.) 
which will reduce extinction risks.
Genetic methods can be used to estimate effective population size (Ne) and monitor 
for population declines (Leberg, 2005). Ne is widely regarded as one of the most im­
portant parameters in both evolutionary biology (Charlesworth, 2009) and conservation 
biology (Nunney and Elam, 1994; Frankham, 2005).
The most widely used genetic method for short-term (contemporary) Ne estimation 
(Krimbas and Tsakas, 1971; Nei and Tajima, 1981; Poliak, 1983) is based on obtaining 
two samples displaced over time (generations) and estimating the temporal variance 
in allele frequencies (F) between them. Luikart et al. (1999) demonstrated that the 
temporal method was far more powerful than tests for loss of alleles or heterozygosity 
for detecting population declines. However little is known about the relative power of 
other Ne estimators for early detection of declines. Single sample methods based on 
linkage disequilibrium (LD), have been proposed (Hill, 1981; Waples, 2006) and have 
been compared to the temporal method for equilibrium (i.e., stable population size) 
scenarios (Waples and Do, 2010). Methods to estimate long-term effective size (Schug 
et al., 1997) are by definition not generally applicable to the problem of detecting a 
recent sudden change in effective size.
Here we evaluate and compare the power, precision and bias of both methods used to 
estimate Ne for early detection of population declines. We use simulated datasets from 
population declines with a wide range of bottleneck intensity, sample size and number of 
loci. We simulate both highly polymorphic loci (microsatellites) and biallelic loci (single 
nucleotide polymorphisms, SNPs). We also study, to a smaller extent, a more recent 
temporal method based on likelihood (Wang, 2001; Wang and Whitlock, 2003).
We address important questions posed by conservation biologists such as, “To es­
tablish a monitoring program, how many individuals and loci are needed to detect a 
decline to a certain Ne?n, “How many SNPs are required to achieve sensitivity equal 
to microsatellites to estimate Ne and detect declines?”, “How many generations after a 
population decline will a signal be detectable?”, “What is the probability of failing to 
detect a decline (Type II error)?”.
11.2 Methods
We conducted simulations using the forward-time, individual based simulator SimuPOP 
(Peng and Kimmel, 2005). The default scenario was based on a constant size population 
of N=600 run until mean heterozygosity reached approximately 0.8 (10 generations) split 
into a number n of subpopulations (n = 1, 2, 3, 6, 12) without any migration. This in
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practice simulates a bottleneck (with the exception of n=l). The average sex ratio was 
1 with random mating. This approximates Nc — Ne. Each scenario was replicated 1000 
times. For convenience, the census size before the bottleneck will be called N\ and after 
will be labelled N^. Unless otherwise stated, when referring to equilibrium scenarios, 
we are mainly concerned with a population of constant size (e.g. N1 — N2 above).
The genome simulated includes, 100 neutral, independent microsatellites initialized 
with a Dirichelet distribution (10 alleles exhibiting a mean of 8 at the generation before 
the bottleneck) and no mutation.
We also compared and evaluated both methods according to:
1. Sensitivity to mutation rate. We used the K-allele model (Crow and Kimura, 
1970) with 10 alleles and a relatively high mutation rate of 10-3 typical of some 
microsatellites (Ellegren, 2004).
2. Usage of SNPs. We conducted simulations using genomes with 100 physically 
unlinked SNPs initiated from a uniform distribution.
3. Sensitiveness to initial population size. We used different initial population sizes 
(2400, 1200, 600, 300) all bottlenecking to an IV2 of 50.
4. Benefits of using additional loci versus additional samples. While for equilibrium 
scenarios adding more loci is roughly equal to adding an equal proportion of indi­
viduals sampled(Waples and Do, 2010; Waples, 1989), we investigated if this sym­
metry holds under a population decline. We constructed a scenario with lVi=300 
and iV2=50 and used different sampling strategies: 50 loci with 10 individuals and 
10 loci with 50 individuals.
The simulation application saves for analysis all individuals in the generation ex­
actly before the bottleneck along with 1, 2, 3, 4, 5, 10 and 20 generations afterwards. 
Each replicate is then sampled to study the effect of the sample size of individuals and 
loci. For Ne estimation we only study a single sub-population after each bottleneck to 
assure independence of all estimated values among replicates. We use for the number 
of loci 10, 20, 40 (and 100 for SNPs) and for the number of individuals 25 and 50. For 
each simulation replicate the following statistics are computed under different sampling 
conditions using Genepop (Rousset, 2008) through Biopython (Cock et ah, 2009): Fst 
(Weir and Cockerham, 1984), expected heterozygosity, and allelic richness.
To study the LD method each simulation replicate was analysed with the LDNe 
application (Waples and Do, 2008) which implements the bias correction (Waples and 
Gaggiotti, 2006) to the original LD method (Hill, 1981). Point estimates and 95% 
confidence intervals (parametric) are stored using only alleles with a frequency of 2% 
or more which is reported to provide an acceptable balance between precision and bias 
(Waples and Do, 2010) for the sample strategies tested.
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For the temporal method we implemented the Ne estimator from Waples (1989) 
based on Nei and Tajima (1981):
iV,=
2 “ 2^ “ 2k]
(11.1)
Where t is the time between generations, So is the sample size at the reference, 
pre-bottleneck point and St at the post-bottleneck generation being considered. The 
Fk estimator was implemented for each locus (l) as (Krimbas and Tsakas, 1971; Poliak, 
1983):
K
Fl = K
{fri fti)
Sri "h fti
(11.2)
Where K is the number of alleles at the current loci, fri is the frequency of allele 
i at the reference time and fa is the frequency of allele i at the current time. The 
generation before the bottleneck is used as the reference point to which all the other 
post bottleneck samples are compared. The F^ value used in the Ne estimator will be 
the weighted arithmetic mean of all locus F^ estimators, being the weight the number 
of alleles.
Confidence intervals on F, which can be used to calculate the Cl of Ne, were com­
puted as follows (Waples, 1989; Sokal and Rohlf, 1995; Luikart et al., 1999):
a(l - a)CIforFl = V2 ! 1X-ct/2[nl) 1 ^•l—a/2[n/].
Where n' is the number of independent alleles given by:
(11.3)
n'-EW-l) (n-4)
2—1
Where Ki is the number of alleles of locus K.
We also studied a more recent version of a temporal based method, MLNE (Wang, 
2001; Wang and Whitlock, 2003) which is based on likelihood estimation of effective pop­
ulation size. The number of cases studied was limited to only two bottleneck scenarios 
as the computational cost makes an exhaustive evaluation expensive.
The Coefficient of Variation (CV) is commonly used as a measure of precision and 
it is useful to compare results with theoretical expectations as these expectations hold 
for equilibrium. The CV for Ne based on LD is (Hill, 1981; Waples and Do, 2010):
CVLD [ft.)
Where n" is:
(11.5)
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The CV provides a theoretical insight on other potential sources of lack of precision 
of the estimator: number of alleles and sample size are also expected to influence the 
precision of the estimator and most previous simulation studies of equilibrium report 
behaviours in line with theory. It is therefore important to investigate if qualitative and 
quantitative results hold for bottleneck cases.
The CV of the temporal estimator was presented in Poliak (1983):
CVT (iVe) 1 + 2JVets (11.7)
Where t is the time number of generations betweens samples and S is the sample 
size. The temporal based estimator has another expected source of imprecision: the 
temporal distance between samples.
We evaluated performance of both methods from three different perspectives:
1. Detection of a decline from the pre-bottleneck effective population size, e.g., to 
detect if the Ne (point estimate) is below 0.8*iVi. This is similar to bottleneck 
tests (e.g. Cornuet and Luikart (1996)), as we are not concerned with the ability 
to approximate N2, only to detect if the population size decreased. The value 
chosen is arbitrary, but close to, and a function of Ni.
2. Approximation of an effective population size that has declined closer to 7V2 than to 
Ni. Here we try to understand if, adding to the previous ability to detect a decline, 
an estimator (point estimate) can approach the new effective size. For instance 
if there is a bottleneck of 771=600 to 7/2=50, we want to study the ability of 
estimators’ point estimate to be below 75, which is 50% above N2. This quantifies 
the ability to detect a change in Ne, but will not distinguish between an unbiased 
estimate of Ar2 and downward bias one.
3. Estimation of N2 with low bias and high precision and reliable confidence inter­
vals. Most studies of equilibrium scenarios (stable population size) are of bias 
and precision and thus most comparable with this third perspective (e.g. England 
et ah (2006); Wang and Whitlock (2003)).
The three perspectives above are presented as they might be useful in different sit­
uations: A practical research question might need only to detect that a population is 
declining (detection perspective) or it might require that a certain conservation thresh­
old (e.g., Ne < 100) has been passed (approximation perspective) or, still, a precise and
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unbiased estimation of population size (estimation perspective). The first two perspec­
tives are not applicable in equilibrium settings, but provide insights needed for practical 
conservation applications.
Methods for detection of population decline are reliable if, when there is no decline, 
the method does not erroneously suggest one (Type I error). This effect is especially 
important with Ne estimators as their variance is known to increase with increasing real 
Ne. As such we also assess how often each estimator to detects a decline when there is 
none (false positive rate).
When characterizing the distribution of Ne across simulations, we use mainly box 
plots. Box plots show the median, 25th and 75th percentiles, the lowest datum within 
1.5 of the lower quartile and the highest datum within 1.5 of the quartile range. Other 
measures like e.g. mean squared error, can be calculated from the supplementary ma­
terial.
We supply, as supplementary material, the distribution of Ne estimates (point, up­
per and lower Cl) according to the boundaries specified in the perspectives above (i.e., 
the percentage of estimations which fall above Ni, O.8JV1, 1.5iV2, O.5JV2 or below O.5./V2 
for all scenarios studied for the first five generations following the population decline. 
We also supply a set of standard population genetics statistics for (Fst, expected het­
erozygosity and allelic richness) starting from the generation before the bottleneck up to 
50 generations after. This material can be loaded in standard spreadsheet software for 
further analysis. Furthermore we also include an extensive number of charts covering all 
statistical estimators for all scenarios studied. Supplementary material is made available 
on http://popgen.eu/ins/ne or on the supplemental CD.
11.3 Results
With a fixed initial effective population size (Ni) of 600 and a population decline to an 
N2 of 50, we could detect a reduction of Ne from the original Ni (detection perspective) 
after only one generation in 80% or more cases for each method when sampling just 25 
individuals and 20 microsatellite loci. For an N2 of 100 the temporal method detected 
the decline only after a few generations or by using more samples or loci, while the LD 
based method still immediately detects a decline with just 25 individuals and loci. If N2 
only drops to 200, the LD method will have still have power above 80% with 20 loci and 
50 individuals at the first generation after the decline. Generally, the ability to detect 
a decline decreases for higher N2 for both estimators as expected from the CV (Waples 
and Do, 2010) of both estimators.
Both methods were able to approximate N2 (i.e. compute an estimation below 
I.5A2) at generation 2 with a severe bottleneck of N2 = 50 if 50 individuals were 
sampled. However the temporal method never had power above 80% for less severe
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bottlenecks (N? = 100) in the first two generations. The power to detect an Ne < 1.5^2 
(approximation perspective) is presented in Figure 11.1.
N=50 N = 100 N=200
2468 10 2468 10 2468 10
Generations
S=25
L=20
S=25
L=40
S=50
L=20
S=50
L=40
Figure 11.1: Power to detect that the effective population size (point estimate) is below 
150% N2. The LD based method is shown as a solid line and the temporal method with 
a dashed line. The horizontal dotted line is the 80% power threshold. Each column 
comprises a different N2 (50, 100, 200). The first row depicts 25 individuals and 20 
loci; the second row 25 individuals and 40 loci; the third 50 individuals and 20 loci; the 
fourth 50 individuals and 40 loci.
As theoretically expected, power for early detection of a decline increases if more 
individuals are used. However, the following deviations from expectations (Waples, 1989; 
Waples and Do, 2010) are observed and further investigated in the Discussion section:
1. For the temporal method and for an N2 of 200, power decreased slightly with more 
samples.
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2. Increasing the number of individuals sampled is more beneficial for both methods 
than increasing the number of loci. This effect is more noticeable with the LD 
method.
For the estimation perspective (i.e. low bias and small confidence intervals; see 
Methods), our bias and precision analysis showed that the temporal method has lower 
precision and, with larger iV2, higher bias upwards than the LD method. With a very 
low number of individuals, the LD method is biased upwards (consistent with England 
et al. (2010)) and less precise than the temporal method in line with the effect presented 
above (Figure 11.2).
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Figure 11.2: Boxplot charts of both the LD and temporal point estimates up to six 
generations after a bottleneck with iVi=600. The top chart reports a TV's=50, and the 
bottom chart a ^2=200. Different sampling strategies are shown on each column. On 
each chart, the top row depicts the LD method while the bottom row is the temporal 
method.
MLNE did not perform better than the original moments-based temporal method. 
We used MLNE with two bottleneck scenarios (N2 of 50 and 200) and a sampling 
strategy using only two time points and MLNE never provided a reliable estimation 
even for large sample of 50 individuals and 40 loci. MLNE results were only usable with
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3 samples in time but estimates were generally above Nz in concordance with Wang 
(2001) which also reports over-estimation of Ne in non-equilibrium scenarios (further 
details and an estimation perspective with MLNE are presented in the supplementary 
material).
In order to understand the relative benefit of increasing the number of loci versus 
increasing the sample size, we simulated bottlenecks with an Ni ~ 300 and a, N2 = 
50 using two radically different sampling strategies: One maximizing the number of 
individuals (i.e., using a sample size equal to N2) but using only 10 loci and another 
using 50 loci but only 10 individuals. The scenario with 5 times more individuals than 
loci gave higher precision in both methods. This effect was more pronounced with the 
LD method as both bias and precision are affected during all the initial five generations 
(Figure 11.3). The temporal method is mainly affected in precision, and only in the two 
initial generations for the scenario studied.
Samples: 50 Loci: 10 Samples: 10 Loci: 50
Gonprailan
Figure 11.3: Boxplot of the Ne during the first five generations of a bottleneck from 
IVi=300 to JV2=50. The left column depicts a sample size of 50 and 10 loci and the 
right column 10 individuals and 50 loci. Top row is the LD method and bottom row, 
the temporal method.
We also studied the behaviour of confidence intervals for both estimators. The upper 
confidence interval of the temporal method is often far higher than the initial population 
size during the initial bottleneck generations in most scenarios. This effect rarely occurs 
with the LD method: only on the very first generation and for high values of A1 2 (Figure 
11.4).
The usefulness of any estimator to detect a decline can be jeopardized by false 
positives, i.e., detection of a reduction in Ne when none occurred. We assessed the false 
positive rate for both estimators, i.e. with a true Ne of 600 (Figure 11.5). The LD-based 
method lower quartile of estimates was always above 400, whereas the lower quartile of 
point estimates for the temporal method approaches 200 when the sample size is only 25 
individuals. For a sample size of 50 the LD method point estimates were normally above
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500 whereas the temporal method point estimates were occasionally only approximately 
100 even though the true Ne was 600.
We also studied how the pre-bottleneck size (iVi) affects the behaviour of the estima­
tors. We simulated bottlenecks with different initial population sizes (initial iVi=1200, 
600, 400, 300, 200 and final ^2=50, supplementary data). The LD method was little 
influenced by initial size, but the temporal method accuracy and precision decreased as 
iVi decreased. This effect was mostly visible on the first generation after the decline, 
and disappears shortly after. This means that, adding to Type I errors which make 
methods less reliable to high N±, the temporal method also has precision problems with 
a lower Ni.
We also quantified precision for bi-allelic markers (i.e., SNPs). Using 10 and 40 mi­
crosatellites and 40 and 100 SNPs a comparison among the distributions of the point 
estimates reveals results consistent with theoretical expectations (Figure 11.6). As an 
example, 10 microsatellite loci gave slightly higher precision than 40 SNPs: As the 
median allelic richness for the microsatellite scenarios after the bottleneck is 6 (supple­
mentary material) the number of degrees of freedom (i.e. approximately the number of 
independent alleles) of the 40 SNPs scenario is smaller (20) than the 10 microsatellite 
scenario (50). The bias with SNPs is slightly lower probably because rare allele effects 
occurred less with bi-allelic markers we simulated. Type I errors also behave as ex­
pected, which for the sampling strategies shown and with equilibrium scenarios, gives 
not enough precision to differentiate between a Type I error and a real decline, again 
making Type I errors a fundamental consideration.
We also quantified the influence of mutation rate on the ability to estimate Ne. The 
number of new mutations is negligible in small populations over 1-10 generations even 
with high mutation rates. As an example, for an Ne of 100 and a relatively high mutation 
rate of 0.001 the expected number of new mutations per generation per locus would be 
0.2 (2 * iVg/i). Simulation results show negligible effect (supplementary material).
11.4 Discussion
Our results show that early detection and reliable size-estimation of population declines 
is increasingly possible using genetic monitoring and estimators of effective population 
size. Early detection is important as it allows for rapid management actions to avoid 
irreversible loss of genetic variation and increased risk of extinction due to genetic and 
demographic factors. Reliable estimation of Ne and the change in Ne is crucial in 
conservation biology but also in studies of evolution and ecology, for example to quantify 
bottleneck size associated with founder events or colonization of new environments.
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LD method
The one-sample LD method generally outperformed the two-sample temporal method 
by allowing earlier detection of less severe population declines (N2 > 100) when using 
sample sizes of loci and individuals typical of studies today. Nonetheless, if the number 
of individuals sampled is low (< 25), the temporal method might be a better option, 
especially if multiple generations pass between temporal samples. Both methods were 
able to approximate the Nc of a bottlenecked population fairly quickly especially for 
Ne below 200, in most cases in less than three generations after the decline event. 
The generation number after the bottleneck might alter the relative performance of the 
estimators in a qualitatively meaningful way (e.g. bias is in an opposite direction for 
each estimator immediately after the bottleneck versus several generations after). Here 
we are concerned with early detection, thus we note that some conclusions here might 
not hold if the generation gap is above 5-10 generations, which we did not study.
Temporal method
Experimental design (e.g. for a monitoring program) is more complex in the temporal 
method. Having two samples that are close temporally can yield relatively low precision 
(Wang and Whitlock, 2003) while having two samples that are separated by many gen­
erations, biases the estimate up-ward (Richards and Leberg, 1996; Luikart et ah, 1999). 
This effect is easier to control in equilibrium scenarios as the underlying assumption of 
equilibrium would allow for some calibration of the distance between samples. But in 
non-equilibrium scenarios the uncertainty of a possible decline event between samples 
makes calibration less obvious.
For the temporal method and large N2, power declines as more individuals are sam­
pled. This counter intuitive result can be attributed to two simultaneous causes: (i) 
Sampling more individuals raises the probability of increasing the number of rare al­
leles detected. Rare alleles are known to bias upward the temporal method (Turner 
et ah, 2001), while the LD-based method includes an explicit cori’ection (Waples and 
Gaggiotti, 2006). (ii) On the other hand, a smaller decline (higher N2) will purge rare 
alleles more slowly. The precision of the temporal method is increasing with the number 
individuals sampled, but it is increasing towards an upward bias result, whereas the 
power definition used (relevant for the detection of a population decline) is concerned 
with detecting a value lower than a certain threshold. A correction to the temporal 
method (Jorde and Ryman, 2007) to deal with upward bias does exist, but it is known 
to have a larger standard deviation than the original method (which is already large for 
the initial generations after the decline).
The MLNE method did not provide any improvement with only two sample time 
points. If more time points are available then MLNE might provide more reliable results, 
but in a context of early and timely estimation of a population decline this requirement
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for extra data might lower the usefulness of the method. Further research in MLNE 
is impaired by its computational cost (a study of the MLNE cost is available in the 
supplementary material).
Confidence intervals for the LD method are generally much tighter than the temporal 
method even after the first 3-5 generations. While the interpretation of confidence 
intervals for both methods is not always straightforward (an exhaustive discussion can 
be seen in (Waples and Do, 2010)) and its relevance is open to discussion, it is clear 
that there is a qualitative difference between estimators for early detection: The upper 
confidence interval for the temporal method often includes very high values, this is 
mainly caused by the known behaviour of the estimator to have poor precision for 
samples with only a few generations between samples.
Equations 11.1 and 11.2 show that the reference (i.e. before decline) and current (i.e. 
after decline) time are commutative in the temporal method. Our results show that the 
temporal method, when using a sample from before the bottleneck and another for after, 
tends towards the lowest value. This fortunate effect is fundamental in order to use the 
temporal approach to detect a decline. If the method did not approximate the lowest 
value then the first reference sample that could be used would be one immediately after 
the bottleneck, therefore delaying any estimation of a decline.
Effect of pre-bottleneck size
The temporal method is also sensitive to the pre-bottleneck size for the estimation of 
Ne after decline. The more similar the size of the population before (iVi) and after 
(Nz) the decline the worse the temporal estimator performs. This has implications 
for the feasibility of genetic monitoring studies based on the temporal method: On 
one hand, as the pre-bottleneck size increases, the Type I error also increases, on the 
other hand the closer N\ is to Ne, the larger the Type II error (i.e. failure to detect a 
decline). Therefore, while the LD method is only sensitive to large pre-bottleneck sizes, 
the temporal method is also sensitive to the relationship between pre- and post-iVe. 
Experimental design (monitoring) with the temporal method could be more complex 
because the effect is more noticeable for relevant values of Ne and the small sample sizes 
common in conservation genetics scenarios. This effect tends to disappear soon after the 
bottleneck, so it will depend on the specific case to determine if very early detection is 
needed or not as that will have implications in the applicability of the temporal method.
Importance of number of samples
When trying to detect population declines, adding more individuals appears more ben­
eficial than adding more loci, especially for the LD method. While previous studies 
(Waples and Do, 2010; Waples, 1989) have suggested that, for equilibrium scenarios, 
adding more loci is roughly interchangeable with adding more individuals, that is not
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the case when precise early detection of population decline is needed. This effect is unfor­
tunate given that the ability to genotype more markers is fast increasing while sampling 
many individuals can be difficult for populations of conservation concern. When deter­
mining the feasibility of genetic monitoring strategies, researchers should be especially 
careful in determining if sampling of enough individuals at any point in time is feasible. 
As the temporal method is often less prone to this effect — in fact it might not even 
be affected at all as empirical analysis suggest (Palstra and Ruzzante, 2008) - if the 
ability to sample many individuals is low then the temporal method might be a bet­
ter option. Further research is needed to formally characterize both estimators after a 
bottleneck, especially trying to understand how past history and current state influence 
precision and bias and why the benefits of adding loci and samples are not similar to 
non-equilibrium scenarios.
Single Nucleotide Polymorphisms (SNPs)
As expected, SNPs provide less precision and accuracy (per locus) than microsatellites 
for estimation of Ne. Both methods depend on the number of independent alleles for a 
precise estimate in equilibrium populations, therefore the expectation is that using bi- 
allelic loci will provide lower precision compared to microsatellites; this also appears true 
for declining populations. Nonetheless, the bias with SNPs is slightly lower (probably 
because rare allele effects occur less with bi-allelic markers we simulated). Again, the 
rate of false positives becomes a fundamental consideration, impairing the ability to 
detect a decline (supplementary material). Further research is needed to quantify effects 
of different numbers of alleles (e.g., replacing microsatellites with a higher number of 
SNPs) in non-equilibrium scenarios, especially as we have demonstrated that, contrary 
to equilibrium scenarios, increasing the number of loci and sample size do not equally 
improve precision and accuracy.
Assumptions
Three assumptions of our work deserve mention and future research. First, future re­
search is needed to quantify the effects of violating the assumption of no migration, 
and to develop methods to jointly estimate Ne and migration that is generalizable over 
a range of metapopulation models. Methods have been proposed (Vitalis and Couvet, 
2001; Wang and Whitlock, 2003) to jointly estimate migration and Ne but have not been 
thoroughly evaluated or are not highly generalizable (e.g. beyond equilibrium popula­
tions or continent-island metapopulation systems). Another important assumption is 
non-overlapping generations. Most methods has not been extended to (or evaluated for) 
species with overlapping generations or age structure (but see Jorde and Ryman (1995) 
and Waples and Yokota (2007)). A third important assumption that requires thorough 
evaluation is mating system or behaviour which could bias the LD method, e.g. if a
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mating system generates LD. Further research is needed to assess the importance of the 
issues presented above before applying the Ne estimators to scenarios mentioned above.
Type I error rate
False positives (i.e., Type 1 errors) are a concern when designing a study or monitoring 
program to detect a population decline, because false positives can lead to the waste 
of conservation resources on populations not actually declining. The temporal method 
is arguably more prone to false positive detection than the LD method. The need for 
more individuals or markers can sometimes be justified not by bias and precision in 
estimating post-bottleneck sizes but mostly by the need to avoid false positives, as Ne 
estimators are less precise with the larger, pre-decline, real Ne. This false positive effect 
might be less important in some conservation cases where the original population is 
known to be very low even pre-bottleneck. As in some conservation management cases 
the consequences of acting when there is no need is normally much smaller than the 
cost of not acting when there is a need (i.e., Type II error), e.g. to avoid extinction, a 
somewhat high probability of false positives might, in any case, be acceptable although 
this will vary from case to case.
Other methods
Several other methods to estimate Ne have been proposed (Tallmon et ah, 2008; No­
mura, 2008) and a comprehensive comparison of performance would be useful. Likeli­
hood based methods (like MLNE) are expected to be computationally intensive making 
comprehensive studies difficult as the computational cost to conduct a large number of 
simulations and posterior evaluation could be prohibitive. This questions the practi­
cal applicability of computationally intensive methods as comprehensive evaluations of 
performance and reliability will require vast amount of computational resources. Thus 
evaluation of performance often will be, in practice, limited to a small number of scenar­
ios. Approximate Bayesian and summary statistic methods including multiple summary 
statistics (e.g. both temporal F and LD) could greatly improve precision and accuracy 
of Ne estimators (Tallmon et al., 2008; Luikart et ah, in press), especially as large pop­
ulation genomic data sets become common making likelihood-based methods even more 
computationally demanding to evaluate (Luikart et ah, 2003).
Conclusion
Early detection of population declines is increasingly feasible with the use of genetic 
monitoring based on effective population size estimators. If the number of samples is 
sufficiently high, LD based method is arguably more powerful and better suited for 
monitoring to detect declines because it is less prone to Type I errors, has tighter
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confidence intervals, and is more flexible with regards to designing different experimental 
design strategies. Nonetheless it is important to further research the behaviour of both 
estimators under an even broader set of realistic scenarios, e.g. with age structure or 
migration, and to understand if variations of the temporal method (Jorde and Ryman, 
1996) or LDNe allow for earlier and more precise estimation of effective population size 
in decline populations. Both methods along with others (e.g. loss of alleles) should 
often be used when monitoring in order to gain a better understanding of the causes, 
consequences and severity of population declines (Luikart et aL, 1999).
As the precision of both estimators requires the true effective population size to be 
relatively small, their use is currently limited to scenarios in conservation biology and 
perhaps studies of the ecology and evolution in small populations. For instance, they 
cannot be used to conduct reliable genetic monitoring when the effective size remains 
larger than approximately 500 to 1000 unless perhaps hundreds of loci and individuals 
are sampled and/or improved estimators are developed.
Simulation evaluations of new statistical methods and increasing numbers of DNA 
markers makes management and genetic monitoring increasingly useful for early de­
tection of population declines, even with non-invasive sampling of elusive or secretive 
species. These results are encouraging and contribute to the excitement and promise of 
using genetics in conservation and management.
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Figure 11.4: Harmonic mean of Ne (solid line) and 95% confidence intervals of 1200 
post-bottleneck replicates (dashed lines) for both methods for two bottleneck scenarios 
and four sampling strategies all with Ni = 600. The first chart reports a N2 = 50 and 
the second a iV2 = 100. Different sampling strategies are shown on each panel from left 
to right: 25 individuals and 20 loci on the first, increasing to 40 on the second; the third 
shows 50 individuals and 20 loci increasing to 40 loci on the far right.
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Figure 11.5: Boxplot of the distribution of point estimates for both estimators under 
equilibrium (N=600) with 25 samples and 40 loci zooming in the area relevant for type 
I error detection. Estimates are biased high because the noise from sampling is often 
greater than the signal from drift or the number of parents.
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Figure 11.6: Boxplot of the Ne of both estimators during the first five generations of a 
bottleneck from 600 to 50 with a fixed sample size of 25. The bottom row depicts SNPs, 
left 40 loci and right 100 loci. The top row depicts microsatellites, left 10 loci and right 
40 loci.
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Estimating effective population size of 
disease vectors: a critical assessment of 
applications and performance
Tiago Antao, Ian M. Hastings, 
Gordon Luikart and Martin J. Donnelly
Abstract
Estimation of the contemporary effective population size (iVe) is increasingly 
conducted for insect disease vectors. It is used to assess changes in genetic diversity 
due to drift and to evaluate the impact of control measures like insecticide-treated 
bed nets (ITNs) or indoor residual spraying (IRS). We evaluated the performance 
of the most commonly used Ne estimator based on F-statistics which uses two 
temporally spaced samples and compared it to two recent estimators based on like­
lihood (another 2-sample temporal method) and linkage disequilibrium (a 1-sample 
method). We simulated large Ne with three different demographies based on re­
alistic parameters for common vector species: a constant population size model, 
bottlenecks to simulate effects of control measures, and a novel model with sinu­
soidal demography to simulate populations whose size fluctuates seasonally with 
dry and wet seasons. Results show that the sample sizes common in empirical stud­
ies (~60 individuals and ~10 microsatellite loci) are not sufficient to estimate Ne 
with precision. We suggest that an increase in temporal spacing between samples 
(e.g. >12 generations) and an increase to ~50 loci provide sufficient precision. The 
likelihood method outperforms the F-statistics moments estimator in most cases. 
In fluctuating populations the temporal and LD methods provide qualitatively dif­
ferent estimates. The LD method is sensitive to immediate demographic changes 
whereas the temporal methods provide an average over several generations. Each 
class of methods may have different applications as the LD method can detect sea­
sonal patterns and control interventions whereas the temporal estimators quantify 
trends over several generations.
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12.1 Introduction
The effective population size (Ne) provides a measure of the rate of random genetic 
change in populations caused by genetic drift (Charlesworth, 2009), and the relative 
efficiency of natural selection in the face of drift. Ne is also a fundamental factor de­
termining population viability as larger Ne entails greater population genetic variability 
which is paramount for species survival and adaptation. Estimation of Ne is increasingly 
conducted for insect disease vectors such as the Anopheles mosquito vectors of malaria 
and the fly Glossina vectors of African trypanosomiasis. Commonly the purpose of 
these studies is to determine whether insecticide-based control measures have success­
fully reduced the contemporary Ne (e.g. Wondji et al., 2005) or to investigate whether 
populations undergo seasonal contractions (e.g. Simard et al., 2000).
Indeed, one of the most widely used estimators of Ne across all taxa was developed 
to study the impact of insecticide resistance (Krimbas and Tsakas, 1971). This moments 
based method of contemporary Ne estimation was further developed (Nei and Tajima, 
1981; Poliak, 1983; Waples, 1989) and is based on obtaining at least two samples dis­
placed over time (generations) and estimating the temporal variance in allele frequencies 
between them.
Luikart et al. (1999) demonstrated that this temporal method was far more powerful 
for detecting population declines than tests based on loss of alleles or heterozygosity for 
detecting population declines. Effective population size should not be confused with 
census size (iVc), i.e. the total number of individuals in a population at any given time. 
Nc is normally larger than Ne for wildlife species with ^ ratios estimated around 0.10 
(Frankham, 1995; Kalinowski and Waples, 2002), although there is only one known study 
for this ratio in parasite vectors (Solano et al., 2009) where ratios calculated exhibit a 
large variance.
The second most widely used class of estimators of contemporary Ne is the single­
sample estimator based the linkage (gametic) disequilibrium (LD) method (Hill, 1981). 
Waples and Do (2010) showed that LDNe can provide precise estimates of Ne in constant­
sized populations with non-overlapping generations by using 10-20 microsatellite loci 
(5-10 alleles/locus) and samples of at least 25-50 individuals, if the effective population 
size is less than approximately 500.
While the temporal estimator has been studied both with constant sized populations 
and bottlenecks (see e.g. Luikart et al., 1999; England et al., 2010; Antao et al., 2011) for 
low JVe, there has never been a critical assessment of its usage alone or in comparison 
to single sample methods (LDNe) in the context of vector biology. This assessment 
is increasingly needed given the importance of vector-borne diseases, increasing risks 
of emerging disease following environmental changes and the need to evaluate control 
interventions to reduce vector population size.
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Standard assumptions for insect vector studies
The assumptions commonly made for vector population studies are that individuals are 
sampled without replacement prior to reproduction (Dyer et al. (2009) and others) which 
is plan II sampling of Waples (1989). Following the work of Lehmann et al. (1998) most 
of authors have take a conservative estimate of 12 generations per year for the African 
malaria vector Anopheles gambiae which allows estimates to be compared between stud­
ies. Researchers on South East Asian anophelines have used a value of 10 generations 
per year (Walton et ah, 2000). Consequently the reported values may underestimate the 
real Ne if there are more generations per year. Authors also generally assume that allele 
frequency change is solely attributable to genetic drift (Dyer et ah, 2009), whereas se­
lection or sampling bias due to substructure could also lead to allele frequency changes. 
The final assumption is of constant population size whereas many insect vectors exhibit 
extreme seasonal variation in census size with populations increasing following the onset 
of favourable conditions. For tropical mosquito species this is often the onset of rainy 
season (Charlwood et al., 1995; Taylor et ah, 1993).
Studies of Ne also use different sampling strategies with varying number of indi­
viduals sampled, number of loci, and especially the temporal spacing between samples. 
It is also assumed that there is independent sampling of individuals and independent 
(unlinked) loci (Dyer et al., 2009). The former assumption may be difficult to defend 
giving the increasing evidence of stratification in vector populations (Weetman et al., 
2010). A representative sample of Ne studies in vectors is shown on Table 12.1. We 
will concentrate on studies reporting high Ne (i.e. above 100), because the behaviour of 
estimates with low Ne (like the values reported in Solano et al. (2009)) has been widely 
studied (e.g Tallmon et ah, 2010; Waples and Do, 2010; Berthier et ah, 2002).
Alternative estimators of contemporary Ne have been proposed, either (i) sophisti­
cated versions of the temporal method using Maximum Likelihood (ML), such as the ones 
implemented in the MLNE (Wang, 2001; Wang and Whitlock, 2003) or TM3 (Berthier 
et ah, 2002) applications or (ii) completely different approaches based on a single sam­
ple and linkage disequilibrium (LD) (Hill, 1981; Waples, 2006) as implemented in LDNe 
(Waples and Do, 2008). MLNE and TM3 were shown to have better performance than 
the standard temporal method for constant sized populations (Wang, 2001; Berthier 
et ah, 2002) but doubts were raised if that was the case with MLNE in bottleneck sce­
narios (Antao et ah, 2011). The LD method has been compared to the temporal method 
for constant population size scenarios (Waples and Do, 2010) and bottleneck detection 
(England et ah, 2010; Antao et ah, 2011).
Here we present a computational study, using individual-based forward-time popula­
tion genetic simulations, evaluating several contemporary Ne estimators using realistic 
demographies for insect vectors. The rationale for this study is two-fold:
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Species Sample
loci and
individuals
Number 
of alleles
Temporal
spacing
Ne Motivation Publication
A. gambiae 11/55 K be­
tween 45 
and 64
85, 98 4,258
to
6,359
Lehmann 
et al. (1998)
A, arabiensis 9/50 7 4, 9, 40 229
to
1046
Seasonal Simard 
et al. (2000)
A. gambiae 12/55 NA 12, 24 1049,
inf,
1457
DDT im­
pact
Pinto et al.
(2003)
A. arabiensis 12/55 8 5, 12,
16, 33
135
to
649
ITN Wondji 
et al. (2005)
G. palpalis 12/35 10 23 229
to
1046
Dyer et al.
(2009)
Table 12.1: Representative sample of empirical studies of contemporary Ne. The sam­
pling strategy includes approximate number of loci and individuals sampled. The num­
ber of alleles is an average approximation of the reported value (with the exception of 
Lehmann et al. (1998) where the total number of independent alleles is reported). The 
sample spacing is in months.
1. We critically appraise existing published studies of Ne in insect vectors and deter­
mine whether
• The number of individuals and loci are sufficient to provide an unbiased 
estimate of Ne with a reasonably narrow confidence interval.
• The temporal spacing between samples spans enough generations to provide 
a accurate estimation of Ne.
• Whether the temporal method will allow us to estimate the impact of vector 
control or seasonality on vector population size.
2. We also provide guidelines for future studies of Ne by
• Investigating if recent approaches to estimate Ne perform better than the 
original moments based temporal method.
• Studying the impact of realistic vector demographies on the estimators.
• Suggesting sampling strategies and which estimator is most capable of pro­
viding sufficient precision when studying the impact of control measures and 
seasonality.
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12.2 Methods
We start by presenting an overview of the standard temporal method, followed by an 
introduction to maximum likelihood temporal estimator and the LD method. We then 
describe the simulations and sampling strategies.
Moment-based Fj, temporal method
For the temporal method we implemented the Ne estimator from Waples (1989) based 
on Nei and Tajima (1981) and Krimbas and Tsakas (1971):
NP =
[a- 12S0 A] (12.1)
Where t is the time between generations, Sq is the sample size (number of individu­
als) at the reference, pre-bottleneck point and St at the post-bottleneck generation being 
considered. This is the estimator for plan II of Waples (1989) (sampling destructively 
before reproduction). Though in our simulations we sample non-destructively (plan 
I), the difference between estimators with high Ne (like the values simulated here) is 
expected to be low (Waples, 1989). The plan II estimator has been extensively evalu­
ated and its usage will allow for comparative analysis, furthermore it is the estimator 
commonly used for vectors.
The Fk estimator is implemented for each locus (l) as (Poliak, 1983):
H =
2 (fri — fti) ^
K fri + fti
(12.2)
Where K is the number of alleles at the current loci, fri is the frequency of allele i at 
the reference time and fa is the frequency of allele i at the current time. The Fk value 
used in the Ne estimator will be the weighted arithmetic mean of all locus Fk estimators 
(equation 12.2), the weight being the number of alleles.
Confidence Intervals (Cl) on F, which can be used to calculate the Cl of IV#, were 
computed as follows (Waples, 1989; Sokal and Rohlf, 1995; Luikart et ah, 1999):
a(l - a)CIforFlk = nFlk nFt (12.3)
.■^a/2[n] ^ -^l—a/2[n]_
Where 1 — o; is the proportion of CIs containing the real Ne and n is the number of 
independent alleles given by:
l
i=l
Where K{ is the number of alleles of locus i.
(12.4)
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The coefficient of variation (CV) of the temporal estimator was presented in Poliak 
(1983):
(12.5)
Where S is the number of individuals sampled. The CV, a measure of dispersion, 
suggests that precision in increased if either the spacing between samples or the number 
of alleles increases. The estimator is also expected to lose precision with large real Ne, 
as the actual value is in the numerator of the CV.
This moment-based estimator is known to be biased upwards (Waples, 1989; Berthier 
et al., 2002) and rare alleles are largely responsible for the overestimation, so we also 
pooled (binned) all alleles with frequency below 2% into a single class. Results from 
binning were compared with the standard (without binning) estimator.
Likelihood-based temporal estimator
Several estimators have been proposed that use temporal sampling and maximum- 
likelihood (ML). For example, the ML method by Berthier et al. (2002) has been used 
in Dyer et al. (2009) to estimate Ne in a Glossina palpalis palpalis population in Equa­
torial Guinea. ML based estimators should provide better precision than moment-based 
estimators because they use more information from the data (Edwards, 1972) and the 
ML method used in Dyer et al. (2009) has been shown to perform better with very low 
Ne (i.e. 20) and when dealing with rare alleles (Berthier et al., 2002). This multiallelic 
method is based on coalescent simulation. Like most ML methods, extensive testing is 
computationally costly in terms of time. Strictly speaking this method is Bayesian as 
a maximum Ne prior has to be supplied. This estimator is implemented in the TM3 
application. The parameters for each estimate were extracted from 20,000 coalescent 
simulations where the Ne estimator prior was capped at 15,000. The following summary 
statistics are computed: mode and the 0.025 and 0.975 quantiles (giving a 95% support 
interval). There is no CV for this estimator, but the same variables that influence the 
moments-based estimator (real Ne, time between samples, number of alleles and sample 
size - equation 12.5) are expected to impact this estimator in qualitatively similar ways.
Linkage disequilibrium estimator
Linkage disequilibrium can be used to estimate effective population size as its magnitude 
is a function of Ne and sample size. (Hill, 1981) noted that the variance of LD estimates 
among loci is a function of the effective population size and proposed an estimator based 
on LD. The original estimator has been shown to be downwardly biased if the sample 
size is smaller than the true Ne (England et al., 2006) and a bias correction has been 
proposed (Waples, 2006). The LD method has one main clear advantage over temporal
12.2. METHODS 131
approaches: it requires only a single sample. The LD method implemented in LDNe 
(Waples and Do, 2008) has been compared to the moment based temporal method 
for equilibrium (i.e., constant population size) scenarios (Waples and Do, 2010) and 
bottlenecks (Antao et al., 2011). Evaluations of performance are also given in Tallmon 
et al. (2010) and England et al. (2010). The CV for this estimator is (Hill, 1981; Waples 
and Do, 2010):
Where n' is:
CVLD (Ne) (12.6)
L-l L
n'=E E (Ki-iK*)-!) (12-7)
j?=£+l
Both the coefficient of variation and computational studies suggest that, like the 
temporal method, the LD estimator has increased absolute precision for low real Ne and 
larger sample sizes (n1 increases with both number of loci and alleles per loci).
Point estimates and 95% confidence intervals (parametric) are computed using only 
alleles with a frequency of 2% or more in order to correct for upward bias. This correction 
is reported to provide an acceptable balance between precision and bias (Waples and 
Do, 2010) for the sample strategies tested (when 5 > 25).
Simulations and demographies
We conducted simulations using the forward-time, individual based simulator simuPOP 
(Peng and Kimmel, 2005). Simulations were performed using a Wright-Fisher model 
with separate sexes, random mating (average sex ratio of 1) and discrete, non-overlapping 
generations. This makes ^ « 1. Each demographic scenario was replicated 1,000 times. 
Simulations had a burn-in phase of at least 10 generations in order to approximate mean 
observed heterozygosity with realistic values (below 0.8). Longer burn-in periods were 
also tested, but results were qualitatively unchanged. The genome simulated included 50 
neutral, independent microsatellite loci initialised with a Dirichelet distribution (10 ini­
tial alleles per locus exhibiting a mean of 8 after burn-in, approximating the conditions 
in Table 12.1) and a mutation rate of 10-4 using a stepwise mutation model (Lehmann 
et al., 1998). Simulations with a larger number of starting alleles (up to 20) were also 
conducted. All simulation data was saved in the Genepop (Rousset, 2008) format and 
automatically processed using Biopython (Cock et al., 2009).
Three different demographies were tested: i) a standard demography of constant size, 
ii) a bottleneck potentially imposed by a transmission control measure such as ITNs or 
IRS and iii) a novel model where the population size varies with a cosine function in 
order to model vector seasonality. The constant scenario was run with a Nc of 200, 400, 
800, 1000 or 2,000. The bottleneck scenario started with a Nc of 5,000 or 2,000 which
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were then reduced ten-fold. The seasonal scenario was based on Acos(^) + B where 
t is the generation, and A and B are parametrised according to the demography. The 
function above implicitly defines a period of 12 generations, based on 12 generations per 
year for A. gambiae. For A and B we used the parameters A = 500, B = 700, making 
the minimum Nc of 200 and the maximum of 1,200.
To perform the Ne estimation we sampled 60 individuals per generation and 10 
microsatellite loci, in line with existing studies. We also studied the impact of doubling 
the sample size (120 individuals) and tested different numbers of loci sampled (20, 50 
and 100). For both temporal methods we tested different temporal distances between 
sampling ranging from 4 generations to 100 (this does not apply to the LD method as it 
is based on a single sample). Due to the extreme computational cost of the ML method 
we only studied 100 replicates (instead of 1,000) per scenario.
12.3 Results
Moment based temporal method in constant populations 
Bias
For a time span of 4 generations, the true Ne is always below the lower quartile 
(the value that defines the 25% of lowest point estimates) of the distribution of 1,000 
independent simulation-based point estimates, and the upper quartile (the value that 
defines the 25% of highest point estimates) is always more than 3 times the real Ne 
value. Figure 12.1 shows the distribution of point estimates for spans of 4, 12 and 
24 generations using different sampling strategies. For Ne of 1,000 and 2,000 the lower 
quartile occasionally lies below the real value, but only due to increased imprecision. For 
time spans of 12 and 24 generations the median point estimate (among 1000 replicates) 
is always above the real value (i.e. there is upward bias), but in most cases the upper 
quartile is below 3 times the true value. Binning, i.e. pooling all alleles with a frequency 
below 2% in a single class in order to reduce upward bias is useful for loci with many 
alleles but rarely reduces bias substantially (results not shown).
Precision and confidence intervals
For an Ne of 2,000, the confidence intervals of point estimates is large and the 
harmonic mean of the upper confidence limit is always above 6,000 (3iVe) assuming that 
the time span between sampled generations is below 25 (Figure 12.2). The Cl for an 
Ne of 1,000, for a typical sampling strategy with 60 individuals and 10 loci will also be 
above 3 times Ne for all time spans. For this sampling strategy, a time span of one year 
with A. gambiae is not enough to have a upper confidence limit below 3 times the Ne 
values simulated (including a Ne of 500). The upper confidence limit will also never be 
below 3 times the Ne for all sampling strategies if the time span between generations 
is below 8 irrespective of Ne. As expected, sampling more individuals and/or more loci
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t=4 t=12 t=24
Figure 12.1: Boxplot charts of temporal point estimates obtained from moments-based 
F method for a time span between samples of 4, 12 and 24 generations. Four sampling 
strategies are considered: 60 individuals with 10, 20 and 50 loci and 120 individuals 
with 10 loci. The first row reports a constant iVe=500, the second line 1,000 and the 
third 2,000.
provides more precise estimates. Sampling more individuals appears to be slightly more 
informative than sampling more loci as the precision of sampling 60 individuals and 20 
loci is slightly lower than the precision with 120 individuals and 10 loci. Figure 12.2 plots 
the harmonic mean for the point estimate and 95% confidence intervals with time spans 
between samplings up to 24 generations using different sampling strategies, estimations 
behind the horizontal line have more than 10% point estimates with infinite.
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Figure 12.2: Harmonic mean of Ne (solid line) and 95% confidence intervals (dashed 
lines) of 1,000 replicates for the moment-based temporal estimator for a time span 
between 1 and 24 generations. Four sampling strategies are considered: 60 individuals 
with 10, 20 and 50 loci and 120 individuals with 10 loci. The first row reports a constant 
7Ve=500, the second row 1,000 and the third 2,000. Curves on the left of each vertical 
line have more than 10% of the 1000 point estimates equal to infinity.
Comparison of methods in constant-size populations
To compare the 3 methods used to estimate contemporary Ne, we show on figure 12.3 
a box plot of the distribution of point estimates. For the temporal methods we include 
2 time spans (4 and 24 generations). The ML method is more precise than the original 
moments based estimator assuming equal time spans with the exception of the typical 
sampling strategy and a time span of 4. A time span of 4 will always produce imprecise 
results unless the ML method is used with 60 individuals and 50 microsatellite loci.
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While TM is more precise, it is also biased downwards with a real Ne of 1,000 as the 
upper quartile of point estimates is below 1,000.
S=60 L=20
1400-
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1500
Figure 12.3: Boxplot charts for the point estimates of all three Ne estimation methods 
using different sampling strategies (60 individuals with 10, 20 and 50 loci) and constant 
Ne of 500 and 1,000. For the both temporal estimators two time spans were considered: 
4 and 24 generations. The moment based temporal method is called “NeF”, and the 
ML version “TM”.
In terms of bias, the LD method is always less biased than any of the temporal 
methods for an Ne of 500. Temporal methods, for a time span of 4 generations, are 
in most cases less precise than LDNe and always more precise with time spans of 24, 
reinforcing the importance of the number of generations between samples.
136 CHAPTER 12. EFFECTIVE POPULATION SIZE OF VECTORS
Fluctuation in population size
For seasonal models, the temporal estimators and the LD method show different be­
haviours. The LD method is most influenced by the Ne value of the previous generation 
whereas the temporal methods will estimate an average between maximum and mini­
mum Ne. This makes the LD estimator vary from generation to generation while the 
temporal estimators are much more stable (figure 12.4 top). While the median estima­
tion of the LD method will approach the Ne of the previous generation, the precision 
of the estimations will produce overlaps of point estimate distributions (figure 12.4 bot­
tom); the precision will be especially poor when the estimator is based on higher Ne 
values. Only between the extremes (Ne of 200 and 1,200) of the simulated sizes is the 
overlap minimal.
The LD method is able to detect a bottleneck (defined here as Ne is below twice 
the post-bottleneck Ne) as early as one generation after it occurs for an Ne of 200 
(figure 12.5) and 500. The temporal methods are much less sensitive, for example, nine 
generations after the bottleneck, the moments based estimator is still above 3 times Ne 
for both bottleneck scenarios. The ML estimator has lower value (i.e. is more influenced 
by the sample with lower Ne) than the moments based version. Again as in the seasonal 
model, the temporal methods average the trend spanning the sampling period while the 
LD method reflects the state at the sampling time.
12.4 Discussion
Our most important and novel results are that LDNe and temporal methods have dif­
ferent behaviour for fluctuating populations and that the re-interpretation of existing 
empirical studies suggests that sample sizes are often too small in order for Ne esti­
mates to be informative. However we discuss results in order of increasing demographic 
complexity starting from classical temporal methods in stable populations.
Comparing temporal methods
For most scenarios tested, precision is more problematic than bias. Though our results 
show bias that can go up to 50% with the temporal method, precision can vary above one 
order of magnitude between the lower and upper quartile. Furthermore, our simulation 
assumption of Wright-Fisher equilibrium (i.e. Nc — Ne) is expected to have a relatively 
large bias with the standard temporal method, whereas for more realistic relationships 
between Nc and iVe, bias can be lower (Waples, 1989). For realistic generation spans (i.e. 
above 4), the sampling strategy has more influence on precision than on bias, therefore 
it is possible to vastly improve precision with a better sampling strategy.
Precision
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With the temporal methods, small timespans between samples severely decreases 
precision and enlarges CIs. A clear example of this effect can be seen in Simard et al. 
(2000) where all estimates made with 4 months of separation (assumed conservatively 
to be approximately 4 generations for A. gambiae) include infinity in the confidence in­
terval. In the same study, estimations with more than 3 years of interval (approximately 
40 generations) do provide much tighter confidence intervals (never including infinity). 
The likelihood approach also provides more precision and tighter confidence intervals 
than the classic estimator in almost all simulated cases. Only with small time spans 
(4 generations) and few loci (10 or 20) is the precision of the ML estimator worse but 
this “advantage” is mostly theoretical as the precision of the classic estimator, while 
better with small time spans is still very bad, i.e,, while the moments based estimator 
performs, in theory, better, it is still unusable. Our results suggest that the temporal 
methods are not useful if the time span is low and the real Ne is equal or larger than 
500. Similar results were observed in Ovenden et al. (2007).
Bias
The classic moments based method produces estimates that are generally biased 
upwards. The strategy of binning rare alleles is not enough to eliminate the bias, though 
it improves results if loci with many alleles are included. Both the LD and ML methods 
are less biased than the moments based method. It is not clear that binning rare alleles 
with the ML method (as done in Dyer et al. (2009)) is a good strategy as this method 
is known to perform well with rare alleles (Berthier et al., 2002) and our results suggest 
that the estimator is normally biased downwards, thus any binning might compound 
the problem. The ML method is only strongly biased upwards when the sample size 
is too low (e.g with 35 individuals and 12 loci as in Dyer et al. (2009)). Indeed, the 
results in Dyer et al. (2009) where the ML estimation is higher than the classic estimate 
suggests that the sampling size might have been insufficient. This relationship between 
estimators happens with small sample size (figure 12.3) and the sample size per time 
point was indeed very low.
Comparing LD with temporal methods
The time span between samples is a crucial parameter in deciding which method to 
use. For large time spans, both temporal estimators provide more precise estimates 
than the single-sample LD method. From a practical perspective the temporal methods 
require twice the sampling effort as two time points are needed to make an estimate. In 
deciding which method to use, researchers should consider not only the possible time 
span between samples in the temporal method, but also the economic issue of using one 
or two time samples: much more precision can be gained from having a single sample 
with 120 individuals and applying the single-sample LD method instead of having two 
time samples of 60 individuals each.
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Interpreting existing empirical studies
Our results suggest that the typical sampling policy of 60 individuals and 10 loci results 
in poor precision in almost all cases and severely limits biological/epidemiological inter­
pretations of the estimates. Only with long time spans between temporal samples and 
where Ne is less than 500 are the estimates relatively precise. In theory increasing the 
number of individuals will achieve a slightly higher increase in precision than increasing 
the number of loci. However, given the problems with collecting some of these vector 
species and the advent of new high throughput genotyping platforms, a more practical 
suggestion in most cases may be to increase the number of loci. Using 60 individuals 
and 50 loci will allow for more precise estimates, if Ne is less than 1,000, though if 
the expected value of Ne is close to 1,000 increased spacing between samples (above 24 
generations) may be required.
Next generation sequencing and SNP chips will allow the usage of thousands of 
SNP markers. Further research should consider the performance of estimators with 
thousands of bi-allelic loci with varying linkage disequilibrium. Our results also suggest 
that, for both methods sampling more individuals yields a bigger increase in precision 
than sampling more loci. This is consistent with results for the ML temporal method 
(Berthier et ah, 2002). For the LD method most other studies (England et al., 2010; 
Antao et al., 2011) (but not all, see Tallmon et al. (2010)) suggest that indeed more 
individuals provide more information.
Higher real Ne decreased precision with all estimators, for example the published 
empirical temporal estimates sampled a year apart (circa 12 generations) in the vector 
control study of Pinto et al. (2003) either include infinity in the upper confidence interval 
(with a high Ne of 1,078) in one case or even the point estimate is infinite in another case. 
The 24 month estimate of 1,457 has a upper confidence interval of almost one order of 
magnitude above (13,677). Such estimates, including infinite in the confidence intervals 
(and even in point estimates) make any inference of the impact of control measures 
unreliable at best.
Population fluctuation
When the population size is not constant the temporal and LD methods have quali­
tatively different behaviours. The LD method is extremely sensitive to the Ne of the 
previous 1 or 2 generations whereas the temporal methods “smooth” the ongoing de­
mographic processes (figures 12.4 and 12.5). This is not a suggestion that one class of 
method is “better” or “worse” than the other, only that they have different applications: 
the LD method is better suited for early detection of bottlenecks (e.g. population re­
ducing interventions) or to study seasonality whereas the temporal estimators provide 
a better picture of the “average” population size. It should be noted however that a 
less naive interpretation of LD results suggests that it might not be applicable to study
12.4. DISCUSSION 139
seasonality as the confidence intervals of the seasonal point estimates overlap (as with 
higher values of Ne the precision drops). Even if the point estimate distribution could 
be tightened (by increasing sample sizes, especially with more individuals sampled as 
the LD method is substantially more sensitive to individuals than loci (Antao et ah, 
2011)), the confidence intervals might still overlap for a fine-grained (monthly) estima­
tion, though detection of extremes will probably be feasible.
Any previous conclusion made about seasonality and control measures using tempo­
ral estimators is thus fraught with uncertainty. While we used the temporal ML method 
in Berthier et al. (2002) as it was used in a vector biology study with large Ne (Dyer 
et al., 2009), more recent ML temporal based methods developed to detect bottlenecks 
(Beaumont, 2003) should be investigated in the context of vector biology to assess their 
performance to detect control interventions and perhaps seasonality.
Simard et al. (2000) suggests (based on Nei and Tajima, 1981; Poliak, 1983) that, 
as the moments-based estimator approximates the harmonic mean of the effective pop­
ulation sizes, it is dominated by the smallest value, a fact also highlighted by O’Ryan 
et al. (1998). Our findings are consistent with this statement but we note the following: 
(i) While this effect is visible, the temporal estimators are still biased high from the 
post-bottleneck Ney (ii) if there is an expansion, the estimator is not useful and (iii) as 
the time distance between the bottleneck and the second sample increases the estimator 
will tend to approach the contemporary value. This latter effect is possibly caused by 
drift.
Computational and biological assumptions
Testing the ML estimator in a wide array of scenarios is not feasible due to the high 
computational cost of the TM3 application (Berthier et al., 2002) (common to most 
likelihood approaches). While running a single instance of the application is computa­
tionally cheap, running thousands of evaluations is prohibitive. At the risk of sparking 
controversy, we raise the following question: if extensive testing of likelihood applica­
tions is computationally unfeasible and only limited ad-hoc tests are possible, can we 
trust the results of ML approaches?
Some simulation assumptions might require further investigation in the particular 
context of vector biology: while random mating might be a reasonable assumption with 
Anophelines, it is less clear that it is acceptable for other vector species such as Glossina 
because polyandry and sperm competition is widespread with insecta (Simmons, 2001; 
Tripet et al., 2001). Age structure might be of particular importance with regards to 
seasonality estimates with the LD method as the signal from previous generations might 
“smooth” the estimation curve. On the other hand, as the ratio between Ne and Nc is 
likely well below 1, bias with the temporal method will most probably be much lower 
than reported here. If a sample is mostly originating in a small breeding site where
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close genetic relatedness between individuals exists, the results above might also not 
be applicable because the data are not independent. A practical recommendation is 
therefore to ensure good quality data, e.g. in the case of A. gambiae which breeds in 
small water bodies, not to take more than one individual per site.
12.5 Conclusion
Our results suggest that many existing empirical studies might require re-interpretation. 
It is not clear that common sampling and genotyping strategies are sufficient to reli­
ably estimate Ne in general or to detect the impact of control measures or to estimate 
seasonality (fluctuation) of vector population size. While previous studies might lack 
sufficient sample sizes (and in some cases enough time between sampled generations), 
contemporary Ne estimators can reliably be used to infer population size and evaluate 
control interventions as long as sample size (of loci and individuals) is enough. The 
temporal and LD methods have different strengths and thus complementary applica­
tions: the temporal methods can provide a useful average measure of Ne over several 
generations of genetic drift (between temporally-separated population samples), while 
the LD method is sensitive enough to provide generation-to-generation estimates of 
Ne and detect sudden changes in population size (in populations with non-overlapping 
generations). Consequently the LD method can be used to assess the success of con­
trol interventions (bottlenecks) and may help infer seasonality patterns of fluctuation 
in effective population size. Choice of estimator type (temporal or LD) will thus be 
dependent on the question being asked.
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1500 -
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Generations after the bottleneck
Figure 12.5: Harmonic mean of Ne (solid line) for all methods for two bottleneck 
scenarios (Ne from 2,000 to 200 and from 5,000 to 500) and a sampling strategy with 
60 individuals and 50 loci. Generations are counted from after the bottleneck event.
Thirteen
Interpreting estimates of effective 
population size in parasites and vectors
Tiago Antao, Andres Perez-Figueroa,
Ian M. Hastings, Martin J. Donnelly and Gordon Luikart
Abstract
Heterozygosity and effective population size are crucial parameters related to 
parasite and vector population viability and are increasingly used in parasitology, 
with potential applications to monitor and evaluate control and elimination policies. 
Here we argue that long-term iVe and heterozygosity estimation do not provide a 
reliable monitoring strategy for evaluating the efficacy of control and elimination 
measures and that current research might be incorrectly using such estimators. 
We suggest that estimation of the contemporary Ne might be used to evaluate 
control and elimination measures as long as the genetic and population samples are 
large. We provide suggestions on how to obtain precise and unbiased estimates of 
both the long-term and the contemporary effective population size. We note that 
studies of species such as Plasmodium falciparum camiot employ available Linkage 
Disequilibrium based estimators of Ne due to its mating system which includes 
selfing.
13.1 Introduction
Effective population size (iVe) determines the rate of neutral genetic change in a pop­
ulation caused by genetic drift (Charlesworth, 2009), consequently it determines the 
relative efficiency of natural selection in the face of drift. Ne has many biological appli­
cations, being a fundamental factor in determining population viability as greater Ne 
allows more genetic variability which is paramount for species survival and adaptation. 
Ne is also a commonly estimated in population genetic studies of Plasmodium falciparum 
at least since Anderson et al. (2000a) and of Anopheles gambiae starting from Lehmann 
et al. (1998). Ne estimation has, also in parasitology, many potential applications from
143
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simply assessing the genetic variability and size of parasite populations (Anderson et al., 
2000a; Iwagami et al., 2009; Susomboon et al, 2008) or vectors (Lehmann et ah, 1998), 
to assessing the impact of control interventions on parasites (Gatei et al., 2010) and 
vectors (Pinto et al., 2002, 2003; Wondji et al., 2005) and monitoring vector seasonality 
(Simard et al., 2000) (seasonality fluctuations in population size).
Estimating Ne mainly uses two different approaches (for reviews see Leberg (2005); 
Wang (2001)):
1. Long-term estimation of Ne is based on the observation that at mutation-drift 
equilibrium the amount of genetic variation is stable and dependent on mutation 
rate. This is applicable to DNA sequences (used with P. falciparum in Hughes 
and Verra, 2001) or microsatellites where the equilibrium heterozygosity can be 
approximated (assuming mutation-drift equilibrium) and that mutation rate can 
be estimated.
2. Short-term (contemporary) Ne estimators can be useful if population effective sizes 
are small, e.g. Ne < 500, but for many parasites and vectors Ne is often too large. 
Contemporary Ne is normally estimated from observed changes in allele frequen­
cies between generations (Krimbas and Tsakas, 1971; Poliak, 1983), from linkage 
disequilibrium patterns (Hill, 1981; Waples and Gaggiotti, 2006) or heterozygote 
excess (Robertson, 1965; Luikart et al., 1998; Balloux, 2004). The estimators of 
the contemporary Ne measure either the variance or inbreeding Ne for details see 
(Schwartz et al., 1999; Leberg, 2005).
Estimations of Ne in P. falciparum have been computed using long-term estima­
tion approaches presumably because Ne is relatively large and contemporary estimators 
of Ne are not precise with high Ne values (Waples, 1989; Waples and Do, 2010). P. 
falciparum effective population size and thus its population genetic diversity increases 
with transmission intensity with estimations varying between 1,000 for low transmis­
sion areas in South America and 20,000 in high transmission areas like Central Africa 
(Anderson et al., 2000a). Estimation is commonly done using an heterozygosity based 
estimator with microsatellites (see e.g. Anderson et al., 2000a; Iwagami et al., 2009; Su­
somboon et al., 2008), therefore the proprieties of heterozygosity estimators have direct 
consequences on this kind of long-term Ne estimation. As far as we know, estimates of 
contemporary Ne have never been reported for P. falciparum, although in areas of low 
transmission (due to expected low Ne) it might be possible to estimate contemporary Ne 
with precision, especially if the sampling strategy includes many individuals and loci.
For vector species both contemporary and long-term estimators have been routinely 
reported (e.g., Simard et al., 2000; Pinto et al., 2003; Dyer et al., 2009). Indeed one 
of the most commonly used contemporary Ne estimator (Krimbas and Tsakas, 1971) 
was developed to study the impact of insecticide resistance. This method requires two
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temporal samples and computes the variance in allele frequencies over time (as the 
variance is directly correlated with the effective size and decreases with Ne).
Here we provide arguments supporting the following conclusions: 1) We cannot use 
long-term Ne estimators and heterozygosity, to monitor the effectiveness of control and 
elimination interventions, 2) Heterozygosity based estimators Ne are not informative of 
contemporary demographic processes, 3) contemporary estimators might be useful if the 
real Ne is relatively low (<1000) and 4) linkage disequilibrium estimation is probably 
inappropriate for species like P. falciparum even with low Ne. We also provide guidelines 
on how to more precisely estimate and interpret Ne.
13.2 Problems with heterozygosity based Ne estimation
Three problems with heterozygosity based Ne estimation exist:
• Different Ne concepts based on heterozygosity exist including long-term and con­
temporary Ne (as well as local and global Ne), but authors are often unclear about 
which concept is being used.
• Misuse occurs such as the use of the long-term Ne estimator to study the contem­
porary Ne.
• Most importantly, low sensitivity is problematic for both the long-term and short­
term Ne estimators based on heterozygosity. This is especially serious when Ne is 
large, precisely the typical scenario of parasitology studies.
For example, in a bottleneck there will be heterozygosity loss at a rate of per 
generation, where Ne is the effective population size after the bottleneck event. Assum­
ing the data presented by Anderson et al. (2000a) that a high-transmission zone has a 
Ne of around 18,000 (He of 0.8) and a low-transmission zone has an Ne of approximately 
1,400 (He of 0.4) then a control intervention that would cause a reduction from 18,000 
to 1,400 would take 1,300 generations (more than 260 years in the case of P. falciparum) 
just to approximate an He of 0.50 (Ne of ss 2, 500). Almost 2,000 generations would be 
needed to approximate a He of 0.40. To put this in perspective, if the usage of Chloro- 
quine (introduced around 1947) were to impose a continuous bottleneck of the intensity 
described above, we would get a reasonably precise estimation of the bottleneck inten­
sity by sampling around the year 2350. This short rate of changes illustrates that there 
is essentially no relationship between changes in heterozygosity (and any heterozygos­
ity based Ne estimator, short- or long-term) and contemporary demographic processes. 
More detailed illustrative examples are presented in appendix C.
These results have direct application on the interpretation of the results presented 
in several papers. For instance Gate! et al. (2010), compared parasite heterozygosity be­
fore and after the introduction of ITNs; the results showed that there was no significant
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difference in expected heterozygosity, which led the authors to conclude that the popu­
lation maintained “overall stability in genetic diversity”. (Gatei et ah, 2010) computed 
the expected heterozygosity using eight “neutral” microsatellites before the introduction 
of ITNs and compared the result with a sampling 5 (approximately 25 P. falciparum 
generations) years after. This was done in western Kenya, a high-transmission area. ITN 
use causes a substantial reduction in malaria cases and human deaths (World Health 
Organization, 2008), thus potentially reducing the size of the parasite population. The 
authors actually report an increase in heterozygosity from 0.75 to 0.79. With regards 
to heterozygosity and the prevalence of mixed infections the authors state:
The stable overall genetic diversity after dramatic reduction in transmis­
sion intensity observed in the current study was unexpected by the initial 
prediction. The counter-intuitive results suggest that other factors may be 
involved in offsetting the effect of transmission reduction on parasite genetic 
diversity and/or stabilisation of the overall genetic diversity of P. falciparum 
parasite.
It seems that that the results are neither “counter-intuitive” nor “unexpected”: ex­
pected heterozygosity is a slow moving indicator especially in high-transmission areas 
even when efficient control measures (i.e. imposing strong bottlenecks) are in place. 
What Gatei et al. (2010) is observing is expected “artifact noise.” In this study, conclu­
sions are probably over-pessimistic: the ITN intervention might be having a impact on 
parasite diversity. We chosen this study just as an example among others where similar 
interpretations were made. For instance similar arguments could be raised for a study 
(Pinto et al., 2002) on A. gambiae about the impact of indoor spraying with DDT or 
several other vector studies which make contemporary inferences using the Ne estimator 
based on heterozygosity. The use of the DNA based long-term estimator in Hughes and 
Verra (2001) to infer about recent population bottlenecks probably suffers from similar 
problems.
Long-term Ne estimation is also influenced by the sample size (i.e. the number 
of individuals and loci sampled) as it influences precision and bias, but this problem 
(further detailed in the appendix C) is of considerable less importance than problems 
caused by misinterpretations of long-term 7Ve estimators for contemporary events. Loci 
under selection will also bias the estimator and, for instance, in Susomboon et al. (2008) 
it is suggested that 3 of the 12 microsatellite loci used to estimate Ne had strong genetic 
differentiation between samples taken in severe and uncomplicated malaria patients, 
though no formal test for selection was conducted. To our knowledge, no studies with 
long-term estimation in parasites or vectors have included tests for selection. Tests 
to detect selection should always be performed because loci documented as neutral in 
the past can be under selection in current or future studies (e.g. different drugs or 
insectides).
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13.3 Contemporary estimation of Ne
Temporal estimators
Contemporary estimation of Ne is mostly used for vectors (see e.g. Dyer et al. (2009); 
Pinto et al. (2003); Simard et al. (2000); Lehmann et al. (1998)). To our knowledge no 
studies with P. falciparum have used these estimators. Most studies of contemporary 
Ne use temporal estimators which require two samples over time. Precision of such 
Ne estimators is poor with large Ne, small temporal spacing between samples, and a 
low number of individuals or loci sampled. Figure 12,1 (from chapter 12) shows the 
impact of these factors on estimator precision and they are further discussed in Box 1. 
Very high Ne and few generations between samples are fundamental factors causing low 
precision. Chapter 12 shows that commonly used temporal based methods might not 
be appropriate to detect bottlenecks (normally resulting from control interventions) or 
seasonality patterns. Temporal based methods are more appropriate to detect averages 
over a period of time. For early detection of interventions, the usage of methods based 
on linkage disequilibrium (LD) was recommended instead (Antao et al., 2011).
Using linkage disequilibrium to estimate Ne
P. falciparum biology is known to diverge from standard population genetic models. For 
instance, selling is common especially in low transmission areas (Arnot, 1998). While 
P. falciparum is not clonal, selfing will impact LD (de Meeus and Balloux, 2004) as 
associations between loci are maintained for several generations in clonal populations. 
This has two important consequences: contemporary estimators of Ne based on LD 
(Hill, 1981; Waples and Gaggiotti, 2006; Waples and Do, 2008) will probably produce 
erroneous results as LD patterns are maintained over time. Also, any study in the 
change of multi-locus LD will probably also be slow moving. Therefore it is probable 
that LD is also of little use to evaluate the impact of malaria control measures (though, 
for other fully sexual, diploidy parasites or vectors, LD might be useful).
13.4 Conclusions and guidelines
Misinterpretation of Ne and heterozygosity estimation results can occur in parasitology 
studies such as assessments of control and elimination measures. Heterozygosity is 
widely known to be an insensitive indicator, thus is not appropriate to detect recent, 
sudden changes in population size. The larger the Ne value, the slower the change 
in heterozygosity. We illustrated, in the appendix, that poor performance expectations 
hold for typical effective population sizes of P. falciparum. Even for extreme bottlenecks 
the Ne estimated after 100 generations (i.e. around 20 years, assuming 5 P. falciparum 
generations per year) is still closer to the original value than to the post-bottleneck value.
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Indeed for areas that have had continuous high-transmission, it is not clear that estimates 
of Ne based on heterozygosity can detect any effect from the introduction of treatment 
drugs like Chloroquine decades ago. While theoretical predictions and simulation studies 
mainly done in conservation genetics would easily predict this estimator to be insensitive, 
it is staggering that some interventions in the distant past, especially in high transmission 
areas, cannot be detected even today using this estimator.
We provide suggestions to help future studies of effective population size, heterozy­
gosity and LD for P. falciparum malaria or insect vectors:
1. Long-term Ne estimators should not be used to infer contemporary demographic 
processes. Little can be inferred from long-term Ne estimators as to the impact of 
control and elimination measures. The same is valid for heterozygosity measure­
ments.
2. Estimators of contemporary Ne cannot be readily applied to P. falciparum malaria 
or other organisms if Ne is above approximately 2,000 as precision decreases with 
increasing Ne value.
3. The number of loci and individuals sampled should be carefully considered, espe­
cially when using contemporary Ne estimators (Details can be seen in e.g. Antao 
et ai. (2011); Tallmon et al. (2010); Berthier et al. (2002); England et al. (2010); 
Waples and Do (2010)). Most studies suggest that sampling more individuals is 
more beneficial than sampling more loci (see e.g Antao et al., 2011; England et al., 
2010). If the number of individuals sampled cannot be increased then sampling 
more loci (feasible with the advent of next generation sequencing) can increase 
estimation precision of Ne. Further research is needed to understand if genotyp- 
ing thousands of SNPs (current studies use microsatellites) can increase precision, 
especially of contemporary estimators.
4. With temporal based estimators of contemporary Ne, generations between samples 
should be as large as possible as precision increases as the generation spacing 
increases.
5. Loci should be tested for selection as selection can bias all Ne estimators. While 
testing for selection is common between populations, in the specific case of par­
asites and vectors, selection over time for the same population is also relevant 
due to the impact of human interventions (e.g., drug deployment and subsequent 
selection for resistance). Many methods developed for spacial selection detection 
can be easily used to detect temporal selection signatures.
6. In the specific case of P. falciparum and due to reproduction with selling, inferences 
based on LD (including contemporary Ne estimators based on LD) should be used
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with great care, most probably avoided. Further research is necessary to evaluate 
these estimators for use with P. falciparum and parasites with similar genetics.
7. The appropriate contemporary estimator should be correctly chosen for different 
research problems. The LD estimator is probably better suited for detecting the 
impact of interventions and seasonal fluctuations, whereas temporal based ap­
proaches can be used to estimate an average Ne over multiple generations. Tem­
poral estimators exist for detecting population fluctuations (see e.g. Beaumont, 
2003), but have never been used or evaluated in parasite or vector contexts.
8. Finally, both parasite or vector populations are not closed and migration is nor­
mally an important factor, especially considering modern human mobility. Migra­
tion will bring increase genetic variability in local populations and thus increase 
short-term Ne.
While it would be important to have an accurate and precise estimate of contempo­
rary effective population size for P. falciparum, its vectors and other parasites, especially 
in the context of control and elimination measures, it is not clear that that objective 
is always feasible: methods explicitly targeted for estimating contemporary Ne are only 
applicable for small populations or will need large amounts of data. Furthermore, het­
erozygosity based methods cannot reliably estimate contemporary Ne, unless it is ex­
tremely small. Some of these limitations are widely known, but unfortunately it is not 
clear that they have been understood by the parasitology community. We recommend 
caution in interpreting Ne estimates and suggest that other strategies should be used 
to complement assessments of impacts of control and elimination measures on parasite 
and vector genetic diversity.
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Box 1: Factors affecting the precision of contemporary Ne 
estimators
The precision of the most widely used temporal-based method for contemporary esti­
mation of Ne is well characterised by its coefficient of variation, which is a measure of 
dispersion:
(13.1)
In the context of this work, more important than any mathematical details, it is the 
intuitive consequences that are important:
Precision increases with n (the number of independent alleles sampled), S (the num­
ber of individuals sampled) and t (the spacing, in generations, between samples).
Interestingly precision to estimate Ne decreases with the real Ne value. This means 
that the higher the Ne the lower the precision obtained (all other variables being equal). 
There is a relationship between the real value and the precision of the estimator.
One of the most widely used linkage disequilibrium estimators is implemented in 
LDNe software application. Its coefficient of variation is also known and is:
(13.2)
Where n' is a slight formal variation of n above, but from a qualitative perspective 
represents the same concept (roughly the number of alleles).
The factors affecting precision of this LD estimator are similar to the temporal 
method (except the temporal spacing between samples, as this LD method uses only a 
single sample).
There is ample literature about the influence of these parameters considering many 
demographic situations, but most of these studies are normally geared for conservation 
genetics, thus the reader is cautioned that the Nes studied are normally lower than the 
typical values in parasitology settings, thus reported recommendations will be insufficient 
due to decreased precision. Researchers are thus strongly recommended to verify if 
the conditions of the literature consulted are applicable to their species and research 
question, and in the scope of parasitology.
Part IV
Discussion and conclusion
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Fourteen
Discussion and conclusion
This thesis follows, very consciously, a strongly empiricist approach. This might seem 
strange at first: in effect this is a theoretical thesis with apparently no empirical data 
supporting it. As we will see, there is absolutely no contradiction in a theoretical work 
being empirical in approach. On the other hand, as we will also see, most of this thesis 
is indeed supported by data. But first we will address the empiricist slant of this work.
The vast majority of existing theoretical work in parasitology is mostly concerned 
with the future: from predicting the impact of new vaccinnes (Smith et al., 2006), 
to models of economic cost (Tediosi et al., 2006) or proposals for malaria elimination 
(Maude et al., 2009) among many others. With a single exception (chapter 4) this work 
is concerned with data interpretation and understanding the past and the present. Even 
the most theoretical part, dedicated to population genetics models of drug resistant 
P. falciparum is mostly empirically driven: Chapter 3 tries to understand the cause of 
stabilization of resistance at intermediate frequencies and provides guidelines to better 
understand linkage disequilibrium. The same pattern occurs in the part dedicated to 
selection detection: Chapter 9 uses empirical data with a known demographic and selec­
tion history (humans) to assess selection detection methods based on Fst and chapter 10 
studies the performance of Fst using simulated data. Chapters 6, 7 and 8 are software 
applications to analyze empirical data. Exactly the same pattern can be observed in 
the final part, dedicated to Ne estimation: all chapters are concerned with suggesting 
realistic sample sizes to infer JVe, furthermore the applicability of several estimators is 
also assessed for different demographies (e.g. bottlenecks caused by control policies or 
seasonality) or parasite biology (e.g. the impact of selfing on linkage disequilibrium).
It should be clear by now that it is possible to be theoretical and empirically oriented 
at the same time. It is actually puzzling (and worrying) that theory and practice seem 
to be so disconnected within the parasitology community:
First, there is no such thing as “a-theoretical” empiricism: a good example of this 
is the (arguably wrong) expectations about positive linkage disequilibrium between re­
sistance genes. There is clearly a (often unconscious) theoretical model of linkage being 
used (namely that there should be a positive association between resistance loci). And
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one has to wonder how many studies of linkage between, e.g. dhfr and dhps, are done 
where equilibrium is found and which are subsequently not reported due to fear of being 
seen as a “wrong” result.
Secondly, theoretical work seems to concentrate on predicting the future: there seems 
to exist an implicit view that the past is somehow perfectly understood, almost as if 
existing knowledge does not require revision. Also, there is clear pressure to concentrate 
on the future, for instance several funding bodies seem to desire, at any cost (especially 
a cost of realism), predictions and strategies to eliminate and eradicate malaria. In 
this context reflections on the past are of little interest. But understanding the past is 
important: it is nothing more than a falacy that we have full (or enough) understanding 
of it. Several examples of the need to revisit the past and re-interpret data and associ­
ated theories were presented here, for instance we noted that exiting interpretations of 
heterozygosity and effective population size might be too pessimistic when assessing the 
impact of control measures on parasite and vector genetic diversity.
It should also be clear by now that empirical data is used: Obviously we use human 
data from the HapMap project in chapter 9, but for most other chapters we made 
sure that our models qualitatively followed field observations and great care was put 
on assuring that our models and computational approaches provided results that were 
consistent with observations. Our approach to “fitting” was qualitative, not quantitative: 
there is no presumption that our simple models will track reality with quantitative 
precision. Interestingly there is a question if complex models can do any better, but 
that is a question that we did not address here. Sometimes we used simulated data 
for analysis, this was always done with an empirical perspective: for instance to try 
to understand the correct sample sizes to precisely estimate Ne. Simulated data is 
fundamental when there is no empirical data available, such can happen in many cases 
and especially with human diseases like malaria where experimental design and data 
collection are strongly limited by ethical issues.
Being a theoretical thesis with an empirical approach makes for inherently modest 
work: Here there are no grand plans on how to eliminate and eradicate malaria. This 
thesis is mostly comprised of suggestions for researchers that do data analysis. Therefore, 
while this work is theoretical in nature, it is intended with an empirical readership in 
mind. It is, in a way, an attempt to approximate the two comunities (theoretical and 
empirical).
After this more philosophical discussion (a gentle reminder that this is a thesis 
submitted for a Philosophical doctor degree) I provide a conclusion for each part of this 
thesis followed by some final remarks.
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14.1 Population genetics models of drug resistant P. 
falciparum
P. falciparum biology has several differences from “standard” population genetics mod­
els. Three differences are worth nothing here: having both an haploid and diploid phase; 
large population size inside humans (up to 1012) contrasting with low size in mosquito 
blood meals (sometimes below 10) and highly inbred mating (due to limited mating op­
tions during the sexual phase inside the mosquito). OgaraK was thus developed to allow 
the simulation of P. falciparum population genetics in the presence of drug resistance. 
This is a novel simulator but very limited in features (only simulates resistance genes, 
with only two alleles per gene, etc...), this became clear in the chapter on the importance 
of Fst in P- falciparum studies, when there was a need to use a different simulator to 
calculate neutral loci. There is evidently room for improvement and future work might 
include the development of a more general simulator of P. falciparum population ge­
netics. Even in its current version, some features are still missing: for instance it is 
not possible to simulate other interactions than full epistasis when simulating combina­
tion therapies. OgaraK is fully open-source allowing for easy repetition of the results 
presented here (and the creation of many other novel simulations). I wonder why such 
openess is not compulsory. If researchers are required to fully report all mathematical 
formulae, why not extend such approach to software applications developed to conduct 
research?
Chapter 3 extended the model of Hastings (2006) to support epistasis and multiple 
drug deployments. It is the basic theoretical work of this part and sets the theoretical 
ground to all other research. There are three main conclusions that are worth revisiting:
1. The impact of epistasis on linkage disequilibrium. Our results provides a sound 
theoretical base suggesting that any kind of linkage disequilibrium (in either mag­
nitude or signal) are plausible. Most notably, researchers should not be reluctant 
to report linkage equilibrium. The magnitude and signal of linkage provide impor­
tant information as to the interactions among genes involved in drug resistance.
2. This chapter also provides a novel justification for the stabilization of resistance 
at intermediate frequencies. As chapter 10 suggests while stabilization of allele 
frequencies might occur, the resistant phenotype might still, in essence, fixate. 
This suggests that, while epistasis is surely part of the explanation for stabilization 
at intermediate frequencies, further research is still needed to understand all the 
causes of stabilization.
3. The mis-intepretation of changes in prevalence of resistance (normally caused by 
control interventions). If MOI is reduced, then any observed decrease in prevalence 
of resistance might be explained not by a reduction of frequency of resistance, but
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simply by MOL Analysis of field data where transmission has changed should 
carefully consider this.
As most of the chapters of this thesis were accepted for publication before submission, 
content, and especially format was affected by restrictions imposed by accepting journals. 
For instance, chapter structure varies considerably and content is sometimes repeated 
in different chapters. In terms of content, only chapter 3 requires further discussion: 
Firstly, the original title was (the arguably more modest) “The influence of selection 
heterogeneity on the spread of drug resistant malaria”, this title puts more emphasis 
on the evolutionary approach of the model, whereas the final title, “Environmental, 
pharmacological and genetic influences on the spread of drug resistant malaria”, is more 
broad in scope. Secondly, and most importantly, the third paragraph “Mathematical 
models play an important role...” engages in what this author sees as proselytising 
about the role of mathematical models, I would clearly have preferred a more “agnostic” 
approach: if mathematical models are important, that is for the reader to make her own 
judgement. But, as a rule, reviewer and editor comments improved the quality of the 
manuscripts in substantial ways.
A final, important, note about this chapter: In hindsight, the fundamental messages 
(for the intended target audience, empirical researchers) are written in the middle of 
many theoretical formulations and discussion. It is not clear that such format is the 
best to convey such important information to empirical researchers. A more compact 
and readable formulation would probably have been desirable.
Chapter 4 is the only chapter that is, in its nature, predictive. Due to serious prob­
lems with multi-drug resistance in other infectious diseases (e.g., MRS A or tuberculosis), 
it was deemed important to analyse the impact of recent proposals regarding drug dis­
tribution policy which make available several first-line treatments simultaneously. There 
will probably be no future attempt to publish this chapter.
This part finalises with a small opinion letter (chapter 5) reflecting on the importance 
of evolutionary approaches in parasitology; most importantly we try to remind the policy 
makers that elimination attempts, if unsucessful might drive resistance dangerously 
higher.
14.2 Fst selection detection and discovering genes 
involved in drug resistance
LOSITAN was developed to study the performance of a widely used Fsx-outlier method 
(Beaumont and Nichols, 1996) to identify loci under selection. Most unfortunately there 
was never real P. falciparum data to be studied (discussed below). Interestingly the ap­
plication has been widely used to study selection accross many taxa. It is nonetheless 
gratifying to know that is was used elsewhere (Vinayak et ah, 2010) to study the spread
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of resistance to Sulfadoxine in P. falciparum. LOSITAN is mostly an easy to use ap­
plication based on the FDIST program, but its features are much more than a simple 
interface: it includes a multi-test implementation, removal of potentially selected loci 
when calculating neutral FgT and correct approximation of neutral Fst- Many selec­
tion detection methods (or much biological software, in general) are difficult to use, 
and consequently prone to being mis-used. Developers of biological applications tend 
to assume that the users will be fully knowledgable about the underlying parameters 
of biological models, here we follow a different approach: we try to help the user avoid 
making parametrization mistakes.
Mcheza is proof that the work conducted here was prone to some fluidity. This 
application was never planned, but many researchers using LOSITAN requested a version 
for dominant markers and therefore we decided to develop and provide it.
interPopula is a library to process HapMap data in Python. It was developed with 
the sole purpose of supporting the evaluation of Fst with HapMap data. The most 
serious drawback of this library comes from the fact that the HapMap project is con­
stantly changing the directory structure of the HapMap repository, making it difficult 
to maintain the library compatible with the repository format.
Chapter 9 evaluates Fst using the HapMap SNP dataset. Our approach is novel as 
we use empirical data to evaluate performance, whereas all known studies use simulated 
data. The strategy is simple: There is relatively much more data available for humans 
(both in terms of dataset size and information about demography and selection) so 
we can compare the results using a more limited methodology (either in data size or 
knowledge about demography and selection): If the more limited methodology is able 
to approach the complete information available, then the more limited methodology 
is reliable. Our results suggest that, while Fst is “noisy” over the genome, it is far 
from being randomly distributed. Current sampling strategies systematically under­
sample the number SNPs per gene necessary to reliably detect selection and probably 
fail to detect many candidate loci for directional selection. Most disturbingly, some 
next generation sequencing technologies might still not have enough markers per gene 
in order to reliably detect loci under selection.
There is an ongoing debate on the usefullness of FsT-outlier approaches to detect 
selection, this part is contribution to that debate, which is clearly far from over.
14.3 Estimating effective population size and assessing 
the success of control and elimination measures
To study the performance of effective population size estimators in parasitology settings 
we start, in chapter 11, by comparing two short term Ne estimators for bottleneck
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detection, but still in low Ne (e.g. conservation) scenarios. There are several reasons for 
this approach:
1. Short term Ne estimators are known to have decreased precision as real Ne in­
creases, therefore low Ne is a starting point before higher Ne values are considered: 
if estimators were to fail in low Ne scenarios, there would be no point in proceeding 
to more computationally expensive simulations of higher Ne.
2. Our evaluation was novel as it evaluated bottlenecked demographies: precisely the 
type of signal that we want to detect in any control and elimination intervention.
3. Most importantly we wanted to attract reviewers and readership with a conserva­
tion background. We will argue below that such audience is probably more capable 
of providing insightful feedback and constructive criticism than parasitologists.
Chapter 12 is another example of a certain degree of fluidity in the development 
of this work: Studying Ne in disease vector scenarios was never planned but, as a 
review of the broad parasitology literature on effective population size made clear, it 
was important to understand the performance of Ne estimators in the context of vector 
biology. Our demographic model designed to approach seasonality (i.e., the impact 
of dry- and wet-season on population size) clearly demonstrated that temporal and 
LD based Ne estimators have qualitatively different interpretations: LD estimators are 
very short-term as they estimate the Ne of the previous generation whereas temporal 
estimators tend to provide an average over a period of time. We also showed that existing 
studies of Ne have an excessively small sample size and that, in some cases the interval 
between generations used with temporal estimators is too short. Nonetheless, as long as 
sampling sizes and temporal spacing between generations are both increased and care 
is taken with the interpretation of results, Ne can be a useful tool to understand the 
impact of vector control measures.
Finally, chapter 13 describes a broad analysis of the usage of effective population 
size estimators in parasitology, especially long-term estimation. It is puzzling, not to 
say shocking, that many basic interpretation mistakes are routinely being made in the 
interpretation of genetic data. The most obvious is, of course, the use of heterozygosity 
(and heterozygosity based Ne estimation) to make conclusions about potential recent 
bottlenecks. Basic population genetics postulates that heterozygosity is “slow moving”, 
and slower with higher population sizes. It has been shown that even for low Ne sce­
narios heterozygosity cannot be used for early detection of bottlencks. It is worrying 
that such results, seen as trivial by most conservation geneticists are not absorbed by 
the parasitology community. Given the existing number of manuscripts making such er- 
rouneous interpretations one can infer that the problem is pervasive: it affects authors, 
reviewers and editors to a reasonable extent.
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It is clear that many biological assumptions made in standard population genetics 
models are not applicable to P. falciparum. There is clearly much work to be done in 
both developing new models targetting malaria and understanding the implications (and 
possible mistakes) of using standard assumptions with P. falciparum. For instance, and 
in the scope of this part: Quantifying the error of LD-based Ne estimation imposed by 
selling in particular and inbreeding of P. falciparum.
14.4 Final remarks
The direction taken by this work was mostly decided after the first year where I started 
to pursue a empiricist-based strategy, as opposed to a predictive approach (where most 
of the first year work was done). It was clear from the onset that having real datasets 
to work with would be a difficult objective to attain: several possible sources of real 
data were considered but it became obvious that access to them would not be possible 
in time to complete this thesis. The responsibility of the path followed relies solely on 
me as I was fully aware of the risks involved. Despite all this, one year lost and no P. 
falciparum datasets to work with, I would, without a shadow of a doubt, repeat the 
same approach: for all time lost and obstacles are easily compensated by doing work in 
which I believed and which was, from my point of view, valuable and worthwhile. Such 
change in strategy and scope requires obviously a very special kind - a rare kind - of 
supervisor: one that understands the value of intelectual freedom and is always there to 
support difficult, but necessary, decisions.
One of the aims of this work is to show that any supposed barriers between theory 
and practice are mostly fabricated. It is possible, and in most cases desirable, to theorize 
about subjects which are important to field researchers.
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ogaraK: Supplementary material
A.l Simulator overview
OgaraK simulates a P. falciparum population which suffers heterogeneous selection pres­
sure over time and space. Here we present the model with a special focus on the biological 
underpinnings and some of the more uncommon properties (i.e. either not captured by 
existing simulators or at least not commonly simulated) are emphasised.
OgaraK tracks the spread of drug resistance using a time-scale of parasite generations 
(a generation is a parasite reproduction cycle from host to host), where resistance to 
each drug is encoded by one or more loci. The main output of the simulator is the 
frequency of resistance genotypes over time.
Biological observations
While we do not intend to present an introduction to P. falciparum biology (see e.g., 
Tuteja (2007)), some observations, especially those that differ from standard population 
genetics, are important in order to understand the main design options of ogaraK:
Plasmodium malaria parasites are haploid and reproduce asexually within humans. 
Infections can include up to 1012 parasites. They undergo a brief diploid phase with 
sexual recombination in the mosquito.
Humans often contain several genetically distinct P. falciparum clones acquired from 
different mosquito bites; the number of clones in a human is called the multiplicity of 
infection (MOI).
For most drug treatments, resistance only emerged in a small number of foci (Wellems 
and Plowe, 2001; Roper et aL, 2004), the notable exception being Atovaquone (Vaidya 
and Mather, 2000). While understanding the appearance of de novo mutations is an 
important topic, (see e.g,, White and Pongtavornpinyo (2003); Pongtavornpinyo et al. 
(2009)), in the vast majority of human populations, resistance will not occur via muta­
tion, but via immigration of resistance genes or is already present for many drugs.
While inside the mosquito, mating options are severely restricted to the gametes 
coming from the blood meal, and mating between genetic equal gametes is not uncom-
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mon. Mating between gametes from the same clone (selling) results in sex between 
identical haploid genotypes resulting in clonal reproduction. Mating between different 
clones (out-crossing) results in genetic recombination and re-assortment of P. falciparum 
genes. If a parasite has a mutation and is in competition with wild-type variant on an 
untreated individual, a fitness penalty is normally incurred by the resistant parasites 
(Babiker et al., 2009). While the fitness penalty probably happens while in direct com­
petition with other infections in the blood stage, the hypothesis of occurring elsewhere 
(e.g. liver stage, or while in transmission) cannot be realistically excluded.
Genetically distinct gametes ingested by a mosquito are therefore related to the MOI: 
the number of distinct genotypes that can be ingested cannot be bigger the the MOI. 
MOI is a proxy for the intensity of transmission: in areas of high transmission the MOI 
is bigger due to repeated sequential infection. Typical MOI values are below 7 with 
higher values occurring in areas of intense transmission.
Humans might develop partial immunity to malaria over time (Langhorne et al., 
2008), this allows for asymptomatic carriers which might be untreated (i.e., without 
selection pressure imposed by a drug). Existing evidence (Osman et al., 2007) suggests 
that most, if not all, loci involved in drug resistance are physically unlinked.
From these biological insights, ogaraK is designed along the following lines:
• The parasite population is defined as the population co-existing with a human host 
population. Different hosts (humans) provide different selection environments, 
e.g., untreated hosts act as potential reservoirs for sensitive parasites and treated 
hosts will kill sensitive forms while resistant infections may survive treatment. 
Each type of environment contains parasites facing different selection pressures.
• Each infection has a certain genetic profile. For each drug a certain number of 
loci are involved in drug resistance. Each locus has two alleles: wild (“sensitive”) 
and mutant (“resistant”). The ability to resist drug treatment is dependent on the 
relationships between resistant loci and is detailed below.
• The demographic model presented is equivalent to an island model with an extreme 
migration rate proportional to the relative size of each environment, making the 
environment to which a parasite is exposed independent of the environment of the 
parent(s). We note that, in most standard demographic models - e.g., island or 
stepping-stone - the migration rate is normally low and there is a large probability 
of an offspring staying within the population of the parents. That is not the case 
here, but strictly speaking we implement an island model.
• Mutated parasites are expected to exist at the onset of the simulation, but we also 
support mutation (de novo emergence).
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• Individual simulation of parasites is impossible because of large population sizes. 
The model used to perform the simulation is detailed below.
• While inside human individuals P. falciparum parasites are only in haploid form, 
therefore no effort is made to model diploidy (e.g., dominance effects) inside hu­
mans. Sexual forms (gametocytes) do exist in the human, but these are still 
haploid.
• The level of parasite inbreeding is directly influenced by the MOI parameter, as the 
mating options inside the mosquito are mostly influenced by the diversity available 
in a single blood meal coming from a single individual.
• All loci are modelled as physically unlinked.
• The fitness penalty can be modelled as blood-stage (erythrocytic) or non-blood 
stage (exo-erythrocytic).
A very simple example is presented on figure A.l. Here a single drug is deployed and 
given to 40% of the population. This means a single selection pressure outside untreated 
individuals, that does not change over time (i.e., the treatment rate is constant). This 
simple example is mainly provided as a basis for a build-up for more complex examples 
provided below.
With the design options presented above, ogaraK is able to approximate the vast 
majority of the literature using a population genetics approach modelling the spread of 
drug resistance.
Epistasis
Resistance to drugs often involves more than one locus. Modes of resistance are not 
fully understood for most drugs, with notable exception of SP (Gregson and Plowe, 
2005). In order to understand the importance of gene interactions when more than 
one locus is involved, ogaraK allows for specification of the epistasis mode among loci. 
Three modes are available: Pull epistasis (requiring all loci to be mutant in order for a 
parasite to be able to resist), duplicate gene function (DGF - only one locus is necessary 
to confer resistance) and asymmetric epistasis (one locus is necessary, while a second 
is irrelevant). Asymmetric epistasis is only invoked in conjunction with other modes 
(see below) and obviously is no different from a single-locus model if used on its own. 
Asymmetry is inspired from the modes of resistance against Chloroquine and SP when 
a “more important” locus (pfcrt in the case of CQ and pfdhfr in the case of SP) is 
complemented by a “less important” one (pfmdr on CQ and pfdhps on SP). A summary 
of supported epistasis modes is presented on table A.l. Interestingly, the most commonly 
modelled epistasis mode in the literature (full-epistasis) does not seem to be the most 
widely reported from empirical studies (like e.g., the CQ and SP cases reported above).
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A single drug used over time
Generation
Figure A.l: One drug is used over 40 generations. 40% of individuals are treated, while 
the reminder remain untreated. Only a single drug is used over time and nothing is said 
about the genetic profile of resistance.
Resistance profile Epistasis mode
Locus 1 Locus 2 Full Asymmetric DGF
Sens Sens Cure Cure Cure
Sens Res Cure Cure Resistance
Res Sens Cure Resistance Resistance
Res Res Resistance Resistance Resistance
Table A.l: The outcome of human drug treatment according to genetic modes of re­
sistance. A single mutation at either loci is enough to confer resistance with duplicate 
gene function (DGF). In asymmetric epistasis, the first locus is necessary and sufficient 
to confer resistance. Mutations at both loci are necessary with full epistasis.
Simulations can therefore be done with different epistasis modes in order to under­
stand the effect of different gene interactions. Most importantly different epistasis modes 
can be used in the same simulation in order to simulate different human environments. 
The reason we define alternate forms of epistasis is that “resistance” is not an intrinsic 
trait of the parasites' genotypes, but depends on the human “environment” in which
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treatment occurs. For example: Parasites may require mutations at both loci (i.e. full 
epistasis) to survive treatment in humans who take a full drug course and have some 
anti-malaria immunity; parasites may require mutations at only the main locus (i.e. 
asymmetric epistasis) to survive treatment in humans who are non-immune or who take 
an incomplete drug course; parasites may require only a single mutation at either locus 
(duplicate gene function) to survive treatment in humans who are non-immune and do 
not take a complete drug course. It is in such context that asymmetric epistasis can 
be useful: While in some human hosts the most important locus is enough to confer 
resistance, in others both loci are required for parasite survival and parasites “jump” 
among different kinds of hosts during the simulation. This can have implications in 
linkage disequilibrium patterns between resistance loci (Antao and Hastings, 2011b). 
An example scenario is presented on figure A.2.
Generation
Figure A.2: One drug is used over 40 generations. 40% of individuals are treated, 
while the reminder remain untreated. Only a single drug is used over time. Half of the 
treated population takes the full treatment course and thus is able to clear all parasites 
except the ones having all mutations related to the drug used. The other half of the 
population, fail to take the full course so are only able to clear the sensitive parasites 
and the infections having only the “least important” mutation in the asymmetric model.
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Mathematical formalisation
In order to simplify the presentation of the mathematical formalisation, we describe a 
single case scenario where 2 drugs are deployed and 2 loci per drug are used to code for 
resistance (the drugs will be non-ACT, i.e., they will not share any resistance loci). MOI 
will be set constant at 2 and the fitness penalty will be modelled at the blood stages. 
A more general formalisation (though not including epistasis) can be seen in Hastings 
(2006).
We note that there are 16 possible genotypes, from a totally sensitive one (genotype 
0 - no mutations) to the multiple-resistant one (genotype 15 - all mutations). The 
resistance profile can be easily computed by imagining the binary representation of a 
clone where the first drug is represented at the right hand side. Clones 1 (0001) and 2 
(0010) have one mutation related to drug one, clone 3 (0011) has both. Clone 13 (1101) 
has both mutations related to drug two and one related to drug one.
The frequency of each resistance profile k transmitted to the next generation will be:
F,=
15 15 2
E E E E/(eMci,c2)p(d)teid(^ci,C2)
ci =0c2 =0e=0d=0
w (A.1)
The structure of the equation can be explained as follows: All possible combinations 
of clones (as MOI is 2 we consider combinations of two, but any number of clones can 
be combined using a multinomial distribution) are considered on the summations of 
ci and c2. Summation of e allows to investigate the contribution of all environments 
(untreated individuals plus one or more different epistasis cases), /(e) is the fraction 
of the host population providing a certain environment (e.g., untreated, treated with 
duplicate gene function, etc.). p(d) is the probability of receiving a certain drug regimen 
where d = 0 means no drug. For the untreated environment p(0) == 1. For other 
environments p(0) = 0 and p(d > 0) is dependent on policy (e.g., ~ with MFT). For 
each environment e there is a different transmission proportion for each profile (tejd, see 
below).
W is a normalisation coefficient equal to the sum of all the numerators (in order to
2!-l ,
assure that the proportions of each type of transmission X) sum to 1).
k=0
Supporting more than one MOI per simulation is done by simply adding similar 
parcels in proportion to the frequency of a certain MOI (details can be seen in Hastings 
(2006)).
The transmission is dependent on the drug applied and epistasis. Two concrete 
examples will make this more clear:
1. If no drug is present and clones 0 (0000) and 3 (0011) mate (i.e., no mutations 
and the two mutations involved in resistance to the first drug) then clones 0, 1, 2 
and 3 might be transmitted. Note that clones 1 and 2 are possible to emerge via
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recombination. Because of fitness penalties clone 0 will have a bigger probability 
of transmitting than 1, 2 and 3. Clones 1 and 2 will have equal probabilities (same 
number of mutations). Clone 3 will be the least probable to transmit.
2. If the second drug is present in an environment with full epistasis and clones 12 
(1100) and 4 (0100) are present (clone 12 has both mutations for the second drug 
and clone 4 only one). In this case, the drug eliminates clone 4. Only clone 12 
transmits with no recombination possible.
A.2 Drug policies
Three drug policies are supported, causing qualitatively different pressure types:
Rotation A drug is replaced by another every n generations to avoid resistance spread­
ing to high levels. Reintroduction is possible after the whole arsenal of drugs is 
used once (figure A.3a). Drugs can be rotated not only every n generations, but 
after resistance to the current drug reaches a certain threshold.
Multiple first line therapies (MFT) All drugs are used simultaneously, but differ­
ent individuals are treated with a single drug (figure A.3b).
Combination therapy Each individual is treated with all the drugs available, this is 
akin to single drug usage when the number of loci involved in resistance to the 
combination cocktail is the sum of all loci involved in each drug.
Drug policies can be combined with different epistasis modes, allowing for quite 
complex scenarios with both spatial and temporal heterogeneity patterns, as an example, 
figure A.4 depicts a scenario where two drugs are deployed in sequence and each drug 
has two epistasis modes.
Artemisinin combination therapies
Artemisinin combination therapies (ACTs) are the current WHO recommended treat­
ment (World Health Organization, 2006) and MFT and rotation of this type of drugs 
provides a novel model of genetic interaction between drugs. AClb, as its name implies 
involve the combination of an Artemisinin derivative with a partner drug. This means 
that, if resistance surfaces, it will probably involve both the Artemisinin derivative and 
the partner drug. The Artemisinin derivative is present in all ACTS, so it is necessary 
to model resistance to ACTs by allowing the genetic mode of Artemisinin resistance to 
be shared among different treatments. ACT drugs always have two loci per drug, but 
one of the loci is shared among all drugs. As such, if 3 ACT drugs are modelled, 4 loci 
are tracked: one for each partner drug, and one representing the Artemisinin derivative 
shared by all.
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Two drugs in rotation
Generation
(a) Rotation
Generation
(b) MFT
Figure A.3: Different drug deployment policies. Rotation entails swapping drugs every n 
generations, MFT using all drugs simultaneously, but only a single drug per individual. 
Different drugs have different resistance mechanisms (i.e. loci).
Mutation
OgaraK main focus is the study of the spread of resistance, but de novo emergence is 
also supported.
OgaraK has no concept of the number of parasites, as it tracks infections. Mutation 
is therefore supported using two parameters: the probability of a mutation occurring 
per generation (applicable to each locus independently) and the percentage of sensitive 
clones which are mutated to resistant. The following important points are noted:
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Figure A.4: Multiple epistasis modes can be combined with different policies. In this 
example, 2 drugs are used with a rotation policy, each drug has two different epistasis 
modes to account for different immunity profiles.
1. We track the conversion of sensitive clones to resistant, but not the other way 
around as such event is not relevant to malaria epidemiology. Even when a drug is 
removed, sensitive clones re-appear from existing sensitive parasites as, in reality 
there is at least residual frequencies of sensitive infections.
2. The concept of de novo mutation occurring rarely (i.e. not in every generation) is 
firmly grounded in empirical data for the emergence of resistance in most drugs.
3. All mutations are independent and all loci have the same probability of mutation.
4. If a mutation occurs, it can happen, randomly, to any clone which is sensitive at 
the mutated locus. A percentage of that clone (specified as a parameter) will be 
converted to a resistant clone.
A fundamental point should be stressed: If mutation is activated, ogaraK which is 
normally a deterministic simulator, becomes stochastic. While for studies of spread of 
resistance (no mutation) the results do not vary with parameters, if mutation is activated 
different runs for the same parameters might have held different results.
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Parallels with sex theory
While ogaraK was not designed with sex theory (Otto and Lenormand, 2002) as its first 
use case, the conceptual parallels between drug rotation and the Red Queen Hypothesis 
and between MFT and spatial heterogeneity are clear and therefore it can be used to 
test some (but not all) existing theories for the evolution of sex and recombination. In 
general, ogaraK can be used to easily simulate very heterogeneous selection patterns.
A.3 Simple user guide
OgaraK is a population genetics simulator, this means that it can be used to generate 
synthetic datasets but not to do data analysis (though we supply many examples of 
example scripts in the Python language). The data that is generated is the frequency 
of genotypes in the parasite population each generation. OgaraK greatly facilitates the 
data analysis procedure by generating output in the Genepop format (Rousset, 2008) 
which can be read by most population genetics data analysis programs like e.g. Arlequin 
(Excoffier et al., 2005). As ogaraK is, in fact, simulating an infinite population, the 
Genepop format (being based on a finite sample) is not enough to capture the genotype 
frequencies with full precision, therefore ogaraK also exports its results in a simple 
format with precise information of genotype frequencies over time. We here describe the 
parameters for ogaraK and the output format.
Example scenarios
Many example scenarios are available (please see the File/Open menu). They are named 
according to the following convention:
EpistasisMOI or
N umberofDr ugsPolicyEpistasisMOI 
Examples:
FullEpistasis2 contains an example for full epistasis with a MOI of 2.
Full+Assym4 is Full Epistasis and Asymmetry (SP-based) with MOI 4.
2MFTFull-fDGF3 is 2 drugs, multiple first line therapies, Full Epistasis and DGF 
with MOI of 3.
2RotFull+DGF3 is 2 drugs, rotation, Full Epistasis and DGF with MOI of 3.
Parameters
ogaraK provides an easy to use interface. The following parameters are available: 
Number of drugs The number of drugs used.
A.3. SIMPLE USER GUIDE 189
Drug type Either “Standard” or “Artemisinin” In standard drugs, loci involved in 
drug resistance are independent from drug to drug. In Artemisinin drugs, there 
are always two loci per drug and one locus is shared among all drugs (see subsection 
A.2).
Loci per drug Number of loci encoding resistance per drug. Always two if the drug 
type is Artemisinin.
Epistasis Either “Full epistasis”, “Duplicate gene function” (DGF), “Full epistasis plus 
DGF” or “Full epistasis plus asymmetry” (see subsection A.l). For “Artemisinin” 
based drugs only “Full epistasis” is expected to be used, but the user can test 
alternative models.
Policy Either “Rotation”, “Multiple first line” or “combination”.
Rotation If policy is rotation, the user can specify the type of rotation: Either “Fixed”, 
i.e., every n generations, n being user specified or “Dynamic” where a drug is 
rotated after a certain resistance threshold for the drug being used is reached.
Infectivity Either “competitive release” or “independent transmission”. In competitive 
release an individual with 1 infection will produce as many secondary infections 
as one with 10. In independent transmission, the number of transmissions is 
proportional to the number of concurrent surviving infections.
Fitness penalty The type of penalty that will be computed, the most commonly used 
being “Erythrocytic”: Here any fitness penalty is modelled as competition in the 
blood stages, this means that the penalty is only useful in cases where the MOI 
is bigger than 1 (i.e., there is more than one infection competing in the blood). 
“Exo-erythrocytic” penalty exists mainly to model a penalty at the transmission 
and liver stages, i.e., it is MOI independent.
Penalty value The fitness penalty incurred per mutation (multiplicative). Specified 
as a range (see below).
Drug usage The percentage of infected humans that are treated. Untreated hosts 
function as sensitive reservoirs. Also specified as a range.
MOI The Multiplicities of Infection in the simulation. The user can specify from a 
MOI of 1 (selling) to 7. All the MOIs must add up to 1. E.g. 0.25 of MOI 1 and 
0.75 of MOI 2, means that 25% of all humans will have only one infection at a 
certain point in time, and the other 75% will have two.
Max generations The maximum generations for which each simulation can be run. 
A simulation can stop for two reasons: Either at the limit specified here or if the 
threshold of resistance is reached (see below).
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Threshold The value of spread of resistance after which the simulation stops. It is 
normally not interesting to run the simulation above certain levels of resistance as 
after certain levels the drugs are not used anymore (as they have long lost efficacy).
Resistance introduction Activates mutation/immigration of resistants.
Prob. introduction The probability of introduction of a resistant per generation. 
Each locus will have the same probability specified here.
Percent replaced The percentage of sensitive alleles that will be replaced with a re­
sistant version.
Initial frequency The initial frequency of the resistant forms.
Sample size The sample size for the Genepop file. While the model is not individual 
based, a sample of the every generation simulated can be produced. The sample 
size is approximated (it can be slightly lower than value requested) in order to try 
to assure a rounded approximation of the existing population.
Both fitness penalty and drug usage can be specified as a single value or as a range. 
If specified as a range, then more than one simulation will be run, example: Fitness is 
specified as range between 0 and 1 with a step of 0.1 and drug usage is specified as a 
range between 0.1 and 0.8 with a range of 0.05, this means that 11x15 simulations will 
be done, with fitness being 0.0,0.1,..., 1.0 and drug usage being 0.1,0.15, ...,0.8. If single 
values are specified for both parameters then only one simulation will be made.
It should be noted that the computational cost of running ogaraK simulations can 
vary widely. Users are recommended to read subsection A.4 before starting simulating 
with ogaraK.
Configuration has to be saved to a file before the simulator can be run. Configuration 
files can be easily edited by hand, this being especially useful for batch mode runs.
When running, the simulator writes all the simulations to disk in an internal format 
(in addition to output formats). This allows to re-use previous simulation results or to 
restart a batch of simulations that might be interrupted. If mutation is activated no 
re-use is done as results can vary due to stochasticity. All data files are written to the 
same directory where the configuration file is written.
Output
Three files are written for every simulation made: one with a sample of individuals 
in Genepop format - each population representing a different generation. A file with 
the frequency of all genotypes per generation and a file noting when drugs are rotated. 
The last file is only created when drug rotation policies are simulated. The files are
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named with the following prefix: freqPOLICY-NUMDRUGSLOCIDRUG-PENALTY- 
DRUGUSAGE, e.g freqMFT-21-005-03 is a the prefix of files containing the results 
from an MFT policy with 2 drugs, 1 locus per drug, a fitness penalty of 0.05 and a drug 
usage of 0.3. The suffixes for file names are .txt for genepop files, .og for the frequencies 
and .sw for the swaps.
While the genepop file adheres to a widely used standard and thus needs no de­
scription, we provide here the description of the content of the frequency and swap 
files.
Frequency files
Each line has the frequency of a certain genotype configuration. This consists of two 
columns: the genotype and the frequency. All genotypes are enumerated, the process 
repeats for all generations simulated. Here is an example where a genome for 2 drugs 
and 1 loci per drug is simulated:
0 0.9
1 0.05
2 0.04
3 0.01
0 0.8
1 0.083
2 0.073
3 0.043
In this case 2 generations are shown: in the first the fully sensitive genotype has 90% 
of frequency, the one resistant to drug 1 has 5%, the one resistant to drug two has 4% 
and the multiple-resistant has 1%.
Drug swap files
Drug swap files depict when drugs are rotated, they format is very simple: each 
lines depicts when a drug is swapped, the first column indicates the generation and the 
second the drug introduced, example
0 0 
7 1 
14 0
Drug 1 (coded as 0) is introduced in generation 0, rotation first happens at generation 
7, and again a 14.
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A.4 Software issues
Complexity and computational cost
The number of different genotypes that must be tracked is equal to 2l, where l is the 
number of drugs times the number of loci per drug (or the number of drugs plus 1 in 
the case of the Artemisinin model). As per the formula above all possible combinations 
of genotypes for each MOI will have to be considered. The number of permutations 
is then 2lM01. This makes the calculation above computationally very intensive, as an 
example studying a clonal multiplicity of 4 with 64 different genotypes (3 drugs with 
2 loci per drug) requires considering 16 million combinations. The most extreme case 
theoretically allowed, with a MOI of 7 would require dealing 4,398,046,511,104 cases 
(which is not feasible in practice). Furthermore, this computation has to be done for 
each environment (untreated and each epistasis mode per drug), for every generation 
and for every simulation (the number of simulations being dependent on the ranges of 
both fitness penalty and drug usage).
Therefore, the user will have to decide on the best compromise between available 
computing resources and the parameter choice (noticing that different parameters have 
a completely different impact on the computational time).
OgaraK tries as much as possible to facilitate the run of computationally intensive 
simulations by doing the following:
1. A relative value of computational cost is presented to the user. Whenever the 
user changes parameters, an estimate of the relative cost can be made. While not 
being related to any physical measure of time, it gives a good relative comparison 
of time among different parameter choices.
2. Simulations are independent and can be run concurrently over a certain range of 
fitness and drug usage. OgaraK will generate different file names based on the 
parameters chosen, facilitating concurrent runs.
3. OgaraK can be run in batch mode (allowing multiple runs being starting auto­
matically by a script on a single computer or on a grid), using a configuration 
file generated by the UI. This can be simple done by calling java malaria. Article 
path-to-database path-to-config-file.
Development infrastructure
The development infrastructure of OgaraK is fully open and public and relies on well es­
tablished platforms for software development. Along with the user site http: //popgen. 
eu/soft/ogaraK there is also a development site https: //launchpad. net/ogarak (the 
same platform used by projects like Ubuntu Linux or MySQL) which includes source
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code development, bug tracking and test infrastructure among other facilities typical of 
professional development projects.
A.5 Example analysis
Here we present two very simple analysis of ogaraK results.
The first one is nothing more that plotting the change in frequency of all parasite 
types over time for a simulation (figure A.5). This example is presented only to exemplify 
the use of the frequency file (the code to generate the chart is available on the web site) 
and strictly as a starting point.
Frequency of haplotypes over generations
jlackjsfullysensitive. bright red multiple-resistant
Generations
Figure A.5: The change in frequency of various genomes over time.
We expect that most data analysis made with ogaraK will be via the genepop output 
as genepop files can be feed to most population genetics analysis programs. The next 
example provided used the Biopython Genepop code to do the analysis. Two points 
should be noted: (i) coding skills are not required to do most analysis with genepop files 
- using one of the many applications will be enough and (ii) the example provided is 
one of the many that can be done, as the possibilities are unbound given the variety of 
methods available.
In our example, we compared the pattern of temporal Fst when using rotation and 
MFT. On figure A.6 we plot the pairwise Fst among all generations (between 0 and 100). 
The x-axis is the difference between the generations involved (e.g. if the comparison is 
between generation 7 and 20, this will fall on 13 on the x-axis). As expected Fst
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increases with distance in MFT as the selection pressure is the same over-time, but with 
rotation the pattern is less clear as the selection pressure is changing thus making the 
pressure for each individual drug intermittent.
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Fst as a function of generation distance - Rotation
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Figure A.6: How pairwise temporal Fst varies with different treatment policies. In the 
x-axis the difference between compared generations is plotted.
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Simulations were run varying drug usage (i.e., proportion of infections treated) and 
fitness penalty between 0.0 and 1.0 in increments of 0.02 for both parameters. The 
models were run with constant MOIs of 1 (100 % selfing), 2, 3 and 4. The application 
to perform these simulations is made available in http://popgen.eu/soft/ogaraK1.
In order to facilitate understanding of the resistance profile of each clone we will use, 
whenever pertinent, a binary representation per locus where 0 represents a locus that 
is sensitive and 1 when a locus might confer resistance. As an example, in a case where 
we model two drugs and 1 resistance locus per drug, the totally sensitive clone can be 
represented by co,o; clone co,i is sensitive to drug 1 and resistant to drug 2. For clarity 
and unless otherwise stated, all textual examples presented below will assume 2 drugs 
with 1 locus per drug.
The following symbols are also employed:
l is the total number of loci involved in drug resistance;
i is the concurrent number of infection on a human host or Multiplicity of infection 
(MOI);
Ffc is the frequency of resistance profile k in the whole population in the current 
generation;
F1/ if the frequency resistance profile k in the whole population in the next gener­
ation;
fk is the frequency of resistance profile k inside a single human individual in the 
current generation;
s is the strength of natural selection acting against each mutation; 
m is the number of mutated loci in each clone, e.g coipi has m = 3;
1ogaraK was accepted after this manuscript, therefore no reference was provided other than the web 
page.
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d is the drug treatment rate, defined as the proportion of infected individuals 
treated. If more than one drug is used, then all are used in equal proportions. 
rid is the number of drugs used.
The calculations will be performed in a computer because, as will become apparent, 
the number of permutations of genotypes becomes huge. Here we provide the algebraic 
basis of the calculations; obviously we cannot describe each case so we will use illustrative 
examples.
Selection pressure is assumed to be mediated through competition between all clones 
in the asexual blood phase in humans. The proportion of transmissions contributed by 
a resistance profile k in any single host is:
£ /c(l - s)mc
(B.l)
When no drug is present; the denominator is the familiar “mean fitness” averaged 
across the c clones of the infection. If a drug is used, only infections that are drug 
resistant are able to transmit (i.e., = 0 for sensitive forms). Being drug resistant
depends on epistasis for models with more than 1 locus per drug: for full epistasis all 
loci are required to be resistant, for duplicate gene function a single locus in enough 
(and having more than one is slightly deleterious) and for asymmetrical epistasis, the 
first locus is required.
After successful transmission to a mosquito via a blood meal, P. falciparum repro­
duces sexually (with the possibility of selling), and as such is subject to recombination. 
This means that new genotypes can originate inside the mosquito, as an example, if a 
clone resistant to drug 1 (co,i) mates with a clone resistant to drug 2 (c^o), 4 types of 
offspring are possible: the initial versions plus profiles co,o and Ci:i, i.e., totally sensitive 
parasites and multidrug-resistant ones.
In the case of two drugs and one locus per drug and assuming that the recombination 
rate among loci is 0.5 (i.e., they are not physically linked) the frequency of transmission 
of sensitive parasites from a certain individual is given by:
/o,o — £o,o + ^o.otfi.o + £o,i) + 0^1,1 + ^i,o£o,i (B-2)
A similar reasoning applies for all other resistance profiles.
In the general case, the probability of a certain infected human host being infected 
with MOI i composed of a certain combination of clonal genotypes is given by:
p(i)p(co,ci,---,ci) (B.3)
p(co,ci,...,q) is calculated from a multinomial distribution using current frequen­
cies of clonal genotypes in the population.
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In our example, this can be read as the probability of having i infections times 
the probability of having a combination of infections composed by cq.o sensitives, co,i 
resistant to drug 1, 01,0 resistant to drug 2 and Citi multidrug-resistant.
The frequency of each resistance profile k transmitted to the next generation will be:
Fh =
i i—Co Ci-i-...—co rid
i=lco=0ci=0 cj=0 e=0ci=0 (B.4)
The structure of the equation can be explained as follows: summation over i allows 
the investigation of all MOI classes in the population (though in the examples researched, 
the value is fixed for the whole population, i.e., everyone has the same MOI). Summation 
over co,ci,...,Ci allows inclusion of all possible combinations of genotypes within the 
MOI class. Summation of e allows to investigate the contribution of all environments 
(untreated individuals plus one or more different epistasis cases), /(e) is the fraction 
of the host population providing a certain environment (e.g., untreated, treated with 
duplicate gene function, etc.). p(d) is the probability of receiving a certain drug regimen 
where d = 0 means no drug. For the untreated environment p(0) = 1. For other 
environments p(0) = 0 and p(d > 0) is dependent on drug policy (e.g. ^ when using 
multiple therapies simultaneously in the same proportion). For each environment e there 
is a different transmission proportion for each profile (tek).
TT is a normalization coefficient equal to the sum of all the numerators (in order to
2*—1. ,
assure that the proportions of each type of transmission Fk sum to 1).
fc=o
A similar approach has been used before (Hastings, 2006), and is now extended to 
allow different environments, more than one drug and several models of epistasis. This 
more complex model has consequences on the computational cost of the simulation.
The number of different genotypes that must be tracked is equal to 2l, where l 
is number of drugs times the number of loci per drug. As per the formula above all 
possible combinations of genotypes for each MOI have to be considered. The number 
of permutations is then 2P. This makes the calculation above computationally very 
intensive. As an example studying a clonal multiplicity of 4 with 64 different genotypes 
(3 drugs with 2 loci per drug) requires considering 16 million cases. The most extreme 
case theoretically allowed, with a MOI of 7 would require dealing 4398046511104 cases 
(which is not feasible in practice). Furthermore, this computation has to be done for 
each environment (untreated and each epistasis mode per drug), for every generation 
and for every simulation (the number of simulations being dependent on the ranges of 
both fitness penalty and drug usage).
Linkage (gametic) disequilibrium is expected to be influenced by epistasis and is a 
necessary parameter to understand the relationship between frequency and prevalence 
of resistance. In order to understand and compare the impact of epistasis on linkage, 
we studied linkage disequilibrium using the correlation coefficient r which, while not
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completely removing the effects of allele frequency (Hedrick, 1987), still allows for a 
standardised qualitative comparison required for this study. Furthermore, unlike Df, it 
preserves the original signal of D which is important to understand epistasis effects.
Epidemiologically realistic MOIs
While the main manuscript only discusses scenarios with constant MOIs (i.e. all humans 
have the same number of infections), epidemiologically realistic settings have mixed 
MOIs (Arnot, 1998). The model presented is capable of simulating mixed MOIs but, 
from a qualitative point of view the results are similar to constant MOIs. Therefore, for 
the sake of simplicity, the main text manuscript presents results with constant MOIs.
Below we present a chart of LD patterns using a more realistic truncated Poisson 
distribution of MOI (truncated at 7 clones with a conditional mean of 2.5). As it can be 
observed, the chart is qualitatively similar to Figure 2 on the main manuscript (constant 
MOI of 2).
1.0
LD patterns for single drug models 
fitness penalty=0.3 and drug treatment rate=0.4
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cExpected heterozygosity: Illustrative 
examples of a slow moving statistic
Here we illustrate, using a computational study, the behaviour of a widely used long­
term Ne estimator based on expected heterozygosity. The simulation results illustrate 
that the long-term estimator, and heterozygosity in general, cannot be used to detect 
the effectiveness of control and elimination interventions.
We also try to make suggestions about sampling sizes required to obtain a reliable 
estimation of heterozygosity based Ne estimation: How many individual samples and 
number of loci are needed for an accurate and precise Ne estimation with both estima­
tors?
While we produce examples with scenarios based on effective population size of P. 
falciparum malaria, but our conclusions are generally applicable to all species where Ne is 
high (i.e. above 1,000). These illustrative simulations are thus concerned with the impact 
of demographic events and sampling strategies on heterozygosity and Ne estimation and 
interpretation. Other important factors, like the assumptions on mutation model and 
rate are not discussed here as they were subject of previous work.
This supplement follows roughly the structure of a research paper, but the results 
presented are not novel, only illustrative of known properties of expected heterozygosity. 
Readers might want to skip the methodological details and read directly the results and 
conclusions or even just inspect the figures and tables.
C.l Methods
The long-term iVe estimator based on heterozygosity assumes that in a population in 
mutation-drift equilibrium heterozygosity is a function of the product of Ne and the 
mutation rate (i. Assuming a stepwise mutation model (SMM) expected in many mi­
crosatellite markers the relationship between iYe, the mutation rate p and He\
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Ne(i =
1 2
1-He
8
1
(C.l)
We also studied the infinite alleles model (IAM), used in loci with patterns of varia­
tion incompatible with the SMM (Anderson et al., 2000a), but results are not shown as 
they are qualitatively similar to SMM results.
Expected heterozygosity {H) at each locus is calculated as (1 — P?)> where n
is the number of markers sampled and pi is the frequency of the ith allele and the factor 
‘(ji-i) is a correction to allow comparison of results obtained from loci with different 
numbers of samples.
Simulations
We conducted simulations using the forward-time, individual based simulator simuPOP 
(Peng and Kimmel, 2005). Simulations were done using a diploid genome with 100 
neutral independent microsatellites, random mating, discrete generations, random vari­
ation in reproductive success and an average sex ratio of 1. Initial allele frequencies were 
constructed in order to replicate the allele frequency distribution expected (both in He 
and number of alleles) for the Stepwise Mutation Model estimating an Ne as observed 
in empirical studies (Iwagami et al., 2009; Anderson et al, 2000a; Susomboon et al., 
2008) using a microsatellite mutation rate is estimated as 1.59 x 10~4 for P. falciparum 
malaria (Anderson et ah, 2000b). The number of initial alleles was varied between 5 
and 24 as observed in Anderson et al. (2000a). For all simulations 100 replicates were 
conducted. Haploid simulations were also conducted in order to research the impact of 
ploidy as P. falciparum has both a haploid and a diploid phase.
To quantify the impact on bias, precision and accuracy of sample sizes, we simulated 
5 constant size populations with Nc (census size) of 20,000, 10,000, 5,000, 1,000 and 500. 
As the simulated populations are assumed to be panmictic and of constant size, Nc is an 
approximation of the contemporary Ne (Charlesworth, 2009). The sampling strategies 
include 10, 20, 50 90, 200 and 300 individuals using 5, 10, 20, 100, 200 and 500 loci.
The ability to detect a sudden contemporary bottleneck (a consequence of a con­
trol or elimination intervention) was simulated using population of initial Ne of 20,000, 
10,000, 5,000 and 1,000 (based on values determined for P. falciparum population in 
high, medium and low transmission sites (Anderson et al., 2000a; Susomboon et al., 
2008)) botlenecked to 50%, 10% and 5% of its original size. We also simulated expan­
sions varying between 2 and 20 times the original size. We then sampled the population 
several generations after the bottleneck/expansion and estimated the Ne using the het­
erozygosity and LD methods. The Ne before the demographic event is termed N\ and 
the Ne afterwards is N2.
To estimate the importance of founding effects we also simulated an initial Ne as 
per the paragraph above then followed by 2 to 10 generations where Ne is either 10
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or 100 (a severe bottleneck representing a minority of individuals migrating to found a 
new population, or after a very severe and successful control programme) and then a 
population expansion to 1,000, 10,000 and 20,000.
C.2 Results and remarks
In low transmission scenarios (Nc below 2,000) the precision of the estimator is mod­
erately dependent on the number of loci and individuals sampled. With a strategy 
containing around 30 haploid samples and 10 loci (common in studies for low transmis­
sion) half of estimates are greater than 20% from the estimated median value. Similar 
precision patterns are observed for high transmission scenarios (Ne > 10,000). Strong 
upward bias is observed with all sampling strategies especially in high transmission sim­
ulations. Bias is stronger with smaller samples (the median estimate is around 15% 
above the real Ne) whereas bias with the larger sampling strategy is only around 5%. 
Bias is higher when the sample size approaches the number of alleles as this causes the 
allele distribution to be more uniform (therefore increasing heteorozygosity). We present 
the distribution of point estimates using multiple sample strategies for a constant Ne of 
1,000 and 20,000 on figure C.l.
In order to understand the relationship between of number of loci with the number of 
individuals genotyped, we used two sampling strategies where the number of loci and in­
dividuals is swapped (i.e., one with 10 loci and 100 haploid individuals and another with 
100 loci and 10 individuals). Accuracy is similar in all scenarios (constant, bottleneck 
and expansion) tested. The two sampling strategies are compared on figure C.l for con­
stant Nc simulations (last two columns). Most importantly interchangeability of number 
of loci and individuals also holds for bottleneck and expansion simulations. Figure C.2 
shows Nc for various bottlenecks and expansions using both sampling strategies.
In bottleneck and expansion scenarios, estimated Ne values overwhelmingly reflect 
pre-bottleneck Ne values even after many generations. This happens for all values of 
Ne (pre- and post-bottleneck/expansion) typically reported for P. falciparum. Even on 
the most extreme scenario, modeling a population decrease from a value typical of high- 
transmission settings (iVe of 20,000) to a value typical low-transmission value (1,000), 
after 100 generations of the bottleneck the estimated Ne is still, on average, 75% of the 
original value or, around 15 times the post-bottleneck value. For a decrease from 20,000 
to 5,000, no estimation decrease whatsoever (due to upward bias) can be detected 100 
generations after the bottleneck. The effect is worse with expansion scenarios: even 
in the most extreme case of an expansion from 1,000 to 20,000, after 100 generations 
the estimator is only 10% above the original value. Bottlenecks are detected faster as 
heterozygosity is decreased via drift whereas in expansion heterozygosity is increased 
via mutation, a slower process. Table C.l shows mean He and Ne values for several
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generations after a range of bottlenecks and expansions using a sampling strategy of 200 
diploid individuals and 100 loci.
With founding models, any estimated Ne is mostly influenced by pre-bottleneck size 
and the size and duration of the migrated population. Contemporary population size has 
minor impact on the estimated value. If the founding population is extremely small or 
the time to found (i.e., the number of generations between leaving the original population 
and starting to expand the new population) is large, then the estimated Ne post-founding 
will be strongly influenced by the migrated population. For instance when only 10 
individuals migrate, and assuming that migration takes 2 generations, there is an average 
loss of heterozygozity of 0.1 (consistent with a theoretical expectation of heterozygosity 
loss of 277 per generation) causing a proportional fall in Ne. If the migration is either of a 
large enough population or of small duration then the Ne estimation post-bottleneck will 
mostly approximate the value pre-migration. Figure C.3 shows Ne up to 20 generations 
post-founding assuming a pre-migration Ne of 20,000 and stable post-founding Ne of 
1,000, contemporary Ne mostly influences the slope which is never steep for typical P. 
falciparum values.
As long as the sample size is enough to accommodate the number of alleles, the 
number of individuals sampled can be exchanged for more loci. This means that, if 
for some reason it is not possible to sample many individuals then sampling more loci 
per individual can compensate in order to increase the accuracy. This is especially 
important because in some situations it is not possible to genotype more individuals 
but with next-generation sequencing, it is feasible to genotype many loci per parasite. 
The ability to exchange individual numbers for loci number happens in constant, bot­
tleneck and expansion scenarios. Evaluating the accuracy trade-off of the estimator is 
particularly important in bottleneck scenarios because it has been demonstrated that, 
with contemporary Ne estimators, sampling more individuals is more informative than 
sampling more loci (England et ah, 2010; Antao, 2010).
The bias and accuracy issues that we researched are due to demographic events and 
sampling strategies. These effects will have to be compounded with the already well 
known impact of varying mutation rates. Indeed, our models took a very benevolent 
approach to both mutation rate and mutation model as we assumed a constant mutation 
rate for all loci based on the value commonly used for Ne estimations with P. falciparum 
malaria and a Stepwise Mutation Model (SMM) whereas some loci show patterns of 
variation which are inconsistent with the SMM (Anderson et al., 2000b). Even with 
such assumptions, several limitations of this estimator of effective population size became 
clear.
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Ni N2
Generation
1 5 10 25 50 100
20000 10000 He 0.811 0.811 0.811 0.811 0.811 0.811
Ne 21196 21203 21201 21260 21151 21138
20000 5000 He 0.811 0.811 0.810 0.810 0.809 0.806
Ne 21238 21152 21101 20936 20698 20184
20000 1000 He 0.811 0.809 0.807 0.802 0.793 0.776
Ne 21159 20721 20289 19178 17510 14924
10000 20000 He 0.730 0.730 0.731 0.731 0.732 0.733
Ne 10018 10033 10041 10073 10134 10226
10000 5000 He 0.731 0.731 0.731 0.730 0.729 0.728
Ne 10078 10044 10044 10018 9952 9814
10000 1000 He 0.730 0.728 0.727 0.722 0.714 0.699
Ne 9991 9849 9731 9408 8834 7903
5000 20000 He 0.630 0.630 0.630 0.631 0.632 0.634
Ne 4946 4956 4969 4986 5018 5093
5000 10000 He 0.630 0.630 0.630 0.631 0.632 0.634
Ne 4956 4960 4964 4979 5007 5067
5000 1000 He 0.630 0.629 0.628 0.624 0.618 0.607
Ne 4949 4920 4884 4780 4601 4296
1000 20000 He 0.340 0.342 0.341 0.344 0.349 0.357
Ne 1017 1027 1025 1041 1067 1113
1000 10000 He 0.340 0.341 0.342 0.344 0.349 0.356
Ne 1020 1023 1027 1042 1066 1112
1000 5000 He 0.340 0.341 0.343 0.344 0.348 0.355
Ne 1020 1025 1033 1043 1061 1101
Table C.l: Mean heterozygosity and effective population size estimated after a bottle­
neck or expansion. Ni is the value before the bottleneck/expansion and N2 the value 
after. Estimations are done 1, 5, 10, 25 50 and 100 generations after the demographic 
event. The sampling strategy includes 200 diploid individuals and 100 loci.
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Ne for different sampling strategies in constant scenarios
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Figure C.l: Boxplot charts of the distribution of Ne point estimates for a scenario of 
constant Ne of 1,000 (top chart) and 20,000 (bottom chart) using different sampling 
strategies. The sampling policy is specified on the X-axis: the first number is the num­
ber of samples and the second number, the number of loci. Sampling policies vary from 
48 diploid samples with 10 loci, typical of empirical studies in malaria low-transmission 
areas to 200 diploid individuals and 100 loci. The last two columns compare the be­
haviour of the estimator with sampling strategies exchanging loci for individuals.
Nc=1000
Nc=20000
24-10 24-50 400-100 10-100 100-10
Sampling strategy (samples - loci)
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Figure C.2: Bar chaxts for the estimation of Ne in bottleneck and expansion scenarios 
where sampling occurs 25 generations after the bottleneck/expansion. Two sampling 
strategies are used one maximising the number of loci (100 loci, 10 individuals), the 
other the number of individuals (10 loci, 100 individuals). The Y-axis is the estimated 
Ne and the X-axis includes both Nc before and after the bottleneck/expansion event. 
Mean and standard deviation are plotted.
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Figure C.3: Mean Ne for four founding scenarios from an initial population of 20,000 
to a final population of 1,000 using 200 diploid individuals and 100 loci. The founding 
population has 10 or 100 individuals and during 2 or 10 generations. The estimated 
value is mostly a function of the original Ne and the size and duration of the founding 
effect. Notably the influence of the contemporary Ne is minimal and only causes a slight 
slope over time.
